Clinical Study Protocol  R668-AD-1924 Amendment 2  
Regeneron Pharmaceuticals, Inc.  Page 1 of 108 
CONFIDENTIALEudraCT: 2019 -003088-22 
IND Number: 107969  Regeneron Pharmaceuticals, Inc.  
Clinical Study Protocol  
A MULTICENTER, RANDOMIZED, DOUBLE -BLIND, PLACEBO -
CONTROLLED, PARALLEL -GROUP STUDY TO  EVALUATE THE 
EFFICACY AND SAFETY OF DUPILUMAB IN ADULT AND 
ADOLESCENT PATIENTS WITH MODERATE -TO-SEVERE ATOPIC 
HAND AND FOOT DERMATITIS  
Compound : Dupilumab  
Study Name:  Liberty-AD-HAFT 
Clinical Phase: 3 
Protocol Number:  R668-AD-1924 
Protocol Version R668-AD-1924 Amendment 2  
Amendment 2 Date of Issue:  See appended electronic signature page
Amendment 1 Date of Issue:  28 Apr 2020  
Original Date of Issue:  03 Oct 2019  
Medical/Study Director:   
 
 
Regeneron Pharmaceuticals, Inc.  
777 Old Saw Mill River Road  
Tarrytown, NY 10591  
 
 
 
 
 
 
VV-RIM-00138022-1.0 Approved - 13 Jan 2021 GMT-5:00[STUDY_ID_REMOVED]

Clinical Study Protocol  R668-AD-1924 Amendment 2  
Regeneron Pharmaceuticals, Inc.  Page 2 of 108 
CONFIDENTIAL  LIST OF ABBREVIATION S AND DEFINITIONS OF  TERMS  
ACD Allergic contact dermatitis  
AD Atopic dermatitis  
ADA Anti-drug antibody  
AE Adverse event  
AESI Adverse event of special interest  
ALT Alanine aminotransferase  
AST Aspartate aminotransferase  
BL Baseline 
BSA Body Surface Area  
BUN Blood urea nitrogen  
CPK Creatine phosphokinase  
CRF Case report form (electronic or paper)  
CRO Contract research organization  
CTCAE Common Terminology Criteria for Adverse Events  
EASI Eczema Area and Severity Index  
EC Ethics Committee  
EDC Electronic data capture  
EOS End of study  
EOT End of treatment  
ET Early termination  
FAS Full analysis set  
FDA Food and Drug Administration  
GCP Good Clinical Practice  
HBcAb Hepatitis B core antibody  
HBsAb Hepatitis B surface  antibody 
HBsAg Hepatitis B surface antigen  
HECSI Hand eczema severity index  
HFD Hand and foot dermatitis  
Hep C Ab  Hepatitis C antibody  
HIV Human immunodeficiency virus  
ICD Irritant contact dermatitis  
ICDRG International Contact Dermatitis Research  Group 
ICF Informed consent form  
ICH International Council for Harmonisation  
IGA Investigator Global Assessment  
IgE Immunoglobulin E  
IL Interleukin  
IL-4Rα IL-4 receptor alpha subunit  
IRB Institutional Review Board  
IV Intravenous  
IVRS/IWRS  Interactive Voice Response System/Interactive Web Response System  
                                        VV-RIM-00138022-1.0 Approved - 13 Jan 2021 GMT-5:00
Clinical Study Protocol  R668-AD-1924 Amendment 2  
Regeneron Pharmaceuticals, Inc.  Page 3 of 108 
CONFIDENTIAL  JAK Janus kinase  
mTLSS Modified Total Lesion Sign Score  
NAb Neutralizing antibody  
NCI-CTCAE National Cancer Institute -Common Terminology Criteria for Adverse Events  
NRS Numerical Rating  Scale 
PGIC Patient Global Impression of Change  
PGIS Patient Global Impression of Severity  
PK Pharmacokinetic  
PPS Per protocol set  
PUVA Psoralen and UVA  
PV Phone visit  
QoL Quality of life  
QOLHEQ  Quality of Life in Hand Eczema Questionnaire  
RBC Red blood cell  
Regeneron  Regeneron Pharmaceuticals, Inc.  
SAE Serious adverse event  
SAF Safety analysis set  
SAP Statistical analysis plan  
SAS Statistical Analysis System  
SC Subcutaneous  
SOC System organ class  
SUSAR Suspected unexpected serious adverse reaction 
TB Tuberculosis  
TCI Topical calcineurin inhibitors  
TCS Topical corticosteroids  
TEAE Treatment -emergent adverse event  
TRUE Thin Layer Rapid Use Epicutaneous  
UVB Ultraviolet B  
WBC White blood cell  
WPAI+CIQ  Work Productivity and Activity Impairment plus Classroom Impairment 
Questionnaire  
WPCBP Women of childbearing potential  
                                        VV-RIM-00138022-1.0 Approved - 13 Jan 2021 GMT-5:00
Clinical Study Protocol  R668-AD-1924 Amendment 2  
Regeneron Pharmaceuticals, Inc.  Page 4 of 108 
CONFIDENTIAL  TABLE OF CONTENTS  
LIST OF ABBREVIATION S AND DEFINITIONS OF  TERMS ................................ .................. 2 
CLINICAL STUDY PROTO COL SYNOPSIS ................................ ................................ .............25 
1. INTRODUCTION  ................................ ................................ ................................ ......33 
2. STUDY OBJECTIVES  ................................ ................................ .............................. 35 
2.1. Primary O bjective ................................ ................................ ................................ .......35 
2.2. Secondary Objectives  ................................ ................................ ................................ .35 
2.3. Exploratory Objectives  ................................ ................................ ............................... 35 
3. HYPOTHESIS AND RATIO NALE ................................ ................................ ..........36 
3.1. Hypotheses  ................................ ................................ ................................ .................. 36 
3.2. Rationale  ................................ ................................ ................................ ..................... 36 
3.2.1.  Rationale for Study Design  ................................ ................................ ......................... 36 
3.2.2.  Rationale for Dose Selection  ................................ ................................ ...................... 38 
3.3. Risk-Benefit ................................ ................................ ................................ ................ 38 
4. ENDPOINTS  ................................ ................................ ................................ ..............40 
4.1. Primary and Secondary Endpoints ................................ ................................ ..............40 
4.1.1.  Primary Endpoint  ................................ ................................ ................................ ........40 
4.1.2.  Secondary Endpoints  ................................ ................................ ................................ ..40 
4.1.3.  Other Endpoints and Assessments  ................................ ................................ ..............41 
4.1.4.  Exploratory Endpoints  ................................ ................................ ................................ 41 
5. STUDY VARIABLES ................................ ................................ ................................ 41 
5.1. Demographic and Baseline Characteristics  ................................ ................................ 41 
5.2. Efficacy Variables  ................................ ................................ ................................ ......41 
5.3. Safety Variables  ................................ ................................ ................................ ..........41 
5.4. Pharmacokinetic Variables  ................................ ................................ ......................... 41 
5.5. Immunogenicity Variables  ................................ ................................ .......................... 42 
5.6. Pharmacodynamic and Other Biomarker Variables  ................................ ................... 42 
6. STUDY DESIGN  ................................ ................................ ................................ .......42 
6.1. Study Description and Duration  ................................ ................................ ................. 42 
6.1.1.  End of Study Definition  ................................ ................................ .............................. 46 
6.2. Planned Interim Analysis  ................................ ................................ ............................ 46 
7. SELECTION, WITHDRAWA L, AND REPLACEMENT O F PATIENTS  ..............46 
                                        VV-RIM-00138022-1.0 Approved - 13 Jan 2021 GMT-5:00
Clinical Study Protocol  R668-AD-1924 Amendment 2  
Regeneron Pharmaceuticals, Inc.  Page 5 of 108 
CONFIDENTIAL  7.1. Number of Patients Planned  ................................ ................................ ....................... 46 
7.2. Study Population  ................................ ................................ ................................ .........46 
7.2.1.  Inclusion Criteria  ................................ ................................ ................................ ........46 
7.2.2.  Exclusion Criteria  ................................ ................................ ................................ .......48 
7.3. Premature Withdrawal from the Study  ................................ ................................ .......53 
7.4. Replacement of Patients  ................................ ................................ ............................. 53 
8. STUDY TREATMENTS ................................ ................................ ............................ 53 
8.1. Investigational and Reference Treatments  ................................ ................................ ..53 
8.2. Background Treatment  ................................ ................................ ............................... 54 
8.3. Rescue Treatment  ................................ ................................ ................................ .......54 
8.4. Dose Modification and Study Treatment Discontinuation Rules  ............................... 55 
8.4.1.  Dose Modification  ................................ ................................ ................................ ......55 
8.4.2.  Study Drug Discontinuation  ................................ ................................ ....................... 55 
8.4.2.1.  Reasons for Permanent Discontinuation of Study Drug  ................................ .............55 
8.4.2.2.  Reasons for Temporary Discontinuation of Study Drug  ................................ ............56 
8.5. Management of Acute Reactions  ................................ ................................ ................ 56 
8.5.1.  Acute Injection Reactions  ................................ ................................ ........................... 56 
8.5.1.1.  Systemic Injection Reactions  ................................ ................................ ...................... 57 
8.5.1.2.  Local Injection Site Reactions  ................................ ................................ .................... 57 
8.6. Method of Treatment Assignment  ................................ ................................ ..............57 
8.7. Blinding ................................ ................................ ................................ ...................... 57 
8.8. Emergency Unblinding  ................................ ................................ ............................... 57 
8.9. Treatment Logistics and Accountability  ................................ ................................ .....58 
8.9.1.  Packaging, Labeling, and Storage  ................................ ................................ ..............58 
8.9.2.  Supply and Disposition of Treatments  ................................ ................................ .......58 
8.9.3.  Treatment Accountability  ................................ ................................ ........................... 58 
8.9.4.  Treatment Compliance  ................................ ................................ ................................ 59 
8.10.  Concomitant Medications and Procedures  ................................ ................................ .59 
8.10.1.  Prohibited Medications and Procedures  ................................ ................................ .....59 
8.10.2.  Permitted Medications and Procedures  ................................ ................................ ......60 
8.10.3.  Skin Protection Measures  ................................ ................................ ........................... 60 
9. STUDY SCHEDULE OF EV ENTS AND PROCEDURES  ................................ ......61 
9.1. Schedule of Events  ................................ ................................ ................................ .....61 
                                        VV-RIM-00138022-1.0 Approved - 13 Jan 2021 GMT-5:00
Clinical Study Protocol  R668-AD-1924 Amendment 2  
Regeneron Pharmaceuticals, Inc.  Page 6 of 108 
CONFIDENTIAL  9.1.1.  Footnotes for the Schedule of Events Table  ................................ ............................... 66 
9.1.2.  Early Termination Visit  ................................ ................................ .............................. 69 
9.1.3.  Unscheduled Visits  ................................ ................................ ................................ .....69 
9.2. Study Procedures  ................................ ................................ ................................ ........69 
9.2.1.  Procedures Performed Only at the Screening/Baseline Visit  ................................ .....70 
9.2.1.1.  Patch Testing  ................................ ................................ ................................ ..............70 
9.2.2.  Efficacy Procedures  ................................ ................................ ................................ ....72 
9.2.2.1.  Investigator Global Assessment of Hand and Foot  ................................ .................... 72 
9.2.2.2.  Modified Total Lesion Sign Score for Hands and Feet  ................................ ..............72 
9.2.2.3.  Hand and Foot Pruritus Numerical Rating Scale  ................................ ........................ 72 
9.2.2.4.  Hand and Foot Skin Pain Numerical Rat ing Scale ................................ ..................... 73 
9.2.2.5.  Sleep Numerical Rating Scale  ................................ ................................ .................... 73 
9.2.2.6.  Hand and Foot Area Involvement of Atopic Dermatitis  ................................ ............73 
9.2.2.7.  Patient Global Impression of Severity  ................................ ................................ ........73 
9.2.2.8.  Patient Global Impression of Change  ................................ ................................ .........73 
9.2.2.9.  Hand Eczema Severity Index  ................................ ................................ ...................... 73 
9.2.2.10.  Quality of Life in Hand Eczema Questionnaire  ................................ ......................... 74 
9.2.2.11.  Eczema Area and Severity Index  ................................ ................................ ................ 74 
9.2.2.12.  Investigator’s Global Assessment  ................................ ................................ ...............74 
9.2.2.13.  Atopic Dermatitis Area Photographs  ................................ ................................ ..........74 
9.2.2.14.  Patient-Assessed EQ -5D ................................ ................................ ............................. 75 
9.2.2.15.  Work Productivity and Activity Impairment Questionnaire Plus Classroom 
Impairment Questions  ................................ ................................ ................................ .75 
9.2.3.  Safety Procedures  ................................ ................................ ................................ .......76 
9.2.3.1.  Vital Signs  ................................ ................................ ................................ .................. 76 
9.2.3.2.  Body Weight and height  ................................ ................................ ............................. 76 
9.2.3.3.  Physical Examination  ................................ ................................ ................................ .76 
9.2.3.4.  Laboratory Testing  ................................ ................................ ................................ ......76 
9.2.4.  Drug Concentration and Measurements  ................................ ................................ .....77 
9.2.5.  Immunogenicity Measurements and Samples  ................................ ............................ 78 
9.2.6.  Pharmacodynamic and Exploratory Biomarker Procedures  ................................ .......78 
9.2.7.  Future Biomedical Research (Optional)  ................................ ................................ .....78 
9.2.7.1.  Pharmacogenomic Analysis (Optional)  ................................ ................................ ......78 
                                        VV-RIM-00138022-1.0 Approved - 13 Jan 2021 GMT-5:00
Clinical Study Protocol  R668-AD-1924 Amendment 2  
Regeneron Pharmaceuticals, Inc.  Page 7 of 108 
CONFIDENTIAL  10. SAFETY EVALUATION AN D REPORTING  ................................ ......................... 79 
10.1.  Recording and Reporting Adverse Events  ................................ ................................ ..79 
10.1.1.  General Guidelines  ................................ ................................ ................................ .....79 
10.1.2.  Reporting Procedure  ................................ ................................ ................................ ...80 
10.1.3.  Events that Require Expedited Reporting to Sponsor  ................................ ................ 80 
10.2.  Definitions  ................................ ................................ ................................ .................. 81 
10.2.1.  Adverse Event ................................ ................................ ................................ .............81 
10.2.2.  Serious Adverse Event  ................................ ................................ ................................ 81 
10.2.3.  Adverse Events of Special Interest  ................................ ................................ .............81 
10.2.4.  Severity ................................ ................................ ................................ ....................... 82 
10.2.5.  Causality  ................................ ................................ ................................ ..................... 82 
10.3.  Safety Monitoring  ................................ ................................ ................................ .......83 
10.4.  Notifying Health Authorities, Institutional Review Board /Ethics Committee, 
and Investigators  ................................ ................................ ................................ .........84 
11. STATISTICAL PLAN ................................ ................................ ................................ 84 
11.1.  Statistical Hypothesis  ................................ ................................ ................................ ..84 
11.2.  Justification of Sample Size ................................ ................................ ........................ 85 
11.3.  Analysis Sets  ................................ ................................ ................................ ...............85 
11.3.1.  Efficacy Analysis Sets  ................................ ................................ ................................ 85 
11.3.2.  Safety Analysis Set  ................................ ................................ ................................ .....85 
11.3.3.  Pharmacokinetic Analysis Set  ................................ ................................ .................... 85 
11.3.4.  Immunogenicity Analysis Sets  ................................ ................................ ................... 86 
11.4.  Statistical Methods  ................................ ................................ ................................ ......86 
11.4.1.  Patient Disposition  ................................ ................................ ................................ ......86 
11.4.2. Demography and Baseline Characteristics  ................................ ................................ .86 
11.4.3.  Efficacy Analyses  ................................ ................................ ................................ .......86 
11.4.3.1.  Primary Efficacy Analysis  ................................ ................................ .......................... 86 
11.4.3.2.  Secondary Efficacy Analysis  ................................ ................................ ...................... 87 
11.4.4.  Control of Multiplicity  ................................ ................................ ................................ 89 
11.4.5.  Safety Analysis  ................................ ................................ ................................ ...........89 
11.4.5.1.  Adverse Events  ................................ ................................ ................................ ...........89 
11.4.5.2.  Other Safety  ................................ ................................ ................................ ................ 90 
11.4.5.3.  Treatment Exposure  ................................ ................................ ................................ ....90 
                                        VV-RIM-00138022-1.0 Approved - 13 Jan 2021 GMT-5:00
Clinical Study Protocol  R668-AD-1924 Amendment 2  
Regeneron Pharmaceuticals, Inc.  Page 8 of 108 
CONFIDENTIAL  11.4.5.4.  Treatment Compliance  ................................ ................................ ................................ 90 
11.4.6.  Pharmacokinetics  ................................ ................................ ................................ ........91 
11.4.6.1.  Analysis of Drug Concentration Data  ................................ ................................ .........91 
11.4.7.  Analysis of Immunogenicity Data  ................................ ................................ ..............91 
11.5.  Timing and Operational Considerations of Statistical Analyses  ................................ 91 
11.6.  Statistical Considerations Surrounding the Premature Termination of a Study  .........92 
12. QUALITY CONTROL AND QUALITY ASSURANCE  ................................ .........92 
12.1.  Data Management and Electronic Systems  ................................ ................................ 92 
12.1.1.  Data Management  ................................ ................................ ................................ .......92 
12.1.2.  Electronic Systems  ................................ ................................ ................................ ......92 
12.2.  Study Monitoring  ................................ ................................ ................................ ........93 
12.2.1.  Monitoring of Study Sites  ................................ ................................ ........................... 93 
12.2.2.  Source Document Requirements  ................................ ................................ ................ 93 
12.2.3.  Case Report Form Requirements  ................................ ................................ ................ 93 
12.3.  Audits and Inspections  ................................ ................................ ................................ 93 
12.4.  Study Documentation  ................................ ................................ ................................ .94 
12.4.1.  Certification of Accuracy of Data  ................................ ................................ ...............94 
12.4.2.  Retention of Records  ................................ ................................ ................................ ..94 
13. ETHICAL AND REGULATO RY CONSIDERATIONS  ................................ ..........95 
13.1.  Good Clinical Practice Statement  ................................ ................................ ...............95 
13.2.  Informed Consent  ................................ ................................ ................................ .......95 
13.3.  Patients Confidentiality and Data Protection  ................................ .............................. 96 
13.4.  Institutional Review Board/Ethics Committee  ................................ ........................... 96 
13.5.  Clinical Study Data Transparency  ................................ ................................ ..............97 
14. PROTOCOL AMENDMENTS  ................................ ................................ .................. 97 
15. PREMATURE TERMINATIO N OF THE STUDY OR CL OSE-OUT OF A 
SITE ................................ ................................ ................................ ............................ 97 
15.1.  Premature Termination of the Study  ................................ ................................ ...........97 
15.2.  Close-out of a Site  ................................ ................................ ................................ ......97 
16. CONFIDENTIALITY  ................................ ................................ ................................ 98 
17. FINANCING AND INSURANCE  ................................ ................................ .............98 
18. PUBLICATION POLICY  ................................ ................................ .......................... 98 
19. REFERENCES  ................................ ................................ ................................ ...........99 
                                        VV-RIM-00138022-1.0 Approved - 13 Jan 2021 GMT-5:00
Clinical Study Protocol  R668-AD-1924 Amendment 2  
Regeneron Pharmaceuticals, Inc.  Page 9 of 108 
CONFIDENTIAL  20. INVESTIGATOR’S  AGREEMENT  ................................ ................................ ........102 
 
LIST OF TABLES  
Table 1:  Schedule of Events  ................................ ................................ ................................ .....62 
Table 2: Summary of Primary Estimand for Primary Endpoint  ................................ ...............87 
Table 3: Summary of Primary Estimand for Key Secondary Endpoint  ................................ ....88 
 
LIST OF FIGURES  
Figure 1: Study Flow Diagram  ................................ ................................ ................................ ......45 
 
LIST OF APPENDICES  
APPENDIX  1. HANIFIN AND RAJKA DIAGNOSTIC CRI TERIA FOR ATOPIC 
DERMATITIS – MAJOR A ND MINOR CRITERIA  ................................ .............103 
APPENDIX  2. INVESTIGATOR GLOBAL ASSESSMENT FOR HAND AND 
FOOT ATOPIC DERMATIT IS ................................ ................................ ...............104 
APPENDIX  3. MTLSS: MODIFIED TOTA L LESION SIGN SCORE FOR HAND 
AND FOOT ATOPIC DERM ATITIS ................................ ................................ ......105 
 
                                        VV-RIM-00138022-1.0 Approved - 13 Jan 2021 GMT-5:00
Clinical Study Protocol  R668-AD-1924 Amendment 2  
Regeneron Pharmaceuticals, Inc.  Page 10 of 108 
CONFIDENTIAL  AMENDMENT HISTORY  
Amendment 2  
The key changes implemented in this protocol amendment are a) Modification of the instrument 
used in assessment of primary endpoint (Investigator Global Assessment [IGA] for hands and 
feet) and b) Revision of the patch test series to be used to exclude pat ients with Allergic Contact 
Dermatitis (ACD).  
The following table outlines the changes made to the protocol and the affected sections:  
Description of Change Brief Rationale  Section Number and Name  
IGA Instrument  
Modified the IGA for hands and feet 
instrument .  Major changes made to 
the IGA instrument were as follows : 
•Consistent with atopic
dermatitis  (AD) trials in the
dupilumab program, the revised
IGA instrument now will be
based on an overall impression of
disease severity of the hands and
feet (rather than assessment of
disease severity of individual
hand and foot separately).  The
investigator will be asked to
assign a single score to reflect this
clinical judgment (rather than
rating each i ndividual hand and
foot separately to assign four
separate IGA scores).
•The IGA score has been
de-coupled from the Modified
Total Lesion Sign Score
(mTLSS).  The IGA score will
now be based on a clinical
assessment rather than an
auto-calculation  based upo n
mTLSS score.
•Multiple permutations for
different IGA severity levels have
been removed.  Each IGA
severity is associated with defined
morphological descriptors to
enable clinical interpretability.In response to comments from a 
health authority which had 
requested that the IGA be a 
clinical assessment of overall 
disease severity of hands and 
feet and be easy to  interpret 
clinically.  Appendix  2 Investigator 
Global Assessment for Hand 
and Foot Atopic Dermatitis  
Appendix  3 mTLSS Mo dified 
Total Lesion Sign Sc ore for 
Hand and Foot Atopic 
Dermatitis  (added)  
Section 7.2.1 Inclusion 
Criteria, #3 and #4  
Section 9.2.2.2 Modified Total 
Lesion Sign Score for Han ds 
and Feet 
                                        VV-RIM-00138022-1.0 Approved - 13 Jan 2021 GMT-5:00
Clinical Study Protocol  R668-AD-1924 Amendment 2  
Regeneron Pharmaceuticals, Inc.  Page 11 of 108 
CONFIDENTIAL  Description of Change Brief Rationale  Section Number and Name  
Inclusion Criteria #3 and #4 (related 
to disease severity  and IGA score) 
were revised accordingly to reflect the 
modified IGA scoring methodology.  
Patch Test  
Patch test series to be used in the 
study during screening period to 
exclude patients with ACD were 
changed as follows:  
• In the US, the American Contact 
Dermatitis Society (ACDS) core 
allergen series was changed to the 
TRUE (Thin layer Rapid Use 
Epicutaneous) test . 
• In the EU, the European Baseline 
Series (EBS) was changed to the 
TRUE test along with  an 
additional panel of allergens 
which are missing in the TRUE 
test but are commonly implicated 
in causing ACD of hands and 
feet. 
• In Japan, the patch test panel was 
changed from the Japan standard 
series to the patch test panel (S).  To use an allergen series which 
is approved by regulatory 
agencies in the corresponding 
geographical regions.  Clinical Study  Protocol 
Synopsis, Study Design  
Section 9.2.1.1 Patch Testing  
 
Updated the statistical power from 
>90% to >85% based on the revised 
assumption for treatment effect.  
 The approved TRUE test has 
fewer number of allergens than 
a broader alle rgen panel such as 
ACDS, which is currently 
unapproved in the US.  The 
TRUE test has been reported to 
miss approximately 33% of 
cases with ACD that are 
detected by ACDS.  With the 
use of the TRUE test there is a 
risk that patients with ACD will 
be enrolled  in this trial.  Based 
on the currently available 
clinical and scientific evidence, 
dupilumab is not expected to be 
effective in this patient group.  Clinical Study Protocol 
Synopsis, Statistical Plan  
Section 11.2 Justification of 
Sample Size  
                                        VV-RIM-00138022-1.0 Approved - 13 Jan 2021 GMT-5:00
Clinical Study Protocol  R668-AD-1924 Amendment 2  
Regeneron Pharmaceuticals, Inc.  Page 12 of 108 
CONFIDENTIAL  Description of Change Brief Rationale  Section Number and Name  
Accordingly, the assumption 
for treatment effect was 
lowered for the enrolled 
population, therefore, the power 
calculation was updated.  
Changes Related to Stratification Factors  
Clarified that the number of adult 
patients will be capped at 
approximately 100 to ensure that, at a 
minimum, approximately 
30 adolescents will be enrolled.  In response to comments from a 
health authority. Clinical Study Protocol 
Synopsis, Sample Size  
Section 6 Study Design  
Figure 1 Study Flow Diagram  
Section 7.1 Number of Patients 
Planned 
Section 8.6 Method of 
Treatment Assignment  
Removed randomization stratification 
factor for presence of AD lesions 
outside hands and/or feet (yes/no).  In response to comments from a 
health authority to limit the 
number of stratification factors 
to reduce the risk of having 
cells with small frequenc ies 
within strata.  This decision was 
supported by further 
discussions with external 
experts who concluded that of 
the various stratification factors 
specified in the protocol, this 
one factor was least likely to 
influence response to treatment.  Clinical Study Protocol 
Synopsis, Statistical Plan: 
Analysis Methods  
Section 3.2.1 Rationale for 
Study Design  
Figure 1 Study Flow Diagram  
Section 6.1 Study Description 
and Duration  
Section 8.6 Method of 
Treatment Assignment  
Section 11.4.3.1 Primary 
Efficacy Analysis  
Section 11.4.3.2 Secondary 
Efficacy Analysis  
Specified the stratification factor of 
geographic region is United States 
versus Japan versus other countries.  In response to a health authority 
request. Clinical Study Protocol 
Synopsis, Statistical Plan: 
Analysis Methods  
Section 3.2.1 Rationale for 
Study Design  
Figure 1 Study Flow Diagram  
Section 6.1 Study Description 
and Duration  
                                        VV-RIM-00138022-1.0 Approved - 13 Jan 2021 GMT-5:00
Clinical Study Protocol  R668-AD-1924 Amendment 2  
Regeneron Pharmaceuticals, Inc.  Page 13 of 108 
CONFIDENTIAL  Description of Change Brief Rationale  Section Number and Name  
Section 8.6 Method of 
Treatment Assignment  
Section 11.4.3.1 Primary 
Efficacy Analysis  
Section 11.4.3.2 Secondary 
Efficacy Analysis  
Changes Related to Endpoints  
In the Secondary Endpoints for 
Efficacy, moved the peak Pruritus 
NRS-related endpoints to before the 
mTLSS-related endpoint.  To highlight the importance of 
pruritus endpoints , as pruritus is  
the most important symptom 
from a patient perspective.  Clinical Study Protocol 
Synopsis, Secondary Endpoints 
for Efficacy  
Section 8.4.2 Secondary 
Endpoints  
Proportion of patients with 
NRS 4-point reduction from baseline 
to week 16 was promoted to key 
secondary endpoint.   To highlight the importance of 
pruritus as a major symptom in 
hand and foot AD which is 
highly correlated with patient 
quality of life.  A reduction in 
4 points has previously been 
established as a clinically 
relevant change in patients with 
AD. Clinical Study Protocol 
Synopsis, Secondary Endpoints 
for Efficacy  
Section 4.1.2 Secondary 
Endpoints  
Section 11.4.3.2 Secondary 
Efficacy Analyses  
Changes to Statistica l Analysis Plan  
Removed description of unblinded 
primary analysis of the study from 
Section 6.2 Planned Interim Analysis , 
as the primary analysis is not an 
interim analysis and the description 
already exists in Section 11.5.  
Changed Section 11.5 heading from 
“Interim Analysis” to “Timing and 
Operational Considerations of 
Statistical Analyses” as there is no 
interim analysis.  For consistency and clarity.   Section 6.2 Planned Interim 
Analysis 
Section 11.5 Timing and 
Operational Considerations of 
Statistical Analyses (revised 
heading) 
Specified important protocol 
deviations that will exclude patients 
from the per protocol set (PPS).  In response to a health authority 
request. Clinical Study Protocol 
Synopsis, Statistical Plan: 
Efficacy Analysis Sets  
Section 11.3.1 Efficacy 
Analysis Sets  
                                        VV-RIM-00138022-1.0 Approved - 13 Jan 2021 GMT-5:00
Clinical Study Protocol  R668-AD-1924 Amendment 2  
Regeneron Pharmaceuticals, Inc.  Page 14 of 108 
CONFIDENTIAL  Description of Change Brief Rationale  Section Number and Name  
Added primary estimand definition  
for the primary and key secondary 
efficacy endpoints  based on 
ICH E9 (R1)  To be compliant with 
ICH E9 (R1). Section 11.4.3.1 Primary 
Efficacy Analysis  
Table 2 Summary of Primary 
Estimand for Primary Endpoint 
(added) 
Section 11.4.3.2 Secondary 
Efficacy Analysis  
Table 3 Summary of Primary 
Estimand for Key Secondary  
Endpoint (added) 
Removal of Assessments  
Removed the following assessments 
from the protocol: Dermatology Life 
Quality Index (DLQI), Children’s 
Dermatology Life Quality Index 
(CDLQI), Hospital Anxiety and 
Depression Scale (HADS), Patient 
Oriented Eczema Measure (POEM), 
ophthalmological examination, body 
surface area (BSA) involvement of 
AD, thymus and activation -regulated 
chemokine (TARC), lactate  
dehydrogenase (LDH), 
immunoglobulin E (IgE), optional 
RNA sample, and research samples 
(serum/plasma).  
 
The frequency of vital signs, clinical 
laboratory, PK, and ADA assessments 
was decreased.  
 To reduce patient burden and 
improve overall compliance 
with study 
procedures/assessments.  
 Clinical Study Protocol 
Synopsis, Objectives , 
Endpoints , Procedures and 
Assessments  
Section 2.2 Secondary 
Objectives  
Section 4.1.2 Secondary 
Endpoints  
Section 5.2 Efficacy Variables  
Section 5.5 Pharmacodynamic 
and Other Biomarker Variables  
Section 8.7 Blinding 
Table 1 Schedule of Events  
Section 9.1.1 Footnotes for the 
Schedule of Events  Table, #11, 
#19, and #28 deleted , and #3, 
#4, #14, #21, and #22 revised. 
Footnotes were r enumbered.  
Section 9.2.2.7 Dermatology 
Life Quality Index  (deleted) 
Section 9.2.2.10 Hospital 
Anxiety and Depression Scale  
(deleted) 
Section 9.2.2.13 Patient 
Oriented Eczema Measure  
(deleted) 
                                        VV-RIM-00138022-1.0 Approved - 13 Jan 2021 GMT-5:00
Clinical Study Protocol  R668-AD-1924 Amendment 2  
Regeneron Pharmaceuticals, Inc.  Page 15 of 108 
CONFIDENTIAL  Description of Change Brief Rationale  Section Number and Name  
Section 9.2.2.16 Body Surface 
Area Involvement of Atopic 
Dermatitis (deleted) 
Section 9.2.3.5 
Ophthalmological Examination  
(deleted) 
Section 9.2.6 . 
Pharmacodynamic and 
Exploratory Biomarker 
Procedures  
Section 9.2.7.1 
Pharmacogenomic Analysis 
(Optional)  
Section 11.4.8 Analysis of 
Pharmacodynamic and 
Exploratory Biomarker Data  
(deleted) 
Section 19 References  
COVID-related Changes  
Added footnote * for In -Clinic Visits 
and footnote ** for Laboratory 
Testing in the Schedule of Events 
table, and revised footnote #15 (which 
became #14 with this amendment)  to 
indicate the following, respectively, in 
case of lack of availability of site staff 
and/or patients to come to site for 
in-clinic visits due to COVID -19 
pandemic:  
• Phone visits/virtual 
visits/telemedicine visits/home 
visits by skilled staff should be 
considered for conducting 
certain assessments . 
• Alternate measures may be used 
for clinical lab testing .  
• The sponsor may implement 
processes for direct -to-patient 
shipment of study drug . To mitigate the risk to patient 
safety and data integrity 
resulting f rom COVID -19 
restrictions/lockdowns.  Table 1 Schedule of Events  
Section 9.1.1 Footnotes for the 
Schedule of Events Table, 
footnote * added, footnote ** 
added, footnote #15 (which 
became # 14) revised 
                                        VV-RIM-00138022-1.0 Approved - 13 Jan 2021 GMT-5:00
Clinical Study Protocol  R668-AD-1924 Amendment 2  
Regeneron Pharmaceuticals, Inc.  Page 16 of 108 
CONFIDENTIAL  Description of Change Brief Rationale  Section Number and Name  
Changes Made for Completeness and Clarity  
The definition of patient population 
was corrected to make it consistent 
with the eligibility criteria by 
changing ‘high potency’ to ‘medium -
to-high potency’ TCS, which now 
reads:  “The proposed study 
population is patients with chronic, 
moderate-to-severe hand and foot  AD 
inadequately responsive to 
medium-to-high-potency TCS or in 
whom medium -to-high-potency TCS 
are inadvisable. ” The study population was 
always intended to be patients 
with chronic, 
moderate-to-severe hand and 
foot AD inadequately 
responsive to 
medium-to-high-potency TCS 
from the beginning. The words 
‘medium to’ were 
inadvertently  left out in the 
previous version of the protocol 
in the study population section, 
although the eligibility criteria 
did specify 
medium-to-high-potency TCS.  Clinical Study Protocol 
Synopsis, Population: Target 
Population  
Section 7.2 Study Population  
Added UVB to the list of treatments 
that require a 4 -week washout period 
prior to the patch testing.  Added 
localized PUVA or narrow band UVB 
on hands and/or feet to the list of 
prohibited medications.  For completeness and clarity . Section 7.2.2 Exclusion 
Criteria, #6c 
Section 8.10.1 Prohibited 
Medications and Procedures  
Section 9.2.1.1 Patch Testing  
Added topical and systemic 
JAK inhibitors to prohibited 
medications.  For complete ness and clarity . Section 7.2.2 Exclusion 
Criteria, #8 
Section 8.3 Rescue Treatment  
Section 8.10.1 Prohibited 
Medications and Procedures  
Section 9.2.1.1 Patch Testing  
Added that latex should be avoided.  For completeness and clarity.  Section 8.10.3 Skin Protection 
Measures  
Corrected footnote designation in the 
Schedule of Events for “Optional 
DNA, RNA sample” from #3 to #4.  
Separated the “Optional DNA and 
RNA sample” into 2 separate rows. Correction of a typo.  Table 1 Schedule of Events  
Section 9.1.1 Footnotes for the 
Schedule of Events  
Added eCOA instruments, eDiaries, 
and tablet devices for For completeness.  Section 12.1.2 Electronic 
Systems 
                                        VV-RIM-00138022-1.0 Approved - 13 Jan 2021 GMT-5:00
Clinical Study Protocol  R668-AD-1924 Amendment 2  
Regeneron Pharmaceuticals, Inc.  Page 17 of 108 
CONFIDENTIAL  Description of Change Brief Rationale  Section Number and Name  
collecting/recording some of the 
efficacy assessment data.  
                                        VV-RIM-00138022-1.0 Approved - 13 Jan 2021 GMT-5:00
Clinical Study Protocol  R668-AD-1924 Amendment 2  
Regeneron Pharmaceuticals, Inc.  Page 18 of 108 
CONFIDENTIAL  Amendment 1  
The following table outlines the changes made to the protocol and the affected sections:  
Change Section Changed  
Added information regarding the “Coronavirus Disease 
2019” (COVID -19) pandemic and its impact on clinical 
trials. Section 3.3  Risk-Benefit 
Section 9.1 Schedule of Events 
Section 11 Statistical Plan  
Details were added regarding injection sites.  Section 8.1  Investigational and Reference 
Treatments  
Added instruments for IGA and Modified Total Lesion 
Sign Score (mTLSS). These instruments incorporate the 
written feedba ck received from a health authority.  Section 9.2.2.1  Investigator Global Assessment 
of Hand and Foot  
Section 9.2.2.2  Modified Total Lesion Sign 
Score for Hands and Feet  
Appendix 2  Modified Total Lesion Sign Score 
and Investigator Global Assessment  
Added statement that a responder threshold (currently 
unknown) for mTLSS in the study population will be 
determined using data gathered from this study.  
Analyses using this responder threshold will be 
conducted to help interpretation of the prespecified 
endpoints for the mTLSS. The methodology to be used 
for determining this responder threshold and the analyses 
will be specified in the SAP.  Section 9.2.2.2  Modified Total Lesion Sign 
Score for Hands and Feet  
 
Added major criteria for the Hanifin and Rajka 
Diagnostic Criteria for AD.  Appendix 1 Hanifin and Rajka Diagnostic 
Criteria for Atopic Dermatitis - Major and Minor 
Criteria 
                                        VV-RIM-00138022-1.0 Approved - 13 Jan 2021 GMT-5:00
Clinical Study Protocol  R668-AD-1924 Amendment 2  
Regeneron Pharmaceuticals, Inc.  Page 19 of 108 
CONFIDENTIAL  Change Section Changed  
Removed randomization stratification factor for disease 
morphology and added stratification for geographic 
region (pooled countries set by interactive voice response 
system/interactive web response system [IVRS/IWRS]).  
Sub-group analysis for treatment effect in patients with 
hands only involvement vs involvement of hands and feet 
or feet only were requested by the health authority. The 
number of patients with hands only involvement will be 
capped at approximately 100.  
In parallel, the stratification factor for disease 
morphology was removed to limit the total number of 
factors. On further discussions with external experts, it 
was felt that  disease morphology should not impact 
response to treatment with study drug. Furthermore, data 
from a prospective observational study with dupilumab 
in patients with AD of hands suggests that disease 
morphology does not impact response to treatment.  Clinical Study Protocol Synopsis : Population , 
Statistical Plans  
Section 3.2.1  Rationale for Study Design  
Section 6 Study Design  
Section 6.1 Study Description and Duration  
Figure 1 Study Flow Diagram  
Section 7.1  Number of Patients Planned  
Section 8.6  Method of Treatment Assignment  
Section 11.4.3.1  Primary Efficacy Analysis  
Section 11.4.3.2  Secondary Efficacy Analysis  
                                        VV-RIM-00138022-1.0 Approved - 13 Jan 2021 GMT-5:00
Clinical Study Protocol  R668-AD-1924 Amendment 2  
Regeneron Pharmaceuticals, Inc.  Page 20 of 108 
CONFIDENTIAL  Change Section Changed  
Changed inclusion criterion #2 to:  Patients with chronic 
hand and/or foot dermatitis diagnosed at least 3 years 
prior to the screening visit for patients ≥18 years old and 
at least 1 year prior to the screening visit for patients 12 
to <18 years old. Previously, this criterion was:  Pa tients 
with chronic hand and/or foot dermatitis diagnosed at 
least 6 months prior to the screening visit.  
This modification will ensure that the disease duration to 
define chronicity is consistent with that used in the 
dupilumab phase 3 global AD trials an d allow sufficient 
time to demonstrate inadequate response to the current 
standard-of-care (topical corticosteroids) for hand and 
foot dermatitis.  
Added inclusion criteria:  Patients with involvement of at 
least 2 anatomical areas with moderate to severe d isease 
(IGA score of 3 or 4, separately for 2 anatomical areas) 
at screening and baseline (both hands, one hand and one 
foot, or both feet) AND Patients need to have an overall 
IGA hand and foot or hand or foot   score of 3 or 4 at 
screening and baseline.  
This will ensure that patients will have extent of disease 
that is sufficient to justify treatment with a biologic.  
Added clarification to criterion #5 regarding inadequate 
AD treatment response to topical medications.  
Added inclusion criterion #9: Treatme nt with an 
investigational drug within 8 weeks or within 5 half -lives 
(if known), whichever is longer, before the baseline visit.  Section 7.2.1  Inclusion Criteria, # 2, #3, #4, #5, 
#9 
                                        VV-RIM-00138022-1.0 Approved - 13 Jan 2021 GMT-5:00
Clinical Study Protocol  R668-AD-1924 Amendment 2  
Regeneron Pharmaceuticals, Inc.  Page 21 of 108 
CONFIDENTIAL  Change Section Changed  
Added a note that patients with a documented diagnosis 
of allergic contact dermatitis of hands and/or feet, who 
have a positive patch test reaction at screening will also 
be excluded fr om the study, regardless of whether history 
of current skin exposure to products containing this 
allergen (current relevance) is present.  
Previously, only patients with a clinically relevant 
positive patch test were excluded from the trial; clinical 
relevance to positive patch testing was based upon 
reporting of exposure to allergen by the patient. 
However, patients might not be able to recall such 
exposure leading to failure to exclude patients whose 
hand and foot dermatitis is caused by allergic contact 
dermatitis, rather than AD.  
Added exclusion criterion: Patients with a known 
diagnosis of protein contact dermatitis of hands and/or 
feet. These are patients with occupational or non -
occupational contact to proteins such as food (eg, wheat, 
milk, fish), la tex etc. with positive prick test who present 
with lesions of contact urticaria or dermatitis on 
hands/feet.  
Patients with protein contact dermatitis are spelled out 
separately from the broad group of allergic contact 
dermatitis as these patients typically have a negative 
patch test. Patients with protein contact dermatitis are not 
expected to benefit from the st udy drug based upon the 
available scientific and clinical evidence.  The study 
population has been limited to patients with AD of hand 
and foot.   
For clarification, combined exclusion criteria #s 2 and 3 
regarding exposure to irritants.  Added guidelines to be 
used in screening to evaluate patient exposure to irritants.  Section 7.2.2  Exclusion Criteria, # 1, #2, #3, #4, 
#13 
                                        VV-RIM-00138022-1.0 Approved - 13 Jan 2021 GMT-5:00
Clinical Study Protocol  R668-AD-1924 Amendment 2  
Regeneron Pharmaceuticals, Inc.  Page 22 of 108 
CONFIDENTIAL  Change Section Changed  
Added further text to skin protection measures. Added a 
row ‘skin protection measures’ to the Schedule of events.  
Also added the following inclusion criterion:  Patients 
need to have been compliant with the skin protection 
measures (as outlined in Section  8.10.3) through the 
entire duration of the screening period (minimum of 4 
weeks but lasting to a maximum of 8 weeks).  This 
includes avoidance of irritants that are identified as 
causing exacerbation of hand and foot AD.   
These additions will ensure that  patients whose disease 
can be managed by simple skin protection measures are 
not un-necessarily enrolled in a clinical trial with a 
biologic. Moreover, compliance with these skin 
protection procedures throughout the duration of the trial 
will prevent conf ounding of effect of study drug.  Section 7.2.1  Inclusion Criteria, # 12 
Section 6.1  Study Description and Duration  
Section 8.10.3  Skin Protection Measures  
Table 1 Schedule of Events  
Reduced the frequency of assessments for patient -
reported outcome measures to reduce patient burden and 
increase compliance.  
Added rows for ‘assign disease morphology’ and ‘assign 
anatomical area of involvement’ to the Schedule of 
Events as these were ina dvertently omitted in the original 
protocol.  Added footnotes to provide details for these 
assessments.  Table 1 Schedule of Events  
Section 9.1.1  Footnotes for the Schedule of 
Events, #9, #10 
Added a sentence in protocol and corresponding row in 
the Schedule of Events that detailed history of exposure 
to irritants in occupational as well as non -occupational 
setting will be elicited to rule out irritant hand and foot 
dermatitis.  This will lead  to informed avoidance of such 
irritants during the screening period and will ensure that 
patients whose disease can be managed by simply 
avoiding irritants are not un -necessarily enrolled in a 
clinical trial with a biologic.  Table 1 Schedule of Events  
Section 9.2.1  Procedures Performed Only at 
the Screening/Baseline Visit  
                                        VV-RIM-00138022-1.0 Approved - 13 Jan 2021 GMT-5:00
Clinical Study Protocol  R668-AD-1924 Amendment 2  
Regeneron Pharmaceuticals, Inc.  Page 23 of 108 
CONFIDENTIAL  Change Section Changed  
Added a window for the second reading for patch test: 
day 3-day 7 assessment (previously only allowed at day 
4). This will provide more flexibility to sites to schedule 
in-patient cli nic visits as per patient convenience.  
Removed the extended European baseline series for 
contact allergens for patch testing and changed it to the 
European baseline series as the testing concentration for 
certain allergens in extended EU baseline series h as not 
been finalized.  
Removed North American Contact Dermatitis Group 
(NACDG) patch test series. as the sponsor is having 
difficulty in sourcing this patch test series.  
A Japan specific patch test series (Patch test panel S) was 
added. 
Added the Austral ian baseline series in Australia.  Table 1 Schedule of Events  
Section 9.1.1  Footnotes for the Schedule of 
Events, #7 
Section 9.2.1.1  Patch Testing  
Removed Pruritus Categorical Scale to reduce patient 
burden.  Section 9.2.2.4 Hand and Foot Pruritus 
Categorical Scale – section removed from 
protocol body  
Added Work Productivity and Activity Impairment plus 
Classroom Impairment Questionnaire (WPAI+CIQ) and 
removed the assessment of missed work/school days.  Clinical Study Protocol Synopsis : Endpoints , 
Study Procedures and Assessments  
Section 4.1.2  Secondary Endpoints  
Section 5.2  Efficacy Variables  
Table 1 Schedule of Events  
Section 9.2.2.19  Work Productivity and 
Activity Impairment Plus Classroom 
Impairment Questions  
Section 9.2.2.11  Assessment of Missed 
Work/School Days – section removed from 
protocol body  
                                        VV-RIM-00138022-1.0 Approved - 13 Jan 2021 GMT-5:00
Clinical Study Protocol  R668-AD-1924 Amendment 2  
Regeneron Pharmaceuticals, Inc.  Page 24 of 108 
CONFIDENTIAL  Change Section Changed  
Made the following clarifications:  
• Details were added regarding moisturizers.  
• Specified that data from patients who receive 
rescue treatment as per adjudication during the 
study will be treated for efficacy analysis 
purposes as outlined in Section 11.4.3.  
• Clarified criteria for temporary discontinuation 
to ALT or AST >3 times ULN.  
• Clarified in the Schedule of Events and 
procedures that vital signs at baseline week 2 and 
week 4 will be done additionally at 30 minutes 
post-injection. 
• Added details regarding research samples and 
future biomed ical research (FBR) samples.  
• Changed heart rate to pulse rate under vital signs 
assessment.  
• Removed alcohol and drug screens.  
• Changed Patient Global Assessment of Disease 
(PGAD) to Patient Global Impression of 
Severity (PGIS) and Patient Global Assessment 
of Treatment (PGAT) to Patient Global 
Impression of Change (PGIC) and corrected the 
description to make it specific for hand and foot 
AD. 
• Added sections to describe the Patient Oriented 
Eczema Measure (POEM) and Body Surface 
Area (BSA) involvement of AD to  match 
assessments in the Schedule of Events.  
• Specified that the Eczema Area and Severity 
Index (EASI) and Investigator’s Global 
Assessment (IGA) will only be performed in 
patients who have AD lesions outside their hands 
and feet. Clinical Study Protocol Synopsis:  Procedures 
and Assessments  
Section 8.2  Background Treatment  
Section 8.3  Rescue Treatment  
Section 8.4.2.2  Reasons for Temporary 
Discontinuation of Study Drug  
Table 1 Schedule of Events  
Section 9.1.1  Footnotes for the Schedule of 
Events, #11, #21, and #28 
Section 9.2.2.7  Patient Global Impression of 
Severity  
Section 9.2.2.8  Patient Global Impression of 
Change   
Section 9.2.2.10  Quality of Life in Hand 
Eczema Questionnaire  
Section 9.2.2.13 Patient Oriented Eczema 
Measure 
Section 9.2.2.14 Eczema Area and Severity 
Index 
Section 9.2.2.15 Investigator’s Global 
Assessment  
Section 9.2.2.16  Body Surface Area 
Involvement of AD  
Section 9.2.3.1  Vital Signs  
Section 9.2.3.4 Laboratory Testing  
Corrected minor typographical and formatting issues.  Throughout protocol.  
                                        VV-RIM-00138022-1.0 Approved - 13 Jan 2021 GMT-5:00
Clinical Study Protocol  R668-AD-1924 Amendment 2  
Regeneron Pharmaceuticals, Inc.  Page 25 of 108 
CONFIDENTIAL  CLINICAL STUDY PROTOCOL SYNOP SIS  
Title A Multicenter, Randomized, Double -Blind, Placebo -Controlled, Parallel -
Group Study to Evaluate the Efficacy and Safety of Dupilumab in Adult and 
Adolescent Patients with Moderate -to-Severe Atopic Hand and Foot 
Dermatitis  
Site Locations  
 Principal Investigator  This is a global, multicenter study.  
To be determined  
Objectives  The primary objective  of the study is to assess the efficacy of dupilumab 
on skin lesions in patients with atopic hand and foot dermatitis.  
The secondary objectives  of the study are:  
• To assess the efficacy of dupilumab on various other domains 
(pruritus, pain, sleep loss, health related quality of life (QoL), work 
life impairment) in patients with atopic hand and foot dermatitis  
• To evaluate the safety and t olerability of dupilumab administered 
to patients with atopic hand and foot dermatitis  
• To evaluate systemic exposure and immunogenicity of dupilumab 
in patients with atopic hand and foot dermatitis  
The exploratory objectives  of the study are:  
• To study dupilumab’s mechanism of action (related to efficacy 
and/or safety), why some patients respond better than others (safety 
and/or efficacy), IL4R pathway, atopic hand and foot dermatitis 
and related diseases  
• To assess the concordance between treatment effec t of dupilumab 
on a) atopic hand and foot dermatitis lesions and b) concomitant 
AD lesions on other parts of the body  
• To evaluate exposure -response relationships  
Study Design  This is a global, multicenter, randomized, double -blind, parallel -group, 
placebo-controlled study investigating the efficacy and safety of dupilumab 
monotherapy in adult and adolescent patients with moderate -to-severe 
atopic hand and foot dermatitis as defined by a specific Investigator Global 
Assessment (IGA) assessment focused on th ese areas of the body.  Eligible 
patients must have a documented history of inadequate response or 
intolerance to treatment of hand and foot dermatitis with topical AD 
medications.  
At the screening visit, adult patients will provide informed consent before  
any other study procedures are conducted.  For adolescent patients, parents 
or legal guardians will provide informed consent and the patients will 
provide assent.  After providing informed consent/assent, the patients will 
                                        VV-RIM-00138022-1.0 Approved - 13 Jan 2021 GMT-5:00
Clinical Study Protocol  R668-AD-1924 Amendment 2  
Regeneron Pharmaceuticals, Inc.  Page 26 of 108 
CONFIDENTIAL  be assessed for study eligibilit y at the screening visit.  During the screening 
period, systemic treatments for AD will be washed out, as applicable, 
according to the eligibility requirements.  Topical treatments for AD of 
hands and feet will also be washed out, according to the eligibil ity 
requirements.  However, patients will be allowed to use topical treatments 
for treatment of AD on other parts of the body with certain restrictions.  
Patients may be re -screened once if they fail the screening evaluation for 
reasons related to incidenta l transitory conditions, unless the reason for the 
screen failure is related to failing the disease severity inclusion criteria.  
Patch testing with a standard series of allergens will also be carried out 
during the screening period to exclude patients with predominantly allergic 
contact dermatitis (ACD) of hand and foot.  The standard series used will 
vary based upon the region of conduct of the study.  Examples  of the 
country-specific series based on countries the study is conducted include 
TRUE test for US, TRUE test and an additional panel of allergens which are 
missing in TRUE test but are commonly implicated in causing ACD of 
hands and feet for patients in the EU, and patch test panel (S) for Japan.  
Patients will need to be discontinued from topical/systemic medications for 
AD prior to the patch testing.  
Patients who meet the eligibility criteria will be randomized (1:1) to 
dupilumab subcutaneously (SC) ever y 2 weeks (Q2W) or matching placebo 
(see details of dosing regimens in the Treatments section).  
During the treatment period, patients will have in -clinic visits at week  2 and 
week 4, and then in -clinic visits every 4 weeks (Q4W) through week 16 with 
bi-weekly phone visits in between the in -clinic visits.  Patients and/or 
parents/caregivers will be trained on injecting study drug during in -clinic 
visit 2 (day 1) to visit 6 (week 4).  During weeks in which no in -clinic visit 
is scheduled, patients will either  self-inject study drug or the 
parent/caregiver will administer study drug to the patient.  In case patients 
do not want to self -inject and the parents/caregivers do not want to 
administer study drug to patient, patients may have the clinic  staff 
administe r all the study drug injections in the clinic.  Safety laboratory tests, 
collection of samples for study drug concentrations and immunogenicity, 
and clinical assessments will be performed at specified clinic visits.  
The end of treatment visit will occur at  week 16, 2 weeks after the last dose 
of study drug.  The primary endpoint will be assessed at this visit.  If patients 
prematurely discontinue study drug, the patients will be encouraged to stay 
in the study to have data collected at all remaining schedul ed visits until 
completion of the planned end of study visit.  
Post-treatment follow -up period: Upon completing the 16 -weeks 
randomized treatment period, patients will enter a 12 -week follow -up 
period.  The end of study visit will occur at week 28.  
                                        VV-RIM-00138022-1.0 Approved - 13 Jan 2021 GMT-5:00
Clinical Study Protocol  R668-AD-1924 Amendment 2  
Regeneron Pharmaceuticals, Inc.  Page 27 of 108 
CONFIDENTIAL  Study Duration The duration of the study for each patient is approximately 28 weeks, 
excluding the screening period.  
End of Study Definition  The end of study is defined as the date of the last visit of the last patient in 
the study.  
Population   
 Sample Size:  Approximately 130 patients (65 patients per arm) will be enrolled at 
approximately 50 global sites.  The number of adult patients will be capped 
at approximately 100 to ensure that, at a minimum, approximately 
30 adolescents will be enrolled.  The number o f patients with hands only 
involvement will be capped at approximately 100.  
 Target Population:  The proposed study population is patients with chronic, moderate -to-severe 
atopic hand and foot dermatitis inadequately responsive to 
medium-to-high-potency topical corticosteroids (TCS) or in whom 
medium-to-high-potency TCS are inadvisable.  Only patients meeting the 
diagnostic criteria for AD will be included in this study.  Patients with a 
confirmed diagnosis of irritant contact dermatitis or ACD as the 
predominant cause of hand and foot dermatitis will be excluded from the 
study. 
Treatments   
 Study Drug  
 Dose/Route/Schedule:  • Dupilumab, administered SC Q2W  
− In adults: dupilumab 300 mg, after a loading dose of 600 mg on 
day 1, irrespective of body weight  
− In adolescents: Body weight ≥60 kg, dupilumab 300 mg, after a 
loading dose of 600 mg on day 1, body weight <60 kg, dupilumab 
200 mg, after a loading dose of 400 mg on day 1  
 Placebo 
 Route/Schedule:  • Matching placebo, administered SC Q2W  
Endpoints   
 Primary:  • Proportion of patients achieving an IGA (hand and foot) score of 0 or 1 
at week 16  
 Secondary:  Key Secondary Endpoint for Efficacy:  
• Proportion of patients with improvement (reduction) of weekly average 
of daily hand and foot peak Pruritus NRS ≥4 from baseline to week 16  
                                        VV-RIM-00138022-1.0 Approved - 13 Jan 2021 GMT-5:00
Clinical Study Protocol  R668-AD-1924 Amendment 2  
Regeneron Pharmaceuticals, Inc.  Page 28 of 108 
CONFIDENTIAL  Secondary Endpoints for Efficacy:  
• Proportion of patients with improvement (reduction) of weekly average 
of daily hand and foot peak Pruritus Numeric Rating Scale (NRS) ≥3 
from baseline to week 16  
• Percent change from baseline to wee k 16 in weekly average of daily 
hand and foot peak Pruritus NRS  
• Percent change in Modified Total Lesion Sign Score (mTLSS) for 
hand/foot lesions from baseline to week 16  
• Percent change from baseline to week 16 in weekly average of daily 
hand and foot peak  Pain NRS  
• Percent change from baseline to week 16 in weekly average of daily 
Sleep NRS  
• Change from baseline to week 16 in percent surface area of hand and 
foot involvement with AD  
• Percent change from baseline to week 4 in weekly average of daily hand 
and foot peak Pruritus NRS  
• Proportion of patients with improvement (reduction) of weekly average 
of daily hand and foot peak Pruritus NRS ≥4 from baseline to week 4  
• For patients with hand dermatitis, percent change from baseline to week 
16 in Hand Eczema Severi ty Index (HECSI) score  
• For patients with hand dermatitis, proportion of patients with HECSI -
75 at week 16  
• For patients with hand dermatitis, proportion of patients with HECSI -
50 at week 16  
• For patients with hand dermatitis, proportion of patients with HEC SI-
90 at week 16  
• For patients with hand dermatitis, change from baseline to week 16 in 
Quality of Life in Hand Eczema Questionnaire (QOLHEQ)  
• Change from baseline to week 16 in Work Productivity and 
Impairment (WPAI) and Classroom Impairment Questionnaire ( CIQ) 
Secondary Endpoints for Safety:  
• Incidence of treatment -emergent adverse events (TEAEs) through 
week 16 
Secondary Endpoints for Clinical Pharmacology and Immunogenicity:  
• Trough concentration of functional dupilumab in serum at various time 
points 
                                        VV-RIM-00138022-1.0 Approved - 13 Jan 2021 GMT-5:00
Clinical Study Protocol  R668-AD-1924 Amendment 2  
Regeneron Pharmaceuticals, Inc.  Page 29 of 108 
CONFIDENTIAL  • Incidence of treatment -emergent anti -drug antibodies (ADA) over time  
Procedures and Assessments  Efficacy will be assessed during the study at specified clinic visits using 
patient reported assessments (including Daily hand and foot peak Pruritus 
NRS, Dail y hand and foot peak Pain NRS, Daily Sleep NRS, QOLHEQ, 
Patient Global Impression of Severity [PGIS], Patient Global Impression of 
Change [PGIC], EQ -5D, WPAI+CIQ) and investigator -reported 
assessments (including IGA for hands and feet, mTLSS, percent surfa ce area 
of hand and foot involvement with AD, HECSI, IGA [ global], and Eczema 
Area and Severity Index [EASI]).  Safety will be assessed by vital signs, 
physical examinations, clinical laboratory tests, and clinical evaluations.  
Patients will be asked to m onitor all adverse events (AEs) experienced from 
the time of informed consent/assent until their last study visit.  Laboratory 
testing will include hematology, blood chemistry, urinalysis, pregnancy 
testing, human immunodeficiency virus (HIV), hepatitis B surface antigen 
(HBsAg), hepatitis B surface antibody (HBsAb), hepatitis B core antibody 
(HBcAb), hepatitis C antibody (Hep C Ab), tuberculosis (TB), DNA.  
Samples for drug concentration and ADA assay  will be collected.   
Statistical Plan  The planned sample size is approximately 130 patients (65 patients in each 
treatment arm).  This sample size will yield >85% power to detect a 
treatment difference of 24% in the proportion of patients achieving 
IGA hand and foot (0, 1) at week 16 between placebo (10%) and dupilumab 
(34%) at a 2 -sided significant level of 5% using Chi -square test and 
assuming a dropout rate of 10%. The assumed treatment difference of 24% 
is based on the effect of 26% observed in dupilumab phase 3 monotherapy 
studies in adul t patients with AD, and adjusted to account for the potential 
inclusion of some patients with ACD who would be missed with certain 
patch testing (ie ,, TRUE test) at screening. It is reasonable to assume that 
the effect size of dupilumab on AD of hands and feet would be similar to 
that seen in in previously conducted phase 3 trials in generalized AD, as the 
underlying pathophysiology is the same. Moreover, a recent observational 
study to compare the effect of dupilumab on hand lesions vs. lesions on other 
parts of the body found a high degree of concordance in terms of onset of 
effect and overall effect at week 16 .  
Efficacy Analysis Sets  
The full analysis set (FAS) includes all randomized patients.  Efficacy 
analyses will be based on the treatment allocated at randomization (as 
randomized).  
The per protocol set (PPS) includes all patients in the FAS except for those 
who are excluded because of specified important protocol  deviations.  
                                        VV-RIM-00138022-1.0 Approved - 13 Jan 2021 GMT-5:00
Clinical Study Protocol  R668-AD-1924 Amendment 2  
Regeneron Pharmaceuticals, Inc.  Page 30 of 108 
CONFIDENTIAL  All efficacy variables will be evaluated on the FAS; the primary endpoint 
will also be evaluated on the PPS.  Analysis on the FAS will be considered 
to be primary.  
Safety Analysis Set  
The safety analysis set (SAF) includes all randomized patients who received 
any study drug; it is based on the treatment received (as treated).  Tre atment 
compliance/administration and all clinical safety variables will be analyzed 
using the SAF.  
Pharmacokinetic Analysis Sets  
The PK analysis population includes all patients/subjects who received any 
study drug and who had a at least 1 non -missing resu lt following the first 
dose of study drug.  
Immunogenicity Analysis Sets  
The ADA analysis set includes all patients who received any study drug and 
had at least 1 non -missing ADA result following the first study dose.  
The neutralizing antibody (NAb) analysis set includes all patients who 
received any study drug and who are negative in the ADA assay or with at 
least 1 non -missing result in the NAb assay (patients who are ADA negative 
are set to negative in the NAb analysis set).  
Analysis Methods:  
Primary Efficacy Analyses  
The primary endpoint of proportion of patients achieving an IGA score of 0 
or 1 on hand and foot at week 16 will be analyzed using the Cochran -Mantel-
Haenszel (CMH) test to assess the difference in the proportion of responders 
in the FAS adjusting for the randomization stratification factors (age [adults 
vs. adolescents], disease severity of IGA hand and foot [3 vs. 4 ], and 
geographic region [United States versus Japan versus other countries] ).  
To account for use of rescue treatment, patients will be considered as 
non-responders for all time points subsequent to the use of rescue treatment 
in the primary analysis.  If a patient has  missing value with any reason for 
IGA on hand and foot assessment at week 16, the patient will be classif ied 
as a non-responder at week 16.  
Sensitivity analysis using the last observation carried forward (LOCF) 
approach or the worst observation carried forward (WOCF) approach to 
determine patient’s status at week 16 will be conducted to assess the 
robustness  of the primary efficacy analysis with regards to handling of 
missing data.  The efficacy data will be set to missing after rescue treatment 
is used, then the LOCF or WOCF method will be used to determine patients’ 
status at week 16.  
                                        VV-RIM-00138022-1.0 Approved - 13 Jan 2021 GMT-5:00
Clinical Study Protocol  R668-AD-1924 Amendment 2  
Regeneron Pharmaceuticals, Inc.  Page 31 of 108 
CONFIDENTIAL  In addition, the CMH method adjusted by randomization strata will also be 
performed on all observed data regardless if rescue treatment is used.  A 
patient with missing data will be counted as a non -responder.  Other 
sensitivity analyses may be conducted.  
Subgroup analysis (eg , by age group, by anatomical area of involvement 
[hand involvement only vs. involvement of hand and foot or foot 
involvement only]) will also be performed.  
Secondary Efficacy Analyses  
Secondary efficacy endpoints that measure binary responses (eg, 
improvement of weekly average of daily peak Pruritus NRS ≥4 from 
baseline to week 16) will be analyzed in the same fashion as the primary 
analysis. 
Continuous secondary efficacy endpoints (eg, percent change mTLSS for 
hand/foot lesions from baseline to week 16) w ill be analyzed using an 
analysis of covariance (ANCOVA) model for the FAS with treatment group, 
randomization stratification factors (age [adults vs. adolescents], disease 
severity of IGA hand and foot [3 vs. 4], and geographic region [United States 
versus Japan versus other countries]), and relevant baseline measurement 
included in the model.  Similarly, to account for the impact of rescue 
treatment on the efficacy effect, patients' efficacy data through week  16 after 
the rescue treatment use will be set to missing.  The missing data for 
continuous endpoints will be imputed by the pattern -mixture approach 
where the WOCF approach will be used for the missing due to rescue 
treatment, AE, and lack of efficacy and the multiple imputation (MI) 
approach will be used for the missing due to other reasons.  The MI 
Statistical Analysis Software (SAS) procedure with Markov Monte Carlo 
algorithm will be applied in the MI for multiple times.  The complete 
datasets created based on the pattern -mixture approach will be an alyzed 
using the ANCOVA model defined previously, and the SAS MIANALYZE 
procedure will be used to generate valid statistical inferences by combining 
results from these multiple analyses using Rubin’s formula.  
All efficacy data will be used for analysis reg ardless of whether the patient 
is on study treatment or discontinues the study treatment but remains in the 
study.  In addition, the MI with the ANCOVA model and the ANCOVA 
model based on LOCF or WOCF imputation method will be performed as 
sensitivity anal yses.  Other sensitivity analysis such as the MI approach with 
ANCOVA model on all observed data regardless of rescue treatment use 
will also be conducted.  Additional details on sensitivity analyses will be 
provided in the SAP.  
Control of Multiplicity  
                                        VV-RIM-00138022-1.0 Approved - 13 Jan 2021 GMT-5:00
Clinical Study Protocol  R668-AD-1924 Amendment 2  
Regeneron Pharmaceuticals, Inc.  Page 32 of 108 
CONFIDENTIAL  Type I error rate will be controlled using a hierarchical testing procedure for 
the primary and secondary efficacy endpoints at the 2 -sided 0.05 level.  The 
hierarchy order will be specified in the SAP prior to database lock.  
Safety Analysis  
Safety analysis w ill be based on the SAF.  This includes reported TEAEs, 
AESIs, and other safety information (eg, clinical laboratory evaluations, 
vital signs).  A summary of safety results for each treatment group will be 
presented.  
                                        VV-RIM-00138022-1.0 Approved - 13 Jan 2021 GMT-5:00
Clinical Study Protocol  R668-AD-1924 Amendment 2  
Regeneron Pharmaceuticals, Inc.  Page 33 of 108 
CONFIDENTIAL  1. INTRODUCTION  
Hand and foot dermatitis is an umbrella term that includes irritant contact dermatitis (ICD), allergic 
contact dermatitis (ACD) and patients with a history of, or presence of concurrent atopic dermatitis 
(AD), which is also known as atopic hand and foot dermatitis ( Agner, 2015 ).  The morphological 
types that have been described in this condition include the following: vesicular (dyshidrotic), 
hyperkeratotic, fissured, and nummular (Menne, 2011 ). 
Patients with AD a re at increased risk of hand dermatitis of any etiology as compared to the general 
population with a 3 to 4 -fold increase of prevalence as compared to controls ( Ruff, 2018 ).  The 
prevalence of hand dermatitis in patients with AD has been reported to be approximately 60% 
(Simpson, 2006 ).  Similarly, the prevalence of foot dermatitis in patients with AD has been 
reported to be approximately 30% ( Holm, 2016 ).  Atopic dermatitis is a known risk factor for 
development of hand dermatitis with approximately 28% of patients with hand dermatitis having 
a history of AD (Petersen, 2014 ).  Similarly, a history of AD is present in approxi mately 14% of 
patients with foot dermatitis ( Agner, 2015 ).  Atopic conditions apart from AD, such as allergic 
rhinitis and asthma, have also been associated with atopic hand and foot dermatitis 
(Scalone, 2015). 
Atopic hands and feet dermatitis (also known as atopic hand and foot eczema)1 presents with 
redness, infiltration, scaling, vesicles, areas of hyperkeratosis, and cracks (fissures) 
(Coenraads  2012).  Lesions are associated with significant itching and pain.  The morphology 
tends to evolve over time and many patients can have a mixed presentation.  In the majority of 
patients, the same morphological subtype is found on the hands and feet ( Brans, 2015 ).  
The disease tends to be chronic and recalcitrant with a substantial impact on quality of life (QoL), 
comparable with other skin diseases like psoriasis ( Agner, 2008 ).  Chronic hand der matitis has 
also been associated with significant detrimental effect on work productivity, activity impairment, 
and heath care costs ( Fowler, 2006 ).  It has been shown that 65% of patients with severe hand 
dermatitis repor ted loss of productivity at work, with an average of 10.1 days per patient per month 
(Politiek, 2016 ).  Moreover, in certain occupations like hairdressers, bakers, and machine workers, 
up to 18% of patients had to change jobs due to hand dermatitis  (Meding, 2005 ). 
Atopic hand and foot dermatitis has the same underlying pathophysiology as in other parts of the 
body and is caused by a complex interaction of genetics, defects in skin barrier  function, 
environmental exposure to irritants, and immunologic responses.  In addition, it has been suggested 
that abnormal cholinergic responses in the form of palmar and plantar hyperhidrosis specifically 
contribute to the development of H -F dermatitis of AD (Lee, 2001 ) Type 2 helper T cell (Th2) 
mediated immune response is believed to play a central role in the pathogenesis of AD, including 
that of hands and feet.  The skin lesions of AD are characterized by increased expression of 
proinflammation type 2 cytokines, such as interleukin (IL) -4 and IL-13, and by skin infiltration of 
Th2 and other inflammatory cells.  The elevated immunoglobulin E (IgE) responses and 
eosinophilia observed in the majority of patients with AD  reflects an increased expression of the 
type 2 cytokines IL -4 and IL-13 (Leung, 1999 )  
                                                 
1 For the purpose of this protocol, atopic hands and feet dermatitis refers to involvement of either hands only, feet 
only, or both hands and feet.    
                                        VV-RIM-00138022-1.0 Approved - 13 Jan 2021 GMT-5:00
Clinical Study Protocol  R668-AD-1924 Amendment 2  
Regeneron Pharmaceuticals, Inc.  Page 34 of 108 
CONFIDENTIAL  The other 2 major causes for hand and foot dermatitis, apart from AD, are ICD and ACD.  It should 
be noted that the morphological pre sentation of all these etiologies can be very similar, and it is 
hard to delineate the etiology just based on clinical examination.  Recently there has been a trend 
to obtain further disease classification in hand and foot dermatitis to focus on etiology r ather than 
morphology as this approach offers the advantage of targeting prevention and, in some cases, also 
providing more specific treatment (Johansen, 2011 ).  These 2 forms of dermatitis are unlike AD; 
these forms are not primarily driven by type 2 immune responses (Gittler, 2013 ). 
The management of AD of hand and foot is based upon prevention and avoidance strategies using 
gloves, reducing exposure to irritants and regular use of emoll ients.  Step therapy is used with an 
approach to initiate treatment with topicals and then progress to systemics in case of inadequate 
response to topicals (Diepgen, 2007 ).  Short courses of topical corticosteroids (TCS) are 
recommended as first line treatment to control flares.  Long term application of TCS comes with 
risk of skin atrophy, dyspigmentation, acneiform eruptions, and risks associated with systemic 
absorption (eg, growth retardation, hypothalamic -pituitary axis effects, etc).  Treatment guidelines 
for hand dermatitis of any etiology recommend continuous long -term treatment beyond 6 weeks 
be performed only when necessary and under careful medical supervision (Diepgen, 2007 ).  
Topical calcineurin inhibitors may be considered for patients with AD of hand and foot who 
require long -term need for treatment, although evidence for their efficacy is limited.  The low 
penetration/permeati on of topical agents through the skin of the hands and feet explains the limited 
efficacy of topical anti -inflammatory agents.  Overnight occlusion may be advocated to allow for 
sufficient penetration of topical anti -inflammatory drugs.  However, in the lo ng-term, such 
measures are frequently unpractical and cumbersome for patients.  
There is no Food and Drug Administration (FDA) approved systemic therapy for localized atopic 
hand and foot dermatitis.  Alitretinoin (oral retinoid) is the only approved system ic therapy in the 
European Union (EU), for severe chronic hand dermatitis  (including AD of hands) but has 
significant side effects (Ruzicka, 2008 ).  Most common adverse events (AEs) seen in phase 3 trials 
were headache, d ry skin, conjunctivitis, hypercholesterolemia, and flushing.  Significant known 
side effects are psychiatric effects such as depression, mood changes and suicidal ideation, changes 
in bone mineralization, and benign intracranial hypertension.  Alitretinoin  also requires strict 
contraception measures in women of childbearing potential due to high teratogenic potential.  
Although systemic corticosteroids can be effective symptomatic treatment in acute hand eczema 
or acute flares of chronic hand eczema, chroni c use is not recommended due to potentially serious 
long-term side effects.  Systemic immunomodulators such as cyclosporine, azathioprine and 
methotrexate have very little evidence from randomized controlled trials to support their use in 
AD of hand and fo ot and are associated with significant side effects.  
Dupilumab (brand name DUPIXENT®) is approved in over 40 countries worldwide including the 
United States (US), EU, and Japan for the treatment of moderate -to-severe AD in adults.  
Dupilumab was also autho rized in the US and EU recently for use in adolescent patients 
(≥12 years) with inadequately controlled moderate -to-severe AD.  Dupilumab is a novel targeted 
immunoregulatory agent that selectively and simultaneously inhibits IL -4 and IL-13 signaling by 
blocking the obligate shared component of the IL -4/IL-13 receptor complex.  It is intended to 
inhibit key disease drivers to achieve clinical benefit without the side effects commonly observed 
with existing non -selective systemic immunosuppressants.  Additio nal background information on 
the study drug and development program can be found in the Investigator’s Brochure.  
                                        VV-RIM-00138022-1.0 Approved - 13 Jan 2021 GMT-5:00
Clinical Study Protocol  R668-AD-1924 Amendment 2  
Regeneron Pharmaceuticals, Inc.  Page 35 of 108 
CONFIDENTIAL  It is known that severe atopic hand and foot dermatitis can be particularly difficult to treat.  
Although dupilumab is efficacious in AD more broadly, its effect specifically in treating localized 
atopic hand and foot dermatitis has not been studied.  Several case reports have recently 
demonstrated efficacy of dupilumab in atopic hand and foot dermatitis (Zirwas, 201 8).  This is not 
surprising given the lesions of AD share the same underlying type 2 driven pathophysiology, 
irrespective of body location.  However, atopic hand and foot dermatitis can be difficult to 
distinguish clinically from allergic or irritant eczem a.  This study, by generating data on the effect 
of dupilumab on AD lesions of the hand and feet and providing an algorithm to identify patients 
who are candidates for dupilumab therapy, is intended to facilitate access to a promising new 
therapy for patie nts with a recalcitrant and debilitating form of AD.  
2. STUDY OBJECTIVES  
2.1. Primary Objective  
The primary objective of the study is to assess the efficacy of dupilumab on skin lesions in patients 
with atopic hand and foot dermatitis.  
2.2. Secondary Objectives  
The secondary objectives of the study are:  
• To assess the efficacy of dupilumab on various other domains (pruritus, pain, sleep 
loss, health related QoL, work life impairment) in patients with atopic hand and foot 
dermatitis  
• To evaluate the safety and tolerability  of dupilumab administered to patients with 
atopic hand and foot dermatitis  
• To evaluate systemic exposure and immunogenicity of dupilumab in patients with 
atopic hand and foot dermatitis  
2.3. Exploratory Objectives  
The exploratory objectives of the study are:  
• To study dupilumab’s mechanism of action (related to efficacy and/or safety), why 
some patients respond better than others (safety and/or efficacy), IL4R pathway, atopic 
hand and foot dermatitis and related diseases  
• To assess the concordance between treatme nt effect of dupilumab on a) atopic hand 
and foot dermatitis lesions and b) concomitant AD lesions on other parts of the body  
• To evaluate exposure -response relationships  
 
                                        VV-RIM-00138022-1.0 Approved - 13 Jan 2021 GMT-5:00
Clinical Study Protocol  R668-AD-1924 Amendment 2  
Regeneron Pharmaceuticals, Inc.  Page 36 of 108 
CONFIDENTIAL  3. HYPOTHESIS AND RATIO NALE 
3.1. Hypotheses  
Signs and symptoms of AD of hands and feet, like other parts of the body, are driven by type 2 
inflammation.  Dupilumab monotherapy, by blocking type 2 inflammation, will result in an 
improvement in various domains of disease in adult and adolescent patients with moderate -to-
severe atopic hand and foot d ermatitis inadequately responsive to topical corticosteroids.  This 
includes effect on various measures of intensity and extent of skin lesions on hand and foot, 
symptoms such as pruritus, sleep loss and pain, QoL, work life impairment, and mental health.  
3.2. Rationale  
3.2.1.  Rationale for Study Design  
Dupilumab is the first globally approved therapy for moderate -to severe AD.  Its efficacy, both as 
monotherapy and in conjunction with corticosteroids, has been demonstrated in multiple double -
blind, randomized, clinic al trials (Simpson, 2016 ) (Thaci, 2016 ).  In all the reported trials inclusion 
criteria mandated that AD must affect greater than 10% of the Body Surface Area (BSA).  Because 
the palm including the fingers comprises 1% of the BSA, the studies specifically excluded patients 
with AD limited to the  hands.  Similarly, the feet represent a small BSA much lower than 10%.  
These trials evaluated the global effect of dupilumab on AD lesions on the whole body without 
discrimination by body regions such as hands and feet.  Similarly, these trials did not e valuate the 
effect of dupilumab on symptoms such as pruritus and pain resulting specifically from hand and 
foot disease.  A dedicated clinical study using investigator assessments and patient reported 
outcomes focused on disease in hand and feet is needed to evaluate such effects.  
Atopic hand and foot dermatitis can be significantly debilitating and can cause unique problems 
such as reduced work productivity, prolonged sick leave and ultimately job loss ( Fowler, 2006 ).  
The impact on QoL of hand dermatitis has been found to be comparable to that with moderate -to-
severe AD (generalized) and psoriasis (Agner, 2008 ).  This study, by generating data on the effect 
of dupilumab on AD lesions of th e hand and feet, is intended to facilitate access to a promising 
new therapy for patients with a recalcitrant and debilitating form of AD.  
Hand and foot dermatitis has multiple underlying etiologies with AD, ACD, and ICD recognized 
as the major causes.  Th e pathophysiology of hand and foot dermatitis varies depending upon the 
underlying etiology ( Gittler, 2013 ).  Atopic hand and foot dermatitis is believed to be classically 
type 2 inflammation -mediated.  Allergic contact de rmatitis is classically believed to be Th1 
mediated disorder.  Irritant contact dermatitis is primarily caused due to damage to skin barrier 
and is believed to be mediated by innate immunity (IL -1, TNFα).  
Several case reports have recently demonstrated ef ficacy of dupilumab in AD of hand and foot 
(Nanda, 2019 ) (Oosterhaven, 2018 ) (Zirwas, 2018 ).  These patients had previously failed treatment 
with various top ical and systemic therapies used in hand and foot dermatitis.  In the case series 
published by Zirwas et al, all 3 patients met the diagnostic criteria for AD and had total BSA<10%.  
All 3 patients underwent comprehensive patch testing and no relevant alle rgens were detected.  In 
contrast to these case reports, dupilumab has been shown to have a variable effect on ACD, with 
many patients reporting no improvement with use of dupilumab ( Stout, 2019 ).  Moreover, there 
                                        VV-RIM-00138022-1.0 Approved - 13 Jan 2021 GMT-5:00
Clinical Study Protocol  R668-AD-1924 Amendment 2  
Regeneron Pharmaceuticals, Inc.  Page 37 of 108 
CONFIDENTIAL  have been cas e reports of patients with AD in whom failure of resolution of lesions in certain parts 
of the body was caused due to concomitant presence of ACD ( Suresh, 2018 ). 
Given the unclear scientific rationale for dupilumab in forms of hand and foot dermatitis other than 
atopic hand and foot dermatitis, as well as the variable results reported in the literature of the effect 
of dupilumab on ACD, the patient population in this study will exclude patients with these other 
dermatides.  
Limiting the study population with moderate -to-severe forms of disease (Investigator Global 
Assessment [IGA] hands and feet of 3  or 4), chronic disease (disease present for at least 6 months 
prior to screening visit) and with disease inadequately responsive to TCS or in patients in whom 
TCS are inadvisable, will ensure that the patients with highest unmet medical need will be enrolled 
in this study.  Moreover, should the study demonstrate adequate safety and efficacy, the approach 
used in this study can be appli ed in clinical practice as an algorithm to identify patients for 
dupilumab therapy.  
A blinded, randomized, placebo -controlled design is chosen to minimize bias in data collection 
and result interpretation.  The presence of a placebo arm is appropriate for the objectives of this 
study as this will allow for the most robust assessment of the efficacy and safety of dupilumab.  
A monotherapy design has been chosen to allow a true estimate of the effect size of dupilumab 
without any confounding by use of topical or systemic therapies.  This is especially pertinent to 
hand and foot dermatitis as due to thicker skin of palms and soles, higher potency TCS or TCS 
under occlusion might be needed which have potential to confound study results.  Patients will be 
allowed to be rescued with topical/systemic therapies in case of intolerable symptoms.  
The primary endpoint used in the study is based on the endpoint used in previous phase 3 
dupilumab AD trials (IGA), which is adapted to assess hand and feet involvement only.  A  similar 
instrument was used in the phase 3 trial for alitretinoin for hand dermatitis.  Moreover, there is 
precedence of adapting the IGA to measure outcomes in localized forms of disease for scalp and 
nail psoriasis in phase 3 trials for biologics (secuk inumab for scalp psoriasis and adalimumab for 
nail psoriasis) (Bagel, 2017 ) (Elewski, 2018 ). 
The 16-week treatment duration is similar to that used in previous adult phase 3 trials in AD.  
Moreover, the selected dupilumab dose regimens will have achieved steady -state concentration by 
the end of this period.  A recent observational study to compare effect of dupilumab on hand lesions 
vs. lesions on other parts of the body found a high degree  of concordance in terms of onset of 
effect and overall effect at week 16 ( Oosterhaven, 2018 ).  The only drug approved for hand 
dermatitis, alitretinoin, is a slow acting drug showing modest efficacy after 24 weeks.  The 
response of hand dermatitis to systemic immunomodulatory agents used in AD is rapid.  As an 
example, oral cyclosporine has shown efficacy in hand dermatitis in a 6 -week randomized 
controlled trial (Granlund, 1996 ). 
The 12-week follow -up period is based on the expected pharmacokinetics (PK) of dupilumab after 
the last dose, ie, the time for serum concentrations to decline to nondetectable levels (below the 
lower limit of quantification) in most patients.  
Randomization will b e stratified to control for potential confounding variables which could impact 
efficacy (age [adults vs. adolescents], disease severity [IGA hand and foot 3 vs. 4], and geographic 
region [United States v ersus Japan versus other countries]).  
                                        VV-RIM-00138022-1.0 Approved - 13 Jan 2021 GMT-5:00
Clinical Study Protocol  R668-AD-1924 Amendment 2  
Regeneron Pharmaceuticals, Inc.  Page 38 of 108 
CONFIDENTIAL  3.2.2.  Rationale for Dose Selection  
The dose regimen of dupilumab selected for this study is an initial (loading) dose of 600 mg 
administered subcutaneously (SC), followed by 300 mg administered SC every 2 weeks (Q2W) in 
adults and a fixed dose tiered by body weight in adolesc ent patients (body weight ≥60 kg, an initial 
[loading] dose of 600 mg administered SC, followed by 300 mg administered SC Q2W; body 
weight <60 kg, an initial [loading] dose of 400 mg administered SC, followed by 200 mg 
administered SC Q2W).  The respective  dose regimens have proven to be effective and have 
demonstrated an acceptable safety profile in adult and adolescent patients with moderate -to-severe 
AD.  Given the substantial evidence gathered regarding dose selection with dupilumab in AD and 
considerin g that pathophysiology of AD elsewhere is identical to that of atopic hand and foot 
dermatitis, the dose of dupilumab approved in the US, EU, and other countries globally for use in 
AD will be tested in this study.  This is especially relevant as atopic ha nd and foot dermatitis tends 
to co-exist with AD on other parts of the body in majority of the patients ( Agner, 2015 ). 
The case reports published in the literature that showed substantial benefit for dupilumab in 
patients with AD of hands and feet used the approved dupilumab dosing regimen, thus provide 
further support for this dosing regimen ( Nanda, 2019 ) (Oosterhaven, 201 8) (Zirwas, 2018 ).  The 
observational study cited in the previous section, which showed a high degree of concordance 
between effect on lesions of atopic hand dermatitis vs. lesions on other parts of the body, also used 
the approved dupilumab dosing regimen pr oviding further credence to this approach  
(Oosterhaven, 2018 ). 
The administration of the loading dose of dupilumab will allow systemic concentrations to reach 
steady-state faster, and potentially reduce the time to onset  of clinical effect.  
3.3. Risk-Benefit 
Benefits 
The efficacy of dupilumab in AD was evaluated in multiple randomized, double -blind, placebo -
controlled studies in adults and in a separate study with a similar study design in adolescents.  In 
all studies, dupilumab demonstrated clinically meaningful and statistically significant 
improvements compared to placebo in disease activity measures assessing objective AD signs 
(IGA, Eczema Area and Severity Index [EASI], SCORing AD [SCORAD], BSA affected by AD), 
subjective symptoms (eg, Pruritus Numeric Rating Scale [NRS], Patient Oriented Eczema Measure 
[POEM]), and quality of life (Dermatology Life Quality Index [DLQI] in adults, Childrens’ 
Dermatology Life Quality Index [CDLQI] in adolescents).  These results form ed the basis for 
approval of dupilumab for moderate -to-severe AD in adults worldwide, and in adolescents in US 
and EU. 
Although the above trials did not specifically look at the effect of dupilumab on hand and foot 
dermatitis, post hoc analyses from phase 3 trials showed that dupilumab works equally well across 
different anatomical regions (upper limbs/lower limbs/trunk/head and neck) (Blauvelt, 2017 ).  In 
the post approval setting, multiple case reports have shown that pat ients with atopic hand and foot 
dermatitis receive substantial clinical benefit from treatment with dupilumab (Nanda, 2019 ) 
(Oosterhaven, 2018 ) (Zirwas, 2018 )This is consistent with the known pathophysiology of AD 
which is driven primarily by type 2 inflammation, irrespective of the site of location.  
                                        VV-RIM-00138022-1.0 Approved - 13 Jan 2021 GMT-5:00
Clinical Study Protocol  R668-AD-1924 Amendment 2  
Regeneron Pharmaceuticals, Inc.  Page 39 of 108 
CONFIDENTIAL  Risks 
The most common adverse drug reactions identified in the dupilumab adult AD clinical program 
were injecti on site reactions common (≥10%).  Other common adverse reactions (≥1% and <10%) 
included conjunctivitis, allergic conjunctivitis, bacterial conjunctivitis, eye pruritus, dry eye, 
blepharitis, oral herpes, herpes simplex (primarily mucocutaneous in nature) and eosinophilia.  In 
the completed adolescent AD studies, the safety profile was consistent with that reported in adults 
and there were no new safety signals detected with dupilumab in the adolescent population.  
Overall, systemic hypersensitivity has been  established an important identified risk with 
dupilumab.  As protein therapeutics, all monoclonal antibodies (mAbs) are potentially 
immunogenic.  Rare serious and systemic hypersensitivity reactions have been observed in the 
dupilumab program including se rum sickness/serum sickness -like reaction in the adult AD and 
anaphylaxis related to dupilumab in the adult asthma clinical trials.  No event of serum 
sickness/serum sickness -like reaction or anaphylaxis related to dupilumab has been reported in the 
adolescent AD program.  
In study R668 -AD-1924, patients will be monitored at the study center for 30 minutes post -dose 
for the first 3 visits at which study drug is administered to facilitate detection and treatment of any 
immediate hypersensitivity reactions to the study drug.  
An important potential risk “Eosinophilia associated with clinical symptoms” has been observed 
in the asthma clinical trials (few cases of eosinophilic granulomatosis with polyangiitis and 
eosinophilic pneumonia) but not in AD clinical stud ies. 
Risk/Benefit Conclusion  
The safety data available to date, in conjunction with the risk monitoring and mitigation strategies 
in the study protocol, and the clinical benefit of dupilumab demonstrated in multiple AD studies 
in adult and adolescent patie nts, support a favorable benefit -risk profile for dupilumab.  
A risk-benefit statement with respect to the overall development program is provided in the 
Investigator’s Brochure.  
Study Conduct in Response to COVID -19 
Recognizing that “Coronavirus Disease 20 19” (COVID -19) pandemic will have an impact on the 
conduct of clinical trials, the Sponsor does not intend to screen any patient in this study until the 
COVID-19 pandemic is deemed manageable and no longer interfering with the conduct of trials 
at individu al sites, and patients can safely participate in the study. Until then, the Sponsor plans to 
obtain approvals from Health Authorities/Ethics Committees to enable initiation of study sites for 
this study, as allowed by local laws and regulations.  
                                        VV-RIM-00138022-1.0 Approved - 13 Jan 2021 GMT-5:00
Clinical Study Protocol  R668-AD-1924 Amendment 2  
Regeneron Pharmaceuticals, Inc.  Page 40 of 108 
CONFIDENTIAL  4. ENDPOINTS  
4.1. Primary and Secondary Endpoints  
4.1.1.  Primary Endpoint  
• Proportion of patients achieving an IGA (hand and foot) score of 0 or 1 at week 16  
4.1.2.  Secondary Endpoints  
Key Secondary Endpoint for Efficacy:  
• Proportion of patients with improvement (reduction) of weekly aver age of daily hand 
and foot peak Pruritus NRS ≥4 from baseline to week 16  
Secondary Endpoints for Efficacy:  
• Proportion of patients with improvement (reduction) of weekly average of daily hand 
and foot peak Pruritus NRS ≥3 from baseline to week 16  
• Percent change from baseline to week 16 in weekly average of daily hand and foot peak 
Pruritus NRS  
• Percent change in mTLSS for hand/foot lesions from baseline to week 16  
• Percent change from baseline to week 16 in weekly average of daily hand and foot peak 
Pain NRS 
• Percent change from baseline to week 16 in weekly average of daily Sleep NRS  
• Change from baseline to week 16 in percent surface area of hand and foot involvement 
with AD 
• Percent change from baseline to week 4 in weekly average of daily hand and foot peak  
Pruritus NRS  
• Proportion of patients with improvement (reduction) of weekly average of daily hand 
and foot peak Pruritus NRS ≥4 from baseline to week 4  
• For patients with hand dermatitis, percent change from baseline to week 16 in Hand 
Eczema Severity Index  (HECSI) score  
• For patients with hand dermatitis, proportion of patients with HECSI -75 at week 16  
• For patients with hand dermatitis, proportion of patients with HECSI -50 at week 16  
• For patients with hand dermatitis, proportion of patients with HECSI -90 at week 16 
• For patients with hand dermatitis, change from baseline to week 16 in Quality of Life 
in Hand Eczema Questionnaire (QOLHEQ)  
• Change from baseline to week 16 in Work Productivity and Impairment (WPAI) and 
Classroom Impairment Questionnaire (CIQ)  
Secondary Endpoint for Safety:  
• Incidence of treatment -emergent adverse events (TEAEs) through week 16  
                                        VV-RIM-00138022-1.0 Approved - 13 Jan 2021 GMT-5:00
Clinical Study Protocol  R668-AD-1924 Amendment 2  
Regeneron Pharmaceuticals, Inc.  Page 41 of 108 
CONFIDENTIAL  Secondary Endpoints for Clinical Pharmacology and Immunogenicity:  
• Trough concentration of functional dupilumab in serum at various time points  
• Incidence of tr eatment-emergent anti -drug antibody (ADA) and titer over time  
4.1.3.  Other Endpoints and Assessments  
Other endpoints and assessments, as applicable, will be specified in the Statistical Analysis Plan 
(SAP). 
4.1.4.  Exploratory Endpoints  
• In patients with AD lesions on oth er parts of the body in addition to hands and feet;  
− Percent change in EASI score from baseline to week 16  
− Proportion of patients with IGA score of 0/1 at week 16  
− Proportion of patients with EASI -75 at week 16  
5. STUDY VARIABLES  
5.1. Demographic and Baseline Characteristics  
Baseline characteristics will include standard demography (eg, age, race, weight, height, etc), 
disease characteristics including medical history, and medication history for each patient.   
5.2. Efficacy Variables  
The efficacy variables include measurements or scores for individual patients for the following:  
• Patient-reported outcome measures: Daily hand and foot peak Pruritus NRS, Daily 
hand and foot peak Pain NRS, Daily Sleep NRS, QOLHEQ, Patient Global Impression 
of Severity (PGIS), Patient Gl obal Impression of Change (PGIC), WPAI+CIQ, and 
EQ-5D 
• Investigator -reported outcomes: IGA for hands and feet, mTLSS, percent surface area 
of hand and foot involvement with AD, HECSI, IGA ( global), and EASI  
5.3. Safety Variables  
The safety variables include reco rdings, measurements or laboratory test results for individual 
patients for the following: AEs, vital signs, physical examinations, hematology, blood chemistry, 
and urinalysis.  
5.4. Pharmacokinetic Variables  
The PK variable is the concentration of dupilumab at each time point.  These sampling timepoints 
are specified in Table 1 . 
                                        VV-RIM-00138022-1.0 Approved - 13 Jan 2021 GMT-5:00
Clinical Study Protocol  R668-AD-1924 Amendment 2  
Regeneron Pharmaceuticals, Inc.  Page 42 of 108 
CONFIDENTIAL  5.5. Immunogenicity Variables  
The immunogenicity variables are ADA status, titer, neutralizing antibody (NAb) status, and time 
point/visit.  Samples in this study will be collected at the clinic visits  specified in Table 1 . 
5.6. Pharmacodynamic and Other Biomarker Variables  
Not applicable.  
6. STUDY DESIGN  
This is a global, multicenter, randomized, double -blind, parallel -group, placebo -controlled study 
investigating the efficacy and safety of dupilu mab monotherapy in adult and adolescent patients 
with moderate -to-severe atopic hand and foot dermatitis.  Eligible patients must have a 
documented history of inadequate response or intolerance to treatment of hand and foot dermatitis 
with topical AD medic ations.  Approximately 130 patients will be enrolled for the study.  The 
number of adult patients will be capped at approximately 100 to ensure that, at a minimum, 
approximately 30 adolescents will be enrolled.  The number of patients with hands only 
involvement will be capped at approximately 100.   
6.1. Study Description and Duration  
The study consists of 3 periods:  
• Screening period (minimum duration of 4 weeks and maximum up to 8 weeks)  
• Randomized treatment period (16 weeks)  
• Post treatment follow -up period (12  weeks) 
At the screening visit, adult patients will provide informed consent before any other study 
procedures are conducted.  For adolescent patients, parents or legal guardians will provide 
informed consent and the patients will provide assent.  After pr oviding informed consent/assent, 
the patients will be assessed for study eligibility at the screening visit.  During the screening period, 
systemic treatments for AD will be washed out, as applicable, according to the eligibility 
requirements.  Topical tre atments for AD of hands and feet will also be discontinued, according to 
the eligibility requirements.  However, patients will be allowed to use topical treatments for 
treatment of AD on other parts of the body with certain restrictions (Section  8.10.2 ).  
A detailed history of exposure to irritants relevant to hand and foot dermatitis in the occupational 
as well as non -occupational setting will be elici ted at screening.  During the screening period, 
patients will be provided instructions on skin protection measures.  Patients will need to follow 
these measures throughout the screening period in order to remain eligible for the study.  It is 
recommended t hat patients continue with these measures during the remaining duration of the 
study (for details of skin protection measures refer to Section  8.10.3 ). 
Patients may be re -screened once if they fail the screening evaluation for reasons related to 
incidental transitory conditions (eg, inability to conduct patch testing during the screening p eriod, 
medication use, intercurrent illness, transient medical condition), unless the reason for the screen 
failure is related to failing the disease severity inclusion criteria.  
                                        VV-RIM-00138022-1.0 Approved - 13 Jan 2021 GMT-5:00
Clinical Study Protocol  R668-AD-1924 Amendment 2  
Regeneron Pharmaceuticals, Inc.  Page 43 of 108 
CONFIDENTIAL  Patch testing with a standard series of allergens will also be carried out d uring the screening period 
to exclude patients with predominantly ACD of hand and foot.  Patients will need to be 
discontinued from topical/systemic medications for AD prior to the patch testing.  Patients will be 
called to the site for multiple visits dur ing the screening period for conducting these patch tests 
(refer to Section  9.2.1.1 for further details on the patch testing procedure).  
Patients who meet the eligibility criteria will be randomized (1:1) to one of the following treatment 
groups:  
• Dupilumab, administered SC Q2W  
− in adults; dupilumab 300 mg, after a loading dose of 600 mg on day 1, irrespective 
of body weight  
− in adolescents;  Body weight ≥60 kg, dupilumab 300 mg, after a loading dose of 
600 mg on day 1, body weight <60 kg, dupilumab 200 mg, after a loading dose of 
400 mg on day 1. 
• Matching placebo with the above respective dupilumab doses, administered SC Q2W  
Randomization wil l be stratified by age (adults vs. adolescents), disease severity (IGA hand and 
foot 3 vs. 4), and geographic region (United States v ersus Japan versus other countries).  
Randomization will be capped for the adults at approximately 100 to ensure that, at a  minimum, 
approximately 30 adolescents will be enrolled.  
Information on the anatomical area of involvement (hands only vs. hands and feet vs. feet only) 
will be collected at baseline prior to randomization.  The number of patients with hands only 
involveme nt will be capped at approximately 100.  
During the treatment period, patients will have in -clinic visits at week2 and week4, and then in -
clinic visits every 4 weeks through week 16 with bi -weekly phone visits in between the in -clinic 
visits.  Patients and/ or parents/caregivers (in case of adolescents as deemed appropriate based on 
age of patient) will be trained on injecting study drug during in -clinic visits when study drug is 
administered (day 1, week 2, and week 4).  During  weeks in which no in -clinic visit is scheduled, 
patients will either self -inject study drug or the parent/caregiver will administer study drug to the 
patient.  In case patients do not want to self -inject and the parent/caregiver do not want to 
administer study drug to patient, patients  may have the clinic staff administer all the study drug 
injections in the clinic.  Safety laboratory tests, collection of samples for study drug concentrations, 
immunogenicity, and clinical assessments will be performed at specified clinic visits, as note d in 
Table 1. 
The use of topical and systemic medications for the treatment of atopic chronic hand and foot 
dermatitis will be prohibited during the trea tment period.  However, patients will be allowed to 
use topical medications for AD on parts of the body other than hand and foot.  These topical 
medications will be limited to low to medium potency TCS creams.  Moreover, patients will be 
advised to either a) use gloves or use tongue depressors while applying these creams if self -
applying or b) have a caregiver apply these treatments.  If medically necessary (ie, to control 
disease flares), rescue treatment in the form of high potency TCS on hand/foot and/or  systemic 
immunosuppressants may be provided to study patients at the discretion of the investigator.  
Patients may continue study treatment if they received rescue treatment.  
                                        VV-RIM-00138022-1.0 Approved - 13 Jan 2021 GMT-5:00
Clinical Study Protocol  R668-AD-1924 Amendment 2  
Regeneron Pharmaceuticals, Inc.  Page 44 of 108 
CONFIDENTIAL  The end of treatment visit will occur at week 16, 2 weeks after the last dose of  study drug.  The 
primary endpoint will be assessed at this visit.  If patients prematurely discontinue study drug, the 
patients will be encouraged to stay in the study to have data collected at all remaining scheduled 
visits until completion of the planne d end of study visit.  
Post-treatment follow -up period: Upon completing the 16 -week randomized treatment period, 
patients will enter a 12 -week follow -up period.  The end of study (EOS) visit will occur at week  28. 
An overview of the study is provided in the  study schematic below ( Figure 1). 
 
                                        VV-RIM-00138022-1.0 Approved - 13 Jan 2021 GMT-5:00
Clinical Study Protocol   R668-AD-1924 Amendment 2  
 
 
Regeneron Pharmaceuticals, Inc.   Page 45 of 108 
CONFIDENTIAL  Figure 1: Study Flow Diagram  
 
D=Day; DB=Double -blind; EOS=End of study; EOT=End of treatment; F/U=Follow -up; OCS=oral corticosteroid; R=Randomization; W=Week.  
 
                                        VV-RIM-00138022-1.0 Approved - 13 Jan 2021 GMT-5:00
Clinical Study Protocol R668-AD-1924 Amendment 2  
 
Regeneron Pharmaceuticals, Inc.  Page 46 of 108 
CONFIDENTIAL  6.1.1.  End of Study Definition  
The end of study is defined as the date of the last visit of the last patient in the study.  
6.2. Planned Interim Analysis  
No interim analysis with  alpha spending is planned for this study.   
Timing of data analyses are described in Section 11.5. 
7. SELECTION, WITHDRAWA L, AND REPLACEMENT O F 
PATIENTS  
7.1. Number of Patients Planned  
Approximately 130 patients (65 patients per arm) will be enrolled at approximately 50 global sites.  
The number of adult patients will be capped at approximately 100 to ensure that, at a minimum, 
approximately 30 adolescents will  be enrolled.  The number of patients with hands only 
involvement will be capped at approximately 100.  
7.2. Study Population  
The proposed study population is patients with chronic, moderate -to-severe atopic hand and foot 
dermatitis inadequately responsive to me dium-to-high-potency TCS or in whom 
medium-to-high-potency TCS are inadvisable.  Only patients meeting the diagnostic criteria for 
AD will be included in this study.  Patients with a confirmed diagnosis of irritant contact dermatitis 
or ACD as the predomin ant cause of hand and foot dermatitis will be excluded from the study.  
7.2.1.  Inclusion Criteria  
A patient must meet the following criteria to be eligible for inclusion in the study:  
1. Male or female ≥12 years old at time of the screening visit.  
2. Patients with chronic hand and foot dermatitis diagnosed at least 3 years prior to the 
screening visit for patients ≥18 years old, and at least 1 year prior to the screening visit for 
patients ≥12 to <18 years old.  
3. Patients with involvement of at least 2 anatomical area s at screening and baseline.  These 
2 anatomical areas could be both hands, 1 hand and 1 foot, or both feet.  
4. Patients need to have an IGA hand and foot score of 3 or 4 (moderate -to-severe disease) 
at screening and baseline.  
Note:  The investigators should assign a single IGA score based on their overall 
impression of disease severity of hands and feet.  Patients need to have overall 
moderate-to-severe disease in hands/feet and involvement of at least 2 anatomical areas 
to be eligible.  
5. Patients with document ed recent history (within 6 months before the screening visit) of 
inadequate response of atopic hand and foot dermatitis to topical medication(s) or for 
                                        VV-RIM-00138022-1.0 Approved - 13 Jan 2021 GMT-5:00
Clinical Study Protocol R668-AD-1924 Amendment 2  
 
Regeneron Pharmaceuticals, Inc.  Page 47 of 108 
CONFIDENTIAL  whom topical treatments of atopic hand and foot dermatitis is medically inadvisable 
(eg, intolerance, b ecause of important side effects or safety risks).  If documentation is 
inadequate, potential patients may be offered a course of treatment with a daily regimen 
of TCS of medium or higher potency (±TCI as appropriate), applied for at least 28 days 
during the screening period, or for the maximum duration recommended by the product 
prescribing information, whichever is shorter.  Patients who demonstrate inadequate 
response during this period, as defined above, will be eligible for inclusion in the study 
following appropriate washout.  
NOTES: 
• Inadequate response is defined as failure to achieve and maintain remission or a low 
disease activity state as per clinical judgment of treating physician despite treatment 
with a daily regimen of TCS of medium to higher po tency (± topical calcineurin 
inhibitor [TCI] as appropriate), applied for at least 28 days or for the maximum duration 
recommended by the product prescribing information (eg, 14 days for super -potent 
TCS), whichever is shorter.  
• Important side effects or sa fety risks from treatment of atopic hand and foot dermatitis 
are those that outweigh the potential treatment benefits and include intolerance to 
treatment, hypersensitivity reactions, significant skin atrophy of hand and feet, and 
systemic effects, as asse ssed by the investigator or by the patient’s treating physician.  
• Acceptable documentation includes contemporaneous chart notes that record topical 
medication prescription and treatment outcome, or investigator documentation based 
on communication with the patient’s treating physician.   
• Patients with documented systemic treatment (systemic immunosuppressant drugs like 
cyclosporine, methotrexate, corticosteroids, alitretinoin, etc) for atopic hand and foot 
dermatitis in the past 6 months are also considered as inadequate responders to topical 
treatments and are potentially eligible for treatment with dupilumab after appropriate 
washout.  However, this does not apply to patients who used these systemic treatments 
for generalized AD lesions throughout the body.   Moreover, this also does not apply to 
cases in which a determination cannot be made with reasonable certainty that the 
systemic treatment was used in the past specifically for atopic hand and foot dermatitis.  
6. Patients need to meet the Hanifin and Rajka c riteria for diagnosis (Hanifin, 1980 ). 
NOTES: 
The diagnosis of AD requires the presence of at least 3 of 4 major criteria:  
a. Pruritus 
b. Dermatitis affecting flexural surfaces in adults and the face and extensors in infants 
(criterion: criterion quoted verbatim, infants will not be included in this study)  
c. Chronic or relapsing dermatitis  
d. Personal or family history of cutaneous or respiratory atopy  
In patients who do not have AD lesions present on parts of the body other than h ands 
and feet at time of screening, the study investigator should check for any prior history 
of presence of AD lesions in typical age specific distribution patterns for eg, flexural 
                                        VV-RIM-00138022-1.0 Approved - 13 Jan 2021 GMT-5:00
Clinical Study Protocol R668-AD-1924 Amendment 2  
 
Regeneron Pharmaceuticals, Inc.  Page 48 of 108 
CONFIDENTIAL  areas (cutaneous atopy).  Prior history of respiratory atopic diseases (f or eg, asthma, 
allergic rhinitis) should also be elicited.  
In addition, 3 out of 23 minor criteria need to be met (refer to Appendix  1 for a list of th e minor 
criteria). 
7. Baseline hand and foot peak Pruritus NRS score for maximum itch intensity ≥4.  
8. At least 11 (of a total of 14*) applications of a topical emollient (moisturizer) during the 
7 consecutive days immediately before the baseline visit (not incl uding the day of 
randomization).  
* Based on application of moisturizer twice daily for 7 days leading up to randomization.  
Application of emollient more than twice in a day is permitted but the additional 
applications will not be counted in the 11 required applications to fulfil eligibility for 
the study.  
9. Willing and able to comply with clinic visits and study -related procedures.  
10. Provide informed consent/assent signed by study patient or legally acceptable 
representative.  
11. Able to understand and comp lete study -related questionnaires.  
12. Patients need to have been compliant with the skin protection measures (as outlined in 
Section 8.10.3) through the e ntire duration of the screening period (minimum of 4 weeks 
but lasting to a maximum of 8 weeks).  This includes avoidance of known irritants that 
are identified as causing exacerbation of one’s hand and foot AD.  
7.2.2.  Exclusion Criteria  
A patient who meets any of the following criteria will be excluded from the study:  
1. Patients with a positive patch test reaction to one or more allergens (a score of 1+ or above 
according to International Contact Dermatitis Research Group [ICDRG] grading scale) in 
either  
a. the baseline patch test series OR  
b. extended baseline or supplemental patch test allergens if such additional testing is 
conducted by the investigator OR  
c. Personal products if testing with such products is conducted by the investigator  
AND  
Which is deemed to be cli nically relevant in the view of the investigator as the current 
cause of the hand and foot dermatitis.  
NOTES: 
• Patch testing with extended baseline series, supplemental series and/or personal 
products will only be carried out if deemed necessary as per clin ical judgment of 
investigator  
                                        VV-RIM-00138022-1.0 Approved - 13 Jan 2021 GMT-5:00
Clinical Study Protocol R668-AD-1924 Amendment 2  
 
Regeneron Pharmaceuticals, Inc.  Page 49 of 108 
CONFIDENTIAL  • The results of the patch tests conducted in the past can be used to determine eligibility 
for a patient as long as ALL of the following are met:  
− the patch testing was conducted no more than 3 years prior to screening visit AND   
− patch testing was conducted with the same battery of allergens as the baseline Patch 
test series or even if conducted with a different series included all the allergens 
included in the baseline patch test series AND  
− the investigator does not deem patch t esting with an extended baseline series, 
supplemental series or with patient’s personal products necessary based on clinical 
judgment.  
• Patients with a documented diagnosis of ACD of hands and/or feet, who have a 
positive patch test reaction at screening will also be excluded from the study, 
regardless of whether history of current skin exposure to products containing this 
allergen (current relevance) is present.  
• Patients with posi tive reactions which are interpreted as irritant reactions based upon 
morphology, timing (eg, 1 +ve at day 2 followed by a decrescendo pattern) will still 
be eligible for study as long as they meet other eligibility criteria for the study.  
2. Patients with a documented diagnosis of protein contact dermatitis of hands and/or feet. 
These are patients with occupational or non -occupational contact to proteins such as food, 
latex etc. with positive prick test who present with lesions of contact urticaria or dermati tis 
on hands/feet.  
3. Patients in whom patch testing cannot be conducted due to any reason (these include but 
are not limited to refusal of patient to have patch testing, inability to take patient off 
systemic immunosuppressants/topical AD medications for the  required washout period 
prior to patch testing, lack of clear skin (free of lesions) on upper back and /or upper arm 
on which to apply patch tests, etc).  
4. Patients with documented exposure to irritants in the occupational or non -occupational 
(household/rec reational) setting that is believed to be a predominant cause of the current 
hand and foot dermatitis as per the judgment of the investigator. A detailed history of 
exposure to irritants in the occupational as well as non -occupational setting will be 
elicited at screening. The site staff will complete a CRF containing a list of irritants 
commonly implicated in causing irritant contact dermatitis at screening.  
NOTES: 
• It is recognized that patients with atopic hand and foot dermatitis may have identified 
irritants which are known to exacerbate their disease.  As long as the irritants are a) 
neither the primary nor the predominant cause for their disease as per clinical 
judgment of investigator and b) the patients are willing to avoid these irritants during 
the entire duration of the study, such patients can be enrolled into the study.  
• Patients whose hand dermatitis, in the clinical judgment of investigator, is 
predominantly irritant contact dermatitis caused due to household or occupational wet 
work exposure will also be excluded. As a guide, investigators can use the following 
                                        VV-RIM-00138022-1.0 Approved - 13 Jan 2021 GMT-5:00
Clinical Study Protocol R668-AD-1924 Amendment 2  
 
Regeneron Pharmaceuticals, Inc.  Page 50 of 108 
CONFIDENTIAL  wet work criteria; (a) activities where workers have to immerse their hands in liquids 
for >2 hours per shift, b) wear waterproof (occlusive) gloves for a corresponding 
amount of time, or c) wash their hands >20 times per shift ( Behroozy et al. 2014 ) to 
make this determination.  
5. Treatment with dupilumab in the past.  
6. Patients who have used any the following treatments within 4 weeks before the baseline 
visit 
a. Systemic corticosteroids  
b. Immunosuppressive/immunomodulating drugs (eg, alitretinoin, cyclosporine, 
mycophenolate mofetil, IFN -γ, systemic Janus kinase inhibitors, azathioprine or 
methotrexate)  
c. Phototherapy (including localized psoralen and UVA [PUVA] o r narrow band 
ultraviolet B [UVB] on hands and/or feet).  
7. Treatment with biologics, other than dupilumab, as follows:  
a. Any cell-depleting agents including but not limited to rituximab: within 6 months 
before the baseline visit, or until lymphocyte and CD 19+  lymphocyte count returns to 
normal, whichever is longer  
b. Other biologics: within 5 half -lives (if known) or 16 weeks prior to the baseline visit, 
whichever is longer  
8. Treatment with TCS or TCI or crisaborole or topical Janus kinase ( JAK) inhibitor within 
2 weeks before the baseline visit on the hand and foot.  
9. Treatment with an investigational drug within 8 weeks or within 5 half -lives (if known ), 
whichever is longer, before the baseline visit.  
10. Treatment with a live (attenuated) vaccine within 4 weeks before the baseline visit.  
11. Planned or anticipated use of any prohibited medications and procedures during study 
treatment.  
12. Known or suspected immunodeficiency, including history of invasive opportunistic 
infections (eg, tuberculosis [TB], histoplasmosis, listerio sis, coccidioidomycosis, 
pneumocystosis, aspergillosis) despite infection resolution, or otherwise recurrent 
infections of abnormal frequency as judged by the investigator.  
13. Known history of human immunodeficiency virus (HIV) infection or HIV seropositivity . 
14. With a current diagnosis of hepatitis B viral infection at the time of screening as evidenced 
by 
a. Positive hepatitis B surface antigen (HBsAg) or  
b. Positive total hepatitis B core antibody (HBcAb) confirmed by positive HBV DNA  
                                        VV-RIM-00138022-1.0 Approved - 13 Jan 2021 GMT-5:00
Clinical Study Protocol R668-AD-1924 Amendment 2  
 
Regeneron Pharmaceuticals, Inc.  Page 51 of 108 
CONFIDENTIAL  NOTE: 
Patients who have gained immunity for hepatitis B virus infection after vaccination 
(patients who are HBsAg negative, hepatitis B surface antibody [HBsAb] positive, and 
HBcAb negative) or after natural infection (patients who are HBsAg negative, HBsAb 
positive, and HBcAb po sitive) are eligible for the study.  These patients will be allowed to 
enroll into the study but will be followed using routine clinical and liver function tests.  
In case of results showing HBsAg negative, HBsAb negative, and HBcAb positive, a HBV 
DNA test ing will be performed prior to randomization to rule out a false positivity and to 
confirm current infection.  Patients who are HBcAb positive and HBV DNA negative will 
be eligible to enroll in the trial.   
15. With a current diagnosis of hepatitis C viral inf ection at the time of screening as evidence 
by 
a. Positive HCV Ab AND  
b. Positive HCV RNA  
16. On current treatment for hepatic disease including but not limited to acute or chronic 
hepatitis, cirrhosis, or hepatic failure, or has evidence of liver disease as indicated by 
persistent (confirmed by repeated tests ≥2 weeks apart) elevated transaminases (alanine 
aminotransferase [ALT] and/or aspartate aminotransferase [AST]) more than 3 times the 
upper limit of normal (ULN) during the screening period.  
17. Presence of any 1 or more of the following abnormalities in laboratory test results at 
screening:  
a. Platelets ≤100 × 103/μL 
b. Neutrophils <1.5 × 103/μL 
18. Diagnosed active endoparasitic infections.  Patients with suspected or high risk of 
endoparasitic infection will be excl uded, unless clinical and (if necessary) laboratory 
assessment have ruled out active infection before randomization.  
19. Presence of skin comorbidities on hand and foot that may interfere with study assessments.  
This includes, but is not limited to palmoplant ar psoriasis, palmoplantar keratoderma, 
lichen planus, pityriasis rubra pilaris, herpes simplex, erythema multiforme, tinea 
mannum/tinea pedis, scabies, granuloma annulare.  
20. History of malignancy within 5 years before the baseline visit, except completely t reated 
in situ carcinoma of the cervix, completely treated and resolved non -metastatic squamous 
or basal cell carcinoma of the skin.  
21. Severe concomitant illness(es) that, in the investigator’s judgment, would adversely affect 
the patient’s participation in the study.  Examples include, but are not limited to patients 
with short life expectancy, patients with uncontrolled diabetes (HbA1c ≥9%), patients with 
cardiovascular conditions (eg, stage III or IV cardiac failure according to the New York 
Heart Associat ion classification), severe renal conditions (eg, patients on dialysis), 
neurological conditions (eg, demyelinating diseases), active major autoimmune diseases 
(eg, Eosinophilic granulomatosis with polyangitis (EGPA), lupus, inflammatory bowel 
                                        VV-RIM-00138022-1.0 Approved - 13 Jan 2021 GMT-5:00
Clinical Study Protocol R668-AD-1924 Amendment 2  
 
Regeneron Pharmaceuticals, Inc.  Page 52 of 108 
CONFIDENTIAL  disease, rhe umatoid arthritis, etc.), other severe endocrinological, gastrointestinal, hepato -
biliary, metabolic, pulmonary or lymphatic diseases.  The specific justification for patients 
excluded under this criterion will be noted in study documents.  
22. Any other medica l or psychological condition (including relevant laboratory 
abnormalities at screening) that, in the opinion of the investigator, may suggest a new 
and/or insufficiently understood disease, may present an unreasonable risk to the study 
patient as a result of his/her participation in this clinical trial, may make patient’s 
participation unreliable, or may interfere with study assessments.  The specific 
justification for patients excluded under this criterion will be noted in study documents.  
23. History of alcoh ol or drug abuse within 2 years before the screening visit.  
24. Patients who are committed to an institution by virtue of an order issued either by the 
judicial or the administrative authorities.  
25. Patient is a member of the investigational team or his/her immed iate family.  
26. Pregnant or breastfeeding women or planning to become pregnant or breastfeed during the 
patient’s participation in this study.  
27. Women of childbearing potential (WOCBP)* who are unwilling to practice highly 
effective contraception prior to the i nitial dose/start of the first treatment, during the 
study, and for at least 12 weeks after the last dose.  Highly effective contraceptive 
measures include:  
a. stable use of combined (estrogen and progestogen containing) hormonal contraception 
(oral, intrava ginal, transdermal) or progestogen -only hormonal contraception (oral, 
injectable, implantable) associated with inhibition of ovulation initiated 2 or more 
menstrual cycles prior to screening  
b. intrauterine device; intrauterine hormone -releasing system  
c. bilateral tubal ligation  
d. vasectomized partner (provided that the male vasectomized partner is the sole sexual 
partner of the WOCBP study participant and that the vasectomized partner has obtained 
medical assessment of surgical success for the procedure)  
e. and/or sexual abstinence†, ‡.  
*Women of childbearing potential are defined as women who are fertile following 
menarche until becoming postmenopausal, unless permanently sterile.  Permanent 
sterilization methods include hysterectomy, bilateral salpingectomy, and bilateral 
oophorectomy.  
A postmenopausal state is defined as no menses for 12 months without an alternative 
medical cause.  A high follicle stimulating hormone (FSH) level in the postmenopausal 
range may be used to confirm a postmenopausal state in women n ot using hormonal 
contraception or hormonal replacement therapy.  However, in the absence of 12 months of 
amenorrhea, a single FSH measurement is insufficient to determine the occurrence of a 
postmenopausal state.  The above definitions are according to Cl inical Trial Facilitation 
Group guidance.  Pregnancy testing and contraception are not required for women with 
documented hysterectomy or tubal ligation.  
                                        VV-RIM-00138022-1.0 Approved - 13 Jan 2021 GMT-5:00
Clinical Study Protocol R668-AD-1924 Amendment 2  
 
Regeneron Pharmaceuticals, Inc.  Page 53 of 108 
CONFIDENTIAL  †Sexual abstinence is considered a highly effective method only if defined as refraining 
from heterose xual intercourse during the entire period of risk associated with the study 
drugs.  The reliability of sexual abstinence needs to be evaluated in relation to the duration 
of the clinical trial and the preferred and usual lifestyle of the patient.  
f. ‡Periodic  abstinence (calendar, symptothermal, post ovulation methods), withdrawal 
(coitus interruptus), spermicides only, and lactational amenorrhea method (LAM) are 
not acceptable methods of contraception.  Female condom and male condom should 
not be used togethe r. 
7.3. Premature Withdrawal from the Study  
A patient has the right to withdraw from the study at any time, for any reason, and without 
repercussion.  
The investigator and/or sponsor have the right to withdraw a patient from the study if it is no longer 
in the interest of the patient to continue in the study, or if the patient’s continuation in the study 
places the scientific outcome of the study at risk (eg, if a patient does not or cannot follow study 
procedures).  An excessive rate of withdrawals would render the study uninterpretable; therefore, 
unnecessary withdrawal of patients should be avoided.  
Patient who are withdrawn prematurely from the study will be asked to complete the early 
termination visit, as described in Section  9.1.2. 
Rules for discontinuation of study treatment (permanent or temporary) are discussed in 
Section 8.4.2. 
7.4. Replacement of Patients  
Patients prematurely discontinued from study or study drug will not be replaced.  
8. STUDY TREATMENTS  
8.1. Investigational and Reference Treatments  
• Dupilumab, administered SC Q2W  
− in adults; dupilumab 300 mg, after a loading dose of 600 mg on day 1, 
irrespective of body weight  
− in adolescents; Body weight ≥60 kg, dupilumab 300 mg, after a loading dose of 
600 mg on day 1, body weight <60 kg, dupilumab 200 mg, after a loading dose of 
400 mg on day 1.  
• Matching placebo, administered SC Q2W  
Randomization is discussed in Section  8.6. 
                                        VV-RIM-00138022-1.0 Approved - 13 Jan 2021 GMT-5:00
Clinical Study Protocol R668-AD-1924 Amendment 2  
 
Regeneron Pharmaceuticals, Inc.  Page 54 of 108 
CONFIDENTIAL  Study drug will be administered by SC injections.  Su bcutaneous injection sites of study drug 
should be alternated among the different quadrants of the abdomen (avoiding navel and waist 
areas), upper thighs, and upper arms so that the same site is not injected for 2 consecutive 
administrations.  
Instructions on dose preparation are provided in the pharmacy manual.  
8.2. Background Treatment  
All patients are required to apply moisturizers on their hands and feet at least twice daily during 
the screening period.  It is recommended that patients continue the use of moi sturizers throughout 
the study (all 28 weeks where applicable).  All types of moisturizers are permitted, but patients 
may not initiate treatment with prescription moisturizers or moisturizers containing additives 
during the screening period or during the study.  Patients may continue using stable doses of such 
moisturizers if initiated before the screening visit.  It is recommended that the moisturizers used 
be free of additives, fragrances, perfumes, and other potentially sensitizing agents.  Moreover, it  
is recommended that the moisturizers not contain any compound with known anti -itch effect (such 
as pramoxine, lidocaine, prilocaine, capsaicin etc.).  
NOTE:  In patients with lesions of AD on parts of the body other than hands and feet, emollients 
are permitted but are not required as background medication for other body regions.  
8.3. Rescue Treatment  
Rescue treatment for worsening of AD of hands and feet may be provided to study patients at the 
discretion of the investigator in the study.  The use of rescue tre atment is only allowed after day 
14 of the study.  Investigators will be required to perform an IGA for hands and feet assessment 
prior to starting rescue treatment and initiate rescue treatment only in patients who have an IGA 
hand and foot score ≥3.  If possible, investigators are encouraged to consider rescue initially with 
topical treatment (high potency or ultra -high potency TCS, TCIs, crisaborole, topical 
JAK inhibitors) and to escalate to systemic medications only for patients who do not respond 
adequately after at least 7 days of topical treatment.  Rescue treatment for the topical therapies 
should be used as per prescribing information and local guidelines.  Patients may continue study 
treatment if rescue consists of topical medications.  
Investigators can also use systemic corticosteroids or non -steroidal systemic immunosuppressive 
drugs (alitretinoin, cyclosporine, methotrexate, mycophenolate -mofetil, azathioprine, 
JAK inhibitors etc) for rescue in patients with worsening of AD of hands a nd feet.  Patients may 
continue study treatment if rescue consists  of these systemic therapies, based upon discretion of 
investigator.  All patients will be asked to complete the scheduled study visits and assessments 
whether or not they complete study tre atment and whether or not they receive rescue treatment for 
AD.  Investigators should make every attempt to conduct efficacy and safety assessments (eg, 
disease severity scores, safety laboratory tests) immediately before administering any rescue 
treatment .  An unscheduled visit may be used for this purpose, if necessary.  For the purpose of 
the efficacy responder analysis, a pre -specified algorithm will be used to classify rescue (details in 
the SAP).  In addition, a blinded review of all post -baseline med ications to adjudicate rescue 
treatment, based on medical judgment, will be performed to adjudicate rescue.  Data from patients 
                                        VV-RIM-00138022-1.0 Approved - 13 Jan 2021 GMT-5:00
Clinical Study Protocol R668-AD-1924 Amendment 2  
 
Regeneron Pharmaceuticals, Inc.  Page 55 of 108 
CONFIDENTIAL  who receive rescue treatment as per this adjudication during the study will be treated for efficacy 
analysis purposes as outline d in Section  11.4.3. 
Note: During the study, patients might also experience flare of AD lesions on parts of the body 
other than hands and feet.  Rescu e treatment (in addition to low to medium TCS that are permitted 
during the study) will be allowed after day 14 of the study.  It is recommended that investigators 
manage these flares using topical therapies, unless the use of systemic therapies is deemed 
necessary based on severity and extent of flare as determined by the investigator.  High/ultra -high 
potency TCS/TCIs/crisaborole can be used in such situations.  The hands and feet should be spared 
from the use of these topical therapies, unless there is e vidence of exacerbation of lesions on hands 
and feet as per clinical judgment of the investigator.  In case systemic corticosteroids or non -
steroidal systemic immunosuppressive drugs are used for controlling flare in AD lesions on parts 
of the body other t han hands and feet, the study drug may be continued, based upon discretion of 
investigator.  
8.4. Dose Modification and Study Treatment Discontinuation Rules  
8.4.1.  Dose Modification  
Dose modification for an individual patient is not allowed.  
8.4.2.  Study Drug Discontinuation  
Patients who permanently discontinue from study drug should be encouraged to remain in the 
study.  Those who agree and do not withdraw from the study  will be asked to return to the clinic 
for all remaining study visits per the visit schedule.  
Patients who permanently discontinue from study drug and who opt to withdraw from the study 
will be asked to complete study assessments, per Section  9.1.2 . 
8.4.2.1.  Reasons for Permanent Discontinuation of Study Drug  
Study drug dosing will be permanently stopped in the event of:  
• Evidence of pregnancy  
• Serious or severe allergic reactions considered related to study drug  
• Specific types of liver dysfunction [eg, Hy’s la w is met ( FDA, 2009 )] 
• Patient or parent/legal guardian withdraws assent or consent  
• Diagnosis of a malignancy during study other than non -melanoma skin cancer or 
carcinoma in situ that is considered curable by local surgery  
• Any infection that is opportunistic, such as TB and other infections whose nature or 
course may suggest an immunocompromised status  
• Severe laboratory abnormalities assessed as related to study drug:  
− Neutrophil count ≤0.5 × 103/µL 
− Platelet count ≤50 × 103/µL 
                                        VV-RIM-00138022-1.0 Approved - 13 Jan 2021 GMT-5:00
Clinical Study Protocol R668-AD-1924 Amendment 2  
 
Regeneron Pharmaceuticals, Inc.  Page 56 of 108 
CONFIDENTIAL  − ALT and/or AST values >3 × ULN with total bilirubin >2 × ULN, excluding 
confirmed Gilbert’s Syndrome  
− Confirmed AST and/or ALT >5 × ULN (for more than 2 weeks)  
NOTE: 
If the laboratory abnormality is considered causally related to study drug, study treatment will be 
permanently discontinued.  In cases in which a causal relationship to study drug can be reasonably 
excluded, (ie, an alternative cause is evident), study treatment will be suspended but it may be 
resumed when the laboratory abnormality is  sufficiently normalized.  A decision to resume study 
treatment will be made jointly by the investigator and medical monitor (medical monitor’s written 
approval is required).  
• Treatment with a live attenuated vaccine (refer to Section  8.10.1 for details)  
• Treatment with an investigational drug  
The investigator may discontinue study treatment at any time, even without consultation with the 
medical monitor if the urgency of the situation requires immediate action and if this is determined 
to be in the patient’s best interest.  However, the medical monitor should be contacted as soon as 
possible in any case of study drug discontinuation.  
8.4.2.2.  Reasons for Temporary Discontinuation of Study Drug  
• Clinically important laboratory abnormalities, such as:  
− ALT or AST >3 × ULN  
− Neutrophil count <1.5 × 103/μL but >0.5 × 103/μL 
− Platelet count ≤100 × 103/μL but >50 × 103/μL 
After the condition leading to suspension of dosing resolves, study treatment may resume at the 
discretion of the investigator in consultation with the medical monitor.  A decision to temporarily 
discontinue study drug and/or to reinstitute study treatment should be discussed with the medical 
monitor. 
The investigator may suspend study treatment at any time, even without consultation with the 
medical monitor if the urgency of the situation requires immediate action and if this is determined 
to be in the patient’s best interest.  However, the medical m onitor should be contacted as soon as 
possible in any case of study drug discontinuation.  
8.5. Management of Acute Reactions  
8.5.1.  Acute Injection Reactions  
                                        VV-RIM-00138022-1.0 Approved - 13 Jan 2021 GMT-5:00
Clinical Study Protocol R668-AD-1924 Amendment 2  
 
Regeneron Pharmaceuticals, Inc.  Page 57 of 108 
CONFIDENTIAL  8.5.1.1.  Systemic Injection Reactions  
Emergency equipment and medication for the treatment of systemic reactions must be available 
for immediate use.  All injection reactions must be reported as AEs (as defined in Section  10.2.1) 
and graded using the grading scales as instructed in Section  10.2.4 . 
Acute systemic reactions following  injection of study drug (SC) should be treated using clinical 
judgment to determine the appropriate response according to typical clinical practice.  
8.5.1.2.  Local Injection Site Reactions  
Local injection site reactions must be reported as AEs and graded according  to Section  10.2.4  
8.6. Method of Treatment Assignment  
Approximately 130 patients will be randomized in a 1:1 ratio to receive either dupilumab or 
placebo according to a central randomization scheme provided by an interactive voice response 
system (IVRS)/interactive web response system (IWRS) to the designated study pharmacist (or 
qualified designee).   
Randomization will be stratified by age (adults vs. adolescents), disease severity (IGA hand and 
foot 3 vs. 4), and geographic region (United States v ersus Japan versus other countries).  
Randomization will be capped for the adults at approximately 100.  
Information on the anatomical area of involvement (han ds only vs. hands and feet vs. feet only) 
will be collected at baseline prior to randomization.  The number of patients with hands only 
involvement will be capped at approximately 100.   
8.7. Blinding 
Study patients, the principal investigators, and study site personnel will remain blinded to all 
randomization assignments throughout the study.  The Regeneron Medical/Study Director, Study 
Monitor, and any other Regeneron and contract research organization (CRO) personnel who are 
in regular contact with the study site will remain blinded to all patient randomization assignments.  
Blinded study drug kits coded with a medication numbering system will be used.  In order to 
maintain the blind, lists linking these codes with product lot numbers will not be accessible to 
individuals involved in study conduct.  
Anti-drug antibody and drug concentration results will not be communicated to the sites, and the 
sponsor’s blinded operational team will not have access to results associated with patient 
identification until after th e database is locked.  
8.8. Emergency Unblinding  
Unblinding of treatment assignment for a patient may be necessary due to a medical emergency or 
any other significant medical event (eg,  pregnancy) and when a treatment decision is contingent 
on knowing the patien t's treatment assignment.  Study drug will be discontinued for patients whose 
treatment has been unblinded (Section  8.4.2). 
                                        VV-RIM-00138022-1.0 Approved - 13 Jan 2021 GMT-5:00
Clinical Study Protocol R668-AD-1924 Amendment 2  
 
Regeneron Pharmaceuticals, Inc.  Page 58 of 108 
CONFIDENTIAL  • If unblinding is required : 
− Only the investigator will make the decision to unblind the treatment assignment.  
− Only the affected patients will be unblinded.  
− The designated study pharmacist(s)/designee at the study site will provide the 
treatment assignment to the investigator.  If there is no study pharmacist, the 
investigator for the site will unblind the patient.  
− The IVRS/IWRS will provide the treatment assignment to the investigator and 
will notify Regeneron of the unblinding transaction.   
− The investigator will notify Regene ron and/or designee as soon as possible after 
unblinding the patient  
Treatment assignment is not to be provided to site personnel, other than the unblinded study 
pharmacist (when applicable), at any time during the conduct of the study, except in the case of a 
true emergency and when a treatment decision is contingent on knowing the patient's treatment 
assignment.  In the event that there is no study pharmacist, the individual at the site fulfilling that 
role will be the only unblinded member of the site pe rsonnel. 
8.9. Treatment Logistics and Accountability  
8.9.1.  Packaging, Labeling, and Storage  
A medication numbering system will be used to label blinded investigational study drug.  Lists 
linking medication numbers with product lot numbers will be maintained by the gr oups (or 
companies) responsible for study drug packaging/clinical drug supply.  In order to maintain the 
blind, these lists will not be accessible to individuals involved in study conduct.  
Study drug will be stored at the site at a temperature of 2ºC to 8ºC; storage instructions will be 
provided in the pharmacy manual.  
8.9.2.  Supply and Disposition of Treatments  
Study drug will be shipped at a temperature of 2ºC to 8ºC to the investigator or designee at regular 
intervals or as needed during the study.  At specif ied time points during the study (eg, interim site 
monitoring visits), at the site close -out visit, and following drug reconciliation and documentation 
by the site monitor, all opened and unopened study drug will be destroyed or returned to the 
sponsor or designee.  
8.9.3.  Treatment Accountability  
All drug accountability records must be kept current.  
The investigator must be able to account for all opened and unopened study drug.  These records 
should contain the dates, quantity, and study medication.  
• dispensed to each patient  
• returned from each patient (if applicable), and  
                                        VV-RIM-00138022-1.0 Approved - 13 Jan 2021 GMT-5:00
Clinical Study Protocol R668-AD-1924 Amendment 2  
 
Regeneron Pharmaceuticals, Inc.  Page 59 of 108 
CONFIDENTIAL  • disposed of at the site or returned to the sponsor or designee.  
All accountability records must be made available for inspection by the sponsor and regulatory 
agency inspectors; photocopies must be provided to the sponsor at the conclusion of the study.  
8.9.4.  Treatment Compliance  
All drug compliance records must be kept current and made available for inspection by the sponsor 
and regulatory agency inspectors.  
8.10. Concomitant Medications and Procedures  
Any treatment administered from the time of informed consent/assent to final study visit will be 
recorded.  Any treatment administered from the time of first dose of study drug to the final study 
visit will be considered concomitant medication.  This includes m edications that were started 
before the study and are ongoing during the study.  
8.10.1.  Prohibited Medications and Procedures  
Treatment with the following concomitant medications is prohibited during the study treatment 
period (through week 16):   
• Topical cortico steroids on hand and foot (may be used as rescue)  
• Topical calcineurin inhibitors on hand and foot (may be used as rescue)  
• Topical crisaborole on hand and foot (may be used as rescue)  
• Topical JAK inhibitors on hand and foot (may be used as rescue)  
• Systemic immunosuppressive/immunomodulating drugs (including, but not limited to 
alitretinoin, cyclosporine, mycophenolate -mofetil, azathioprine, methotrexate, IFN -γ, 
systemic JAK inhibitors, or other biologics) (may be used as rescue)  
• Systemic corticosteroids (may  be used as rescue)  
• Treatment with an investigational drug  
• Treatment with a live (attenuated) vaccine  
                                        VV-RIM-00138022-1.0 Approved - 13 Jan 2021 GMT-5:00
Clinical Study Protocol R668-AD-1924 Amendment 2  
 
Regeneron Pharmaceuticals, Inc.  Page 60 of 108 
CONFIDENTIAL  Chickenpox (varicella)  
FluMist-Influenza  
Intranasal influenza  
Measles (rubeola)  
Measles-mumps-rubella combination  
Measles-mumps-rubella-varicella 
combination 
Mumps 
Oral polio (Sabin)  Oral typhoid  
Rubella 
Smallpox (vaccinia)  
Yellow fever  
Bacille Calmette -Guerin 
Rotavirus  
Varicella zoster (shingles) 
(use of Zostavax is prohibited 
as it is live attenuated; use of 
Shingrix is allowed as it is 
non-live) 
Note:  If at screening visit, there is an anticipated need for use of live vaccines during the study, 
the patient should receive the vaccine during the screening period at least 4 weeks prior to baseline 
visit. 
The following concomitant procedures are prohibited  during study treatment through week  16: 
• Major elective surgical procedures  
• Phototherapy (ultraviolet A [UVA], UVB, narrowband UVB [nbUVB], high dose 
UVA, and PUVA), localized PUVA or narrow band UVB on hands and/or feet  
• Tanning in bed/booth  
8.10.2.  Permitted Med ications and Procedures  
Other than the prohibited medications listed in Section  8.10.1, treatment with concomitant 
medications are permitted during the  study.  Topical treatments used for AD lesions on parts of 
the body other than the hands and feet will be permitted.  This includes low to medium potency 
TCS (high potency/ultra -high TCS are prohibited), TCIs and crisaborole.  In order to avoid 
confoundin g of assessment of AD lesions on the hands, patients will be asked to either a) use 
gloves or tongue depressors if applying themselves or b) have a caregiver apply topical treatments 
on these lesions.  In addition, use of contraceptives and basic skin care  (cleansing and bathing 
including bleach baths) as well as treatment with emollients, topical anesthetics, antihistamines, 
topical and systemic anti -infective medications for any duration are permitted.  
Medications used to treat chronic disease such as dia betes and hypertension are also permitted.  If 
there is any question regarding whether a concomitant medication may be used during the study, 
the study site should contact the medical monitor.  
In patients with lesions of AD on parts of the body other than hands and feet, emollients are 
permitted but are not required as background medication for other body regions.  
8.10.3.  Skin Protection Measures  
Patients will be required to follow routine skin protection measures throughout the duration of the 
screening period in order to be eligible for the study.  It is recommended that patients continue 
with these measures during the duration of the study.  These measures will include the following:  
                                        VV-RIM-00138022-1.0 Approved - 13 Jan 2021 GMT-5:00
Clinical Study Protocol R668-AD-1924 Amendment 2  
 
Regeneron Pharmaceuticals, Inc.  Page 61 of 108 
CONFIDENTIAL  • Avoidance of identified irritants for hand and foot dermatitis.  
• Using protectiv e gloves when performing wet work.  It should be ensured that 
protective gloves should be intact and clean and dry inside.  When protective gloves 
are used for a long period of time, cotton gloves should be worn underneath.  Latex is 
best avoided for risk of contact urticaria and/or ACD.  
• Washing hands in lukewarm (not hot) water and to rinse and dry hands thoroughly 
after washing.  
• Minimize excessive hand washing with soaps and substitute with alcohol disinfection 
when hands are not visibly dirty.   
• Application of moisturizers, preferably those which are free from fragrances and with 
preservatives having the lowest allergen potential.  
The site staff will instruct the patients on further skin protection measures, if applicable.  
9. STUDY SCHEDULE OF EV ENTS AND PR OCEDURES  
9.1. Schedule of Events  
Study assessments and procedures are presented by study period and visit in Table 1. 
In light of the public health emergency related to COVID -19, the continuity of clinical study 
conduct and oversight may require implementation of temporary or alternative mechanisms.  
Examples of such mechanisms may include, but are not limited to, any of the following:  phone 
contact, virtual visits, telemedicine visits, online meetings, non -invasive remote monitoring 
devices, use of local clinic or laboratory locations, and home visit s by skilled staff.  Additionally, 
no waivers to deviate from protocol enrollment criteria due to COVID -19 will be granted. All 
temporary mechanisms utilized, and deviations from planned study procedures are to be 
documented as being related to COVID -19 and will remain in effect only for the duration of the 
public health emergency.  
 
                                        VV-RIM-00138022-1.0 Approved - 13 Jan 2021 GMT-5:00
Clinical Study Protocol  R668-AD-1924 Amendment 2  
Regeneron Pharmace uticals, Inc.  Page 62 of 108 
CONFIDENTIAL  Table 1: Schedule of Events 
Study Period Screening  Treatment Period   Follow-up      
Study Milestone   BL 
    
    
    
    
    
    
    
  EOT   
  
EOS    
In-Clinic Visit (V)* or 
Phone Visit (PV)  V1 V1a V2 V3 V4 PV51 V6 PV71 V8 PV91 V10 V11 Unsched
uled 
visit2 ET visit 
Week (W)      W2 W4 W6 W8 W10 W12 W14 W16 W28     
Study Day (D)  D-56 to  
D-1 D1 D15 D29 D43 D57 D71 D85 D99 D113 D197     
Visit Window in Days     ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±4     
Screening/ Baseline                                     
Informed co nsent/assent  X                               
Informed consent/assent 
for optional genomic sub -
study3 X                              
Informed consent/assent 
for optional future 
biomedical research sub -
study4 X              
Informed 
consent/assent for  
optional use  
of photographs for 
educational/marketing 
purposes 
(selected study  
sites only)  X              
Inclusion/Exclusion 
criteria X  X                             
Patch testing5,6,7,8   X             
Medical History  X                               
History of exposure to 
irritants relevant to hand 
and foot dermatitis  X              
Assign disease 
morphology9   X            
Assign anatomical area 
of involvement10   X            
                                        VV-RIM-00138022-1.0 Approved - 13 Jan 2021 GMT-5:00
Clinical Study Protocol  R668-AD-1924 Amendment 2  
Regeneron Pharmace uticals, Inc.  Page 63 of 108 
CONFIDENTIAL  Study Period Screening  Treatment Period   Follow-up      
Study Milestone   BL 
    
    
    
    
    
    
    
  EOT   
  
EOS    
In-Clinic Visit (V)* or 
Phone Visit (PV)  V1 V1a V2 V3 V4 PV51 V6 PV71 V8 PV91 V10 V11 Unsched
uled 
visit2 ET visit 
Week (W)      W2 W4 W6 W8 W10 W12 W14 W16 W28     
Study Day (D)  D-56 to  
D-1 D1 D15 D29 D43 D57 D71 D85 D99 D113 D197     
Visit Window in Days     ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±4     
Demographics  X                                
Randomization     X                             
Patient diary training11 X  X                              
Treatment                                    
Injection training/ 
observation12    X  X  X    X    X       
      
Administration of study 
drug    X13  X  X  X  X  X  X  X          
Patient dosing diary 
completion            X    X     X          
Patient counseling for 
diary completion     X  X  X     X     X             
Study drug dispensation14         X     X     X         X X 
Study drug 
accountability14            X    X    X        
Con meds/procedures  X X X X X X X X X X X X X X 
Skin protection measures  X X X X X X X X X X X X X X 
Efficacy15                            
Patient assessment of 
hand and foot pruritus 
intensity using NRS via 
diary (daily)  X X X X X X X X X  X X X X X 
Patient assessment of 
hand and foot skin pain 
and sleep NRS16 X X X X X            X X      
                                        VV-RIM-00138022-1.0 Approved - 13 Jan 2021 GMT-5:00
Clinical Study Protocol  R668-AD-1924 Amendment 2  
Regeneron Pharmace uticals, Inc.  Page 64 of 108 
CONFIDENTIAL  Study Period Screening  Treatment Period   Follow-up      
Study Milestone   BL 
    
    
    
    
    
    
    
  EOT   
  
EOS    
In-Clinic Visit (V)* or 
Phone Visit (PV)  V1 V1a V2 V3 V4 PV51 V6 PV71 V8 PV91 V10 V11 Unsched
uled 
visit2 ET visit 
Week (W)      W2 W4 W6 W8 W10 W12 W14 W16 W28     
Study Day (D)  D-56 to  
D-1 D1 D15 D29 D43 D57 D71 D85 D99 D113 D197     
Visit Window in Days     ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±4     
IGA (hand and foot), 
mTLSS, hand and feet  
area involvement, 
HECSI17 X  X X X    X     X    X X X X 
EQ-5D18, WPAI+CIQ18  X  X    X              
  X X   X 
PGIS18, QOLHEQ17,18 X  X X X  X  X  X X  X 
PGIC18    X X  X  X  X X  X 
IGA (global)19, EASI19   X  X      X X  X 
Photograph areas of 
atopic hand or foot 
dermatitis (select sites)     X                    X X   X 
Safety                                
Weight X  X                    X X   X 
Height X                        X       
Vital signs  X  X13             X X X X 
Physical examination  X                        X  X X X 
Adverse events  X X X X X X X X X X X X X X 
Laboratory Testing20**                                 
Hematology  X  X                   X  X X X 
Chemistry  X  X                 X  X X X 
Urinalysis  X  X                   X X X X 
Pregnancy test, WOCBP 
only Serum  Urine        Urine    Urine    Urine Urine Urine Urine 
                                        VV-RIM-00138022-1.0 Approved - 13 Jan 2021 GMT-5:00
Clinical Study Protocol  R668-AD-1924 Amendment 2  
Regeneron Pharmace uticals, Inc.  Page 65 of 108 
CONFIDENTIAL  Study Period Screening  Treatment Period   Follow-up      
Study Milestone   BL 
    
    
    
    
    
    
    
  EOT   
  
EOS    
In-Clinic Visit (V)* or 
Phone Visit (PV)  V1 V1a V2 V3 V4 PV51 V6 PV71 V8 PV91 V10 V11 Unsched
uled 
visit2 ET visit 
Week (W)      W2 W4 W6 W8 W10 W12 W14 W16 W28     
Study Day (D)  D-56 to  
D-1 D1 D15 D29 D43 D57 D71 D85 D99 D113 D197     
Visit Window in Days     ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±4     
HIV, HBsAg, HBsAb, 
HBcAb21, HBV DNA22, 
Hep C Ab23, HCV 
RNA24, TB25 X                          
Optional DNA sample3     X                            
PK and ADA Sample20               
                
Functional dupilumab PK 
sample    X           X X X X 
Anti-dupilumab antibody 
sample    X                X X X X 
ADA=anti -drug antibody; BL=baseline; D= Day;  EASI=Eczema Area and Severity Index; EOS=end of study; EOT=end of treatment; ET=early te rmination; FBR 
= future biomedical research HBcAb=hepatitis B core antibody; HBsAg=hepatit is B surface antigen; HECSI=Hand Eczema Severity Index; HIV=human 
immunodeficiency virus; IGA=Investigator Global Assessment; mTLSS=Modified Total Lesion Sign Score; NRS=Numerical Rating Scal e; PGIC=Patient Global 
Impression of Change; PGIS=Patient Global Impression of Severity; PK=pharmacokinetic; PV=phone visit;  TB=tuberculosis; V=visit; W=week; 
WPAI+CIQ=WPAI plus Classroom Impairment Questionnaire; WOCBP=women of childbearing potential . 
 
                                        VV-RIM-00138022-1.0 Approved - 13 Jan 2021 GMT-5:00
Clinical Study Protocol  R668-AD-1924 Amendment 2  
Regeneron Pharmaceuticals, Inc.  Page 66 of 108 
CONFIDENTIAL  9.1.1.  Footnotes for the Schedule of Events Table  
*Phone visits/virtual visits/telemedicine visits/home visits by skilled staff should be considered 
in case of lack of availability of site  staff and/or patients to come to site for in -clinic visits due to 
COVID-19 pandemic . The following investigator -performed assessments, if feasible, should be 
performed using telemedicine/virtual visits/home visits by skilled staff:  
i. IGA (hand and foot)  
ii. mTLSS 
iii. Hand and feet area involvement  
iv. HECSI 
Site staff should make every effort to conduct telephone interviews to complete the following 
questionnaires:  
i. EQ-5D 
ii. WAPI + CIQ  
iii. PGIS 
iv. QOLHEQ  
v. PGIC 
Site staff should also collect information on AEs and concomitant medications.  
Site staff should conduct the telephone interviews on the date of scheduled site visit by following 
an interview guide provided by the sponsor. Patient responses from the interviewer -administered 
questionnaires will be captured by the site sta ff directly into the tablet OR onto a paper -copy 
printout of the questionnaire screenshots. In case telephone interviews cannot be conducted, the 
questionnaires may be sent by mail/email to the patient’s home. Questionnaires should be 
completed by patients  and returned to the site.  
1. The site will contact the patient by telephone to conduct these visits.  The patient or 
caregiver (in case of adolescents, if applicable) may administer study drug on these days.  
Patients who receive study drug outside the study  center will complete a dosing diary to 
document compliance with study drug administration and to document any related issues.  
Site staff will also remind the patients to either a) use gloves or tongue depressors if 
applying themselves or b) have a caregi ver apply, when patients are using TCS treatment 
on lesions of AD other than hands and feet.  
2. Unscheduled visits may be necessary to repeat testing following abnormal laboratory 
results, for follow -up of AEs, or for any other reason (eg, before a rescue).  The assessments 
and procedures performed during an unscheduled visit will depend upon the reason for the 
visit.  During an unscheduled visit, any of the study procedures noted may be performed, 
but not all are required.  If the unscheduled visit is due to an AE, collect samples for PK 
and ADA analysis  
                                        VV-RIM-00138022-1.0 Approved - 13 Jan 2021 GMT-5:00
Clinical Study Protocol  R668-AD-1924 Amendment 2  
Regeneron Pharmaceuticals, Inc.  Page 67 of 108 
CONFIDENTIAL  3. For patients who decide to participate and provide a specific written informed 
consent/assent for the optional genomics sub -study (DNA sample collection).  DNA 
sample should be collected at the day 1 visit (pr edose) but can be collected at any visit 
during the study.   
4. FBR samples will be optional.  No additional samples are collected for patients who sign 
the FBR consent. FBR analyses will be performed on leftover biological samples (PK and 
ADA).    
5. Patch test ing with a standard series of allergens will be carried out in all patients unless 
there is documented evidence that patient has been previously patch tested with the same 
series (or an expanded series which contains all the allergens in the standard serie s tested 
in this study) within last 3 years and the investigator determines from clinical judgment 
that further patch testing is unnecessary.  In that case, the results from the previous patch 
test will be used for determining eligibility  
6. In addition to st andard baseline series, additional patch testing with expanded series and/or 
patient personal products may be carried out if deemed necessary by the investigator  
7. Patients will need to visit the site at least 3 times during the screening period for the cond uct 
of patch tests (day of application, reading of results at day 2, reading of results at day 3 to 
day 7).  In some patients a reading after 7 to 10 days may be taken when the clinical history 
strongly supports sensitization  
8. Patients will need to disconti nue topical and systemic therapies for AD for a certain period 
prior to patch testing.  Please refer to Section  9.2.1.1 for further details on patch t esting 
9. Investigators will assign patients to the following disease morphology for each 
anatomical area of hand and foot involvement:  
• Hyperkeratotic  
• Dyshidrotic  
• Pulpitis 
• Nummular eczema  
• Chronic dry fissured forms of eczema  
• Unspecified  
It is acknowledged that a mixed pattern might be present in some patients.  Investigators should 
identify the predominant morphology in such cases and assign patients accordingly.  
Investigators will also assign an overall disease morphology which will be b ased upon the disease 
morphology of the anatomical area with most severe disease (in some cases, a different 
morphology may be present in hands vs. feet).  In these scenarios, investigators should assign 
morphology based on the region with higher severity of involvement (hands or feet).  
10. Investigators will assign patients to the following anatomical areas of involvement:  
• Hands only  
• Hands and feet  
                                        VV-RIM-00138022-1.0 Approved - 13 Jan 2021 GMT-5:00
Clinical Study Protocol  R668-AD-1924 Amendment 2  
Regeneron Pharmaceuticals, Inc.  Page 68 of 108 
CONFIDENTIAL  • Feet only  
11. Training of patients regarding completion of diary to record a) administration of each dose 
of drug out side the clinic by patient, b ) completion of assessment of pruritus using NRS 
scale, c) completion of assessment of pain using NRS scale, d) completion of assessment 
of sleep loss using NRS scale, and e) twice daily application of emollients  
12. Patients or caregivers (in case of adolescents, if applicable) will be trained on how to 
administer study drug  under observation by site staff to ensure correct administration 
technique .  This would enable administration at home in between clinic visits.  
13. Patients will be monitored at the study site at visit 2 for a minimum of 30 minutes after 
study drug administration.  Vital signs (blood pressure, respiratory rate and pulse rate) and 
AE assessments will also be assessed at 30 minutes (+/ - 10 minutes) post -injection, in 
addition to pre -dose assessment.   
14. Starting at visit 4, study drug will be dispensed to the patient for the dose that will be 
administered at home before the next clinic visit.  Patients will return the study kit box (for 
prefilled syringes)  at each subsequent clinic visit.  At these in -clinic visits, sites will 
perform accountability assessment for the study drug that the patients have returned to the 
site.  In case of lack of availability of site staff and/or patients to come to the site for 
in-clinic visits due to the COVID-19 pandemic, the sponsor may implement processes for 
direct-to-patient shipment of study drug.  
15. Assessments/procedures should be conducted in the following order: patient -reported 
outcomes, investigator assessments, safet y and laboratory assessments, administration of 
study drug.  
16. Pain and sleep quality will be assessed daily throughout the screening period, the 7 days 
leading up to the week 2 visit, the 7 days leading up to the week 4 visit, the 7  days leading 
up to the we ek 16 visit, and 7 days leading up to the week 28 visit.  Patients will complete 
a daily diary on these days to record skin pain and sleep quality NRS.  
17. The HECSI and QOLHEQ will only be performed in patients with presence of hand 
dermatitis at baseline  
18. The questionnaires will be administered only to the subset of patients who speak fluently 
the language in which the questionnaire is presented (based on availability of validated 
translations in participating countries).  
19. Standard assessments for AD lesions o ver the whole body, not just limited to hands and 
feet. As part of these assessments, sites will answer the question: Does the patient have AD 
lesions outside the hands and/or feet? These assessments will only be performed in patients 
who have AD lesions o utside their hands and feet.  
20. Samples will be collected before the injection of study drug.  Serum samples will be 
collected for the determination of dupilumab concentration in and for the immunogenicity 
assessment of dupilumab.  In the event of suspected s erious adverse events (SAEs), such 
as anaphylaxis or hypersensitivity, additional PK and ADA samples may be collected at or 
near the event.  Samples positive in the ADA assay will be analyzed in the NAb assay.  
                                        VV-RIM-00138022-1.0 Approved - 13 Jan 2021 GMT-5:00
Clinical Study Protocol  R668-AD-1924 Amendment 2  
Regeneron Pharmaceuticals, Inc.  Page 69 of 108 
CONFIDENTIAL  ** Alternate measures for laboratory testing s hould be considered in case of lack of availability 
of site staff and/or patients to come to the site for in -clinic visits due to the COVID-19 
pandemic. Assessments, including but not limited to, which can be performed are as follows:  
a. Hematology  
b. Chemistry  
c. Urinalysis  
d. Pregnancy test  
21. In case of results showing HbsAg negative, HbsAb negative and HbcAb positive, 
HBV DNA testing will be performed prior to randomization to rule out a false positivity 
and to confirm current infection.  
22. Only performed in patients who se serology results show HbsAg negative, HbsAb 
negative and HbcAb positive . 
23. In case of results showing positive hepatitis C antibody (Hep C Ab), a n HCV RNA will 
be performed to rule out a false positivity and to confirm current infection.  
24. Only performed in  patients whose serology results show positive Hep C Ab . 
25. TB testing will be performed on a country -by-country basis, according to local guidelines 
if required by regulatory authorities or ethics boards.  
9.1.2.  Early Termination Visit  
Patients who are withdrawn fr om the study before the primary endpoint visit (week 16) will be 
asked to return to the clinic for an early termination visit consisting of the early termination 
assessments described in Table 1.  
9.1.3.  Unscheduled Visits  
All attempts should be made to keep patients on the study schedule.  Unscheduled visits may be 
necessary to repeat testing following abnormal laboratory results, for follo w-up of AEs, or for any 
other reason, as warranted.  
9.2. Study Procedures  
Assessments/procedures the clinic visit should be performed in the following order:  
1. Patient Reported Outcomes  
2. Investigator assessments (performed only by adequately trained and qualifie d investigators 
or sub-investigators; it is recommended that the same investigator or sub -investigator 
perform all the evaluations for a given patient throughout the entire study period)  
3. Safety and laboratory assessments (including sample collection for A DA, PK, and optional 
DNA). 
4. Administration of study drug  
                                        VV-RIM-00138022-1.0 Approved - 13 Jan 2021 GMT-5:00
Clinical Study Protocol  R668-AD-1924 Amendment 2  
Regeneron Pharmaceuticals, Inc.  Page 70 of 108 
CONFIDENTIAL  9.2.1.  Procedures Performed Only at the Screening/Baseline Visit  
The following procedures will be performed for the sole purpose of determining study eligibility 
or characterizing the baseline population:   
• Medical History  
• Detailed occupational, social, and personal history relevant to hand and foot 
dermatitis  
• Demographics  
• Inclusion/Exclusion criteria, including hepatitis and HIV serology, and TB (if 
required per local regulation)  
• Patch Testing  
• Patient diar y training  
9.2.1.1.  Patch Testing  
Patch testing with a standard series of allergens will be conducted during the screening period for 
determining eligibility.  Patch testing should normally be conducted after other screening 
procedures (eg, lab testing) have been c ompleted and eligibility for the study confirmed.  Patients 
need to discontinue therapies for AD before the patch testing is conducted.  The wash out period 
will be as follows:  
1. 1 week for TCS/TCI /topical JAK inhibitor/crisaborole application ( this applica tion will 
not be allowed only on the region of the body where patch testing is planned which in 
most cases would be the upper back)  
2. 4 weeks for UVA and UVB  
3. 4 weeks for oral corticosteroids  
4. 4 weeks for other systemic immunomodulators such as cyclosporine (CsA), 
mycophenolate mofetil (MMF), methotrexate (MTX), Alitretinoin, systemic 
JAK inhibitors etc.  
The standard series used will vary based upon the region of conduct of the study, eg, TRUE test 
in the US, The TRUE test and an additional panel of allergen s (provided in the study manual) 
which are not included in TRUE test but are commonly implicated in causing ACD of hands and 
feet in patients in the EU, and patch test panel (S) in Japan. In case other countries/regions are 
added to the study, country specific patch test series may be used as applicable. In case of patients 
who have had patch testing with the same country -specific series of allergens within 3 years prior 
to screening visit, the patch testing does not need to be repeated and results from  the previous patch 
test can be used for study purposes.  
In addition, patch testing with extended baseline  series, supplemental series and/or personal 
products may be carried out as per clinical judgment of investigator.  
Patients will be called to the sit e for 3 visits for the patch testing  
                                        VV-RIM-00138022-1.0 Approved - 13 Jan 2021 GMT-5:00
Clinical Study Protocol  R668-AD-1924 Amendment 2  
Regeneron Pharmaceuticals, Inc.  Page 71 of 108 
CONFIDENTIAL  1. Appointment 1 (day 0): Application of patch tests  
2. Appointment 2 (reading of results at day 2): the patches will be removed, and reading 
will be taken 20 to 30 minutes after removal of the patches.  
3. Appointment 3 (reading  of results at day 3 to day 7): A second reading will be taken  
In some patients a reading after day 7 may be taken when the clinical history strongly supports 
sensitization.  This is especially relevant for contactants such as metals (nickel sulfate, gold sodium 
thiosulfate, palladium chloride, potassium dichromate, cobalt chloride), some antibiotics 
(neomycin), TCS (tixocortol -21-pivalate, budesonide), and dyes (para -phenylenediamine).  
The patch test should be applied on normal appearing skin free from ski n diseases such as AD.  
The upper back is preferred site for the application of patch tests.  In case not suitable for patch 
testing, or is fully used already, the upper parts of the arm may be used.  
The patch tests will be read using the globally recogni zed the ICDRG criteria:  
Symbol Morphology  Assessment  
- No reaction  Negative reaction  
?+ Faint erythema only  Doubtful reaction  
+ Erythema, infiltration, 
possibly 
papules Weak positive  
reaction 
++ Erythema, infiltration, 
papules, 
vesicles Strong positive 
reaction 
+++ Intense erythema, infiltrate,  
coalescing vesicles  Extreme positive  
reaction 
For the purpose of this study, a score of 1+ and above will be considered a positive result.  The 
investigators should be careful to exclude irritant reacti ons which typically appear within the first 
48 hours and tend to disappear (decrescendo effect) by 96 hours, whereas allergic reactions tend 
to increase (crescendo effect).  Moreover, the morphology of these irritant reactions can differ 
from allergic reac tions with presence of necrosis and bullae.  
The history and physical examination must be correlated with the result of the PT to establish 
clinical relevance.  A positive PT may be clinically relevant depending on current or past 
exposures.  
Current relevan ce will be defined as definite if the PT or use test with the suspected material is 
positive This occurs if an allergen is found in the patient’s environment (example: fragrance in the 
patient’s personal care products), the dermatitis corresponds to the po int of contact with allergen 
(face), and the dermatitis improves with avoidance or recurs with rechallenge.  Relevance is 
probable if the antigen is present in known skin contactants and the clinical presentation is 
consistent with that exposure.  This can  occur if the allergen is found in the patient’s environment 
and the dermatitis corresponds to the point of contact with allergen but follow -up information on 
improvement with avoidance or rechallenge not available.  Relevance is possible if skin contact 
with materials known to contain the allergen was likely.  Past relevance is considered if the PT is 
positive but the exposure was in the past, and not the present.  
                                        VV-RIM-00138022-1.0 Approved - 13 Jan 2021 GMT-5:00
Clinical Study Protocol  R668-AD-1924 Amendment 2  
Regeneron Pharmaceuticals, Inc.  Page 72 of 108 
CONFIDENTIAL  Further instructions on patch testing and guidance to the patients will be provided in the st udy 
manual. 
9.2.2.  Efficacy Procedures  
9.2.2.1.  Investigator Global Assessment of Hand and Foot  
The IGA for hands and feet is an adaptation of the physician global assessment instrument which 
has been previously used in registrational studies in hand dermatitis ( Ruzicka, 2008 ).  The global 
IGA for generalized AD lesions throughout the body has been previously used in dupilumab 
studies in patients with AD  (Simpson, 2016 ). 
Investigators will be asked to a ssess the severity of signs of disease on hands and feet on this scale.  
It is important that this assessment be limited to only the hands and feet and not be influenced by 
severity of AD lesions on other parts of the body.  The IGA score will be assessed at time points 
according to Section  9.1 . 
The IGA is provided in Appendix  2 . 
9.2.2.2.  Modified Total Lesion Sign Score for Hands and Feet  
The Modified Total Lesional Sign Score is adapted for hands and feet; which has been previously 
used in registrational studies in hand dermatitis ( Ruzicka, 2008 ).  A similar instrument, Global 
Individual Sign Score, has been previously used for assessment of severity of generalized AD 
lesions in dupilumab studies in patients with AD (Simpson, 2016 ). 
It is impo rtant that this assessment be limited to only the hands and feet and not be influenced by 
severity of AD lesions on other parts of the body.  The mTLSS for hands and feet will be assessed 
at time points according to Section  9.1 . 
The mTLSS for hands and feet is provided in Appendix 3  
A responder threshold (currently unknown) for mTLSS in the study population will be determined 
using blinded interim data gathered from this study utilizing an anchor -based approach. Both 
dynamic responder definition (eg, change scores) and static severity bands (eg, none, mild, 
moderate, severe) will be explored. Treatment arms will be pooled to perform the analysis in a 
blinded fashion. Analyses using this responder threshold will be conducted to help interpretation 
of the prespecified endpoints for the mTLSS.  The methodology to be used for determining this 
responder threshold will be specified in the psychometric anal ysis plan and the determined 
responder threshold will be specified in the SAP.  
9.2.2.3.  Hand and Foot Pruritus Numerical Rating Scale  
The Pruritus NRS is a simple assessment tool that patients will use to report the intensity of their 
hand and foot pruritus (itch) during a 24 -hour recall period.   
Patients will be instructed on using the patient diary to record their Pruritus NRS score at the 
screening and baseline visits.  Patients will complete the rating scale DAILY according to the time 
points in Table 1.  Clinical sites will check and remind patient to complete the diary at each visit.  
The pruritus NRS score will be calculated as the average of the last 7 days w ith a minimum of 
4 daily scores.  
                                        VV-RIM-00138022-1.0 Approved - 13 Jan 2021 GMT-5:00
Clinical Study Protocol  R668-AD-1924 Amendment 2  
Regeneron Pharmaceuticals, Inc.  Page 73 of 108 
CONFIDENTIAL  9.2.2.4.  Hand and Foot Skin Pain Numerical Rating Scale  
Hand and foot skin pain will be measured using a skin pain NRS.   
Clinical sites will check and remind the patient to complete the scale according to the time  points 
in Table 1.  Patients will be instructed on using the scale to record their skin pain score at the 
screening visit.  Patients will complete the rating scale DAILY throughout the screening period, 
for the 7 days prior to the week 2 visit, for the 7 days prior to the week 4 visit, and for the 7  days 
prior to the week 16 visit.  Clinical sites will check patient data collected using an e -diary for 
protocol compliance a nd remind patients to complete their e -diary throughout the study.  
9.2.2.5.  Sleep Numerical Rating Scale  
Sleep quality will be measured using a sleep quality NRS.  This is an 11 -point scale (0 to 10) in 
which 0 indicates worst possible sleep while 10 indicates best  possible sleep.  The patients will be 
asked to select the number that best describes the quality of their sleep during the previous night.  
Clinical sites will check and remind the patients to complete the scale according to the time  points 
in Table 1.  Patients will be instructed on using the scale to record their sleep quality score at the 
screening visit.  Patients will complete the rating scale DAILY th roughout the screening period, 
for the 7 days prior to the week 2 visit, for the 7 days prior to the week 4 visit, and for the 7  days 
prior to the week 16 visit.  Clinical sites will check patient data collected using an e -diary for 
protocol compliance and  remind patients to complete their e -diary throughout the study.  
9.2.2.6.  Hand and Foot Area Involvement of Atopic Dermatitis  
This assessment will be performed at time points according to Section  9.1 .  The hand and foot 
area assessment tool is provided in the study reference manual.  
9.2.2.7.  Patient Global Impression of Severity  
The PGIS will be assessed at time points according to Table 1.  This instrument is provided in 
the study reference manual.  
9.2.2.8.  Patient Global Impression of Change  
The PGIC will be assessed at time points according to Table 1.  This instrument is provided in 
the study reference manual  
9.2.2.9.  Hand Eczema Severity Index  
The HECSI is similar to scoring systems in AD (EASI) and Psoriasis vulgaris (PASI) in 
incorporating both the extent and the intensity of the disease.  Each hand is divided into 5 areas 
[fingertips, fingers (except the tips), palms, back of hands and wrists].  For each of these areas the 
intensity of the 6 following clinical signs: erythema, in duration ⁄papulation, vesicles, fissuring, 
scaling and oedema is graded on the following scale: 0, no skin changes; 1, mild disease; 2, 
moderate, and 3, severe.  For each location (total of both hands) the affected area is given a score 
from 0 to 4 (0, 0%;  1, 1 to 25%; 2, 26 to 50%; 3, 51 to 75%, and 4, 76 to 100%) for the extent of 
clinical symptoms.  Finally, the score given for the extent at each location is multiplied by the total 
sum of the intensity of each clinical feature, and the total sum called t he HECSI score is calculated, 
                                        VV-RIM-00138022-1.0 Approved - 13 Jan 2021 GMT-5:00
Clinical Study Protocol  R668-AD-1924 Amendment 2  
Regeneron Pharmaceuticals, Inc.  Page 74 of 108 
CONFIDENTIAL  varying from 0 to a maximum severity score of 360 points.  The HECSI has been previously 
validated in patients with hand dermatitis ( Held, 2005 ).  
The HECSI will only be performed in patients  with presence of hand dermatitis at baseline.  This 
assessment will be performed at time points according Section  9.1 .  The HECSI is provided in the 
study reference manual.  
The HECSI will be assessed at time points according to Table 1. 
The HECSI assessment tool is provided in the study reference manual.  
9.2.2.10.  Quality of Life in Hand Eczema Questionnaire  
The QoLHEQ will be assessed at time points according to Table 1 
The QoLHEQ is provided in the study reference manual.  
9.2.2.11.  Eczema Area and Severity Index  
This assessment is not limited to just evaluation of hands and feet lesions, but will assess severity 
of AD lesions across the body. This assessment will only be performed in patients who have AD 
lesions outside their hands and feet.  
The EASI is a validated measure used in clinical practice and clinical trials to assess the severity 
and extent of AD ( Hanifin, 2001 ).  The EASI is a composite index with scores ranging from 0 to 
72.  Four AD disease characteristics (erythema, thickness [induration, papulation, edema], 
scratching [excoriation], and licheni fication) will each be assessed for severity by the investigator 
or designee on a scale of “0” (absent) through “3” (severe).  In addition, the area of AD 
involvement will be assessed as a percentage by body area of head, trunk, upper limbs, and lower 
limbs, and converted to a score of 0 to 6.  In each body region, the area is expressed as 0, 1  (1% to 
9%), 2 (10% to 29%), 3 (30% to 49%), 4 (50% to 69%), 5 (70% to 89%), or 6 (90% to 100%).  
The EASI will be assessed at time points according to Table 1. 
The EASI assessment tool is provided in the study reference manual.  
9.2.2.12.  Investigator’s Global Assessment  
This assessment is not limited to just evaluation of hand s and feet lesions, but will assess severity 
of AD lesions across the body. This assessment will only be performed in patients who have AD 
lesions outside their hands and feet.  
The IGA is an assessment instrument used in clinical studies to rate the severi ty of AD globally, 
based on a 5 -point scale ranging from 0 (clear) to 4 (severe).  
The IGA score will be assessed at time points according to Table 1. 
The IGA assessment tool is provided in the study reference manual.  
9.2.2.13.  Atopic Dermatitis Area Photographs  
At select study sites, photographs will be taken of a representative area of atopic hand and foot 
dermatitis involvement.  Subsequent photographs of the same  area will be taken at time points 
according to Table 1. 
                                        VV-RIM-00138022-1.0 Approved - 13 Jan 2021 GMT-5:00
Clinical Study Protocol  R668-AD-1924 Amendment 2  
Regeneron Pharmaceuticals, Inc.  Page 75 of 108 
CONFIDENTIAL  Instructions  for taking the photographs are provided in the photography reference manual.  
9.2.2.14.  Patient-Assessed EQ -5D 
This assessment is based on general AD, not only of atopic hand and foot dermatitis.  
The EQ-5D is a standardized measure of health status developed by the EuroQOL Group in order 
to provide a simple, generic measure of health for clinical an d economic appraisal.  The EQ -5D 
consists of 2 parts: the descriptive system and the EQ Visual Analogue Scale (EQVAS).  The 
EQ-5D descriptive system comprises the following 5 dimensions: mobility, self -care, usual 
activities, pain/discomfort, and anxiety/d epression.  Each dimension has 3 levels of perceived 
problems: “no problem” (level 1), “some problems” (level 2), “extreme problems” (level 3).  The 
respondent is asked to indicate his/her health state by ticking (or placing a cross) in the box against 
the most appropriate statement (ie, no problems, some problems, or severe problems) in each of 
the 5 dimensions; this results in a 1 -digit number expressing the level for that dimension.  The 
digits for 5 dimensions can be combined in a 5 -digit number describ ing the respondent’s health 
state.  
The EQVAS records the respondent’s self -rated health on a vertical, visual analogue scale where 
the endpoints are labeled “best imaginable health state (100)” and “worst imaginable health state 
(0)”.  This information can be used as a quantitative measure of health outcome as judged by the 
individual respondents.  
The questionnaire will be administered only to the subset of patients who fluently speak a language 
in which the questionnaire is presented (based on availability of validated translations in 
participating countries), at time points according to Table 1. 
The EQ-5D is provided in the study reference manual.  
9.2.2.15.  Work Productivity and Activity Impairment  Questionnaire Plus Classroom 
Impairment Questions  
The WPAI+CIQ is a self -administered instrument used to assess the impact of disease on 
productivity. An adaptation of WPAI, the WPAI+CIQ incorporates classroom impairment 
questions in the original WPAI to  assess classroom impairment.  The WPAI+CIQ measures 
work/classroom productivity loss due to general health or a specified health problem in past 7  days. 
The question can be adapted based on the specific condition of study.  For this study, WAPI+CIQ -
AHFD w ill be used to capture the impairment to work productivity/classroom impairment and 
activity due to atopic hand and foot dermatitis. The WPAI+CIQ yields 4 types of scores: 
absenteeism (work/classroom time missed), presenteeism (impairment at work/classroom  or 
reduced on -the-job/classroom effectiveness), work/classroom productivity loss (overall 
work/classroom impairment divided by absenteeism plus presenteeism), and activity impairment. 
All scores range from 0 to 100% with 100% indicating total work/classro om productivity 
impairment and 0 no impairment at all.  
The WPAI+CIQ will be administered to every patient.  Depending on whether the patients are 
currently employed or attending classes, the patients will answer the applicable questions in WAPI 
components  or CIQ components or both.  
The WPAI+CIQ will be administered at time points according to Table 1  
                                        VV-RIM-00138022-1.0 Approved - 13 Jan 2021 GMT-5:00
Clinical Study Protocol  R668-AD-1924 Amendment 2  
Regeneron Pharmaceuticals, Inc.  Page 76 of 108 
CONFIDENTIAL  9.2.3.  Safety Procedures  
9.2.3.1.  Vital Signs  
Vital signs (including pulse rate, sitting blood pressure, body temperature, and respiratory rate) 
will be collected pre -dose at time points according to Table 1. 
At the first 3 administrations of study drug, sitting blood pressure, respiratory rate and pulse rate 
will also be assessed at 30 minutes (+/ - 10 minutes) post -injection.  
9.2.3.2.  Body Weight and height  
Body weight and height will be measured at time points according to Table 1. 
9.2.3.3.  Physical Examination  
A thorough and complete physical examination will be performed at time points according to  
Table 1.  Care should be taken to examine and assess any abnormalities that may be present, as 
indicated by the patient’s medical history.  
9.2.3.4.  Laboratory Testing  
Hematology, chemistry, urinalysis,  and pregnancy testing samples will be analyzed by a central 
laboratory.  Detailed instructions for blood sample collection are in the laboratory manual provided 
to study sites.  
Samples for laboratory testing will be collected at visits according to Table 1.  Tests will include:  
Blood Chemistry  
Sodium Total protein, serum  Total bilirubin1 
 
Potassium  Creatinine  Total cholesterol2 
Chloride Blood urea nitrogen (BUN)  Triglycerides  
Carbon dioxide  Aspartate aminotransferase (AST)  Uric acid 
Calcium Alanine aminotransferase (ALT)  Creatine phosphokinase (CPK)3 
Glucose Alkaline phosphatase   
Albumin Lactate dehydrogenase (LDH)   
1 Direct and indirect bilirubin will be measured when the total bilirubin is above the ULN  
2 Low-density lipoprotein and high -density lipoprotein  
3 CPK isoenzymes will be measured when CPK >5× the ULN  
                                        VV-RIM-00138022-1.0 Approved - 13 Jan 2021 GMT-5:00
Clinical Study Protocol  R668-AD-1924 Amendment 2  
Regeneron Pharmaceuticals, Inc.  Page 77 of 108 
CONFIDENTIAL  Hematology  
Hemoglobin  Differential:  
Hematocrit   Neutrophils  
Red blood cells (RBCs)   Lymphocytes  
White blood cells (WBCs)   Monocytes  
Red cell indices   Basophils  
Platelet count   Eosinophils  
Urinalysis  
Color Glucose RBC 
Clarity Blood Hyaline and other casts  
pH Bilirubin Bacteria 
Specific gravity  Leukocyte esterase  Epithelial cells  
Ketones Nitrite Crystals 
Protein WBC Yeast 
Other Laboratory Tests  
Serum and urine pregnancy testing will be performed for all female patients of childbearing 
potential at time points according to Table 1 . 
The following tests will be performed at screening: HIV, HBsAg, HBsAb, HBcAb, HBV DNA 
(only in patients who are HBsAg negative, HBsAb negative, and HBcAb positive), hepatitis C 
antibody, HCV  RNA (only in patients who are HCV Ab positive), and tuberculosis (will be 
performed on a country -by-country basis according to local guidelines if required by regulatory 
authorities or ethics boards).  
Abnormal Laboratory Values and Laboratory Adverse Even ts 
All laboratory values must be reviewed by the investigator or authorized designee.  
Significantly abnormal test results that occur after start of treatment must be repeated to confirm 
the nature and degree of the abnormality.  When necessary, appropriate  ancillary investigations 
should be initiated.  If the abnormality fails to resolve or cannot be explained by events or 
conditions unrelated to the study medication or its administration, the Medical/Study Director must 
be consulted.   
The clinical signifi cance of an abnormal test value, within the context of the disease under study, 
must be determined by the investigator.  
Criteria for reporting laboratory values as an AE are provided in Section  10.1.1. 
9.2.4.  Drug Concentration and Measurements  
Serum samples for measuring functional dupilumab concentrations will be collected at time points 
according to Table 1. 
                                        VV-RIM-00138022-1.0 Approved - 13 Jan 2021 GMT-5:00
Clinical Study Protocol  R668-AD-1924 Amendment 2  
Regeneron Pharmaceuticals, Inc.  Page 78 of 108 
CONFIDENTIAL  9.2.5.  Immunogenicity Measurements and Samples  
Serum samples for ADA and NAb assessment will be collected at time points according to  
Table 1. 
9.2.6.  Pharmacodynamic and Exploratory Biomarker Procedures  
Not applicable.  
9.2.7.  Future Biomedical Research (Optional)  
Patients who agree to participate in the future biomedical research sub -study will be required to 
consent to this optional sub -study before samples are banked in long -term storage.  The unused 
PK and ADA samples will be stored for up to 15 years after the final date of the database lock.  
The unused samples may be utilized for future biomedical research of AD and  related diseases, 
dupilumab and related pathways.  After 15 years, any residual samples will be destroyed.  The 
results of these future biomedical research analyses will not be presented in the CSR.  
9.2.7.1.  Pharmacogenomic Analysis (Optional)  
Patients who agree t o participate in the genomics sub -study will be required to consent to this 
optional sub -study before collection of the samples.  Whole blood samples for DNA extraction 
should be collected on day 1/baseline (predose) but can be collected at a later study v isit.  
DNA samples will be collected for pharmacogenomics analyses to understand the genetic 
determinants of efficacy and safety associated with the treatments in this study and the molecular 
basis of AD and related diseases.  These samples will be single -coded as defined by the 
International Council on Harmonisation (ICH) guideline E15.  Samples will be stored for up to 
15 years after the final date of the database lock.  If there are specific site or country requirements 
involving the pharmacogenomic analyses wh ich the sponsor is unable to comply with, samples 
will not be collected at those sites.   
The purpose of the pharmacogenomic analyses is to identify genomic associations with clinical or 
biomarker responses to dupilumab, other AD clinical outcome measures and possible AEs.  In 
addition, associations between genomic variants and prognosis or progression of AD as well as 
related diseases may also be studied.  These data may be used or combined with data collected 
from other studies to identify and validate ge nomic markers related to the study drug, target 
pathway, or AD and related diseases.  
Analyses may include sequence determination or single nucleotide polymorphism studies of 
candidate genes and surrounding genomic regions.  Other methods, including whole -exome 
sequencing, whole -genome sequencing, DNA copy number variation, may  also be performed.  The 
list of methods may be expanded to include novel methodology that may be developed during the 
course of this study or sample storage period.  Results from the genomic analyses will not be 
reported in the CSR.  
                                        VV-RIM-00138022-1.0 Approved - 13 Jan 2021 GMT-5:00
Clinical Study Protocol  R668-AD-1924 Amendment 2  
Regeneron Pharmaceuticals, Inc.  Page 79 of 108 
CONFIDENTIAL  10. SAFETY EVALUATION AN D REPORTING  
10.1. Recording and Reporting Adverse Events  
10.1.1.  General Guidelines  
The investigator must promptly record all clinical events occurring during the study data collection 
period from the  time of signing the ICF to the end of study.  Medical conditions that existed or 
were diagnosed prior to the signing of the Informed Consent will be recorded as part of medical 
history.  Abnormal laboratory values and vital signs observed at the time of I nformed Consent 
should also be recorded as medical history.  Any subsequent worsening (ie, any clinically 
significant change in frequency and/or intensity) of a pre -existing condition that is temporally 
associated with the use of the study drug should also  be recorded as an AE.  
At each visit, the investigator will determine whether any AEs have occurred by evaluating the 
patient.  Adverse events may be directly observed, reported spontaneously by the patient, or by 
questioning the patient at each study vis it.  Patients should be questioned in a general way, without 
asking about the occurrence of any specific symptoms.  The investigator must assess all AEs to 
determine seriousness, severity, and causality, in accordance with the definitions in Section  10.2.  
The investigator’s assessment must be clearly documented in the site’s source documentation with 
the investigator’s signature.  The investigator shoul d follow up on SAEs (and AESIs) until they 
have resolved or are considered clinically stable; AEs should be followed until they are resolved 
or last study visit, whichever comes first.  
Always report the diagnosis as the AE or SAE term.  When a diagnosis is  unavailable, report the 
primary sign or symptom as the AE or SAE term with additional details included in the narrative 
until the diagnosis becomes available.  If the signs and symptoms are distinct and do not suggest 
a common diagnosis, report them as in dividual entries of AE or SAE.   
Laboratory results, vital signs, and other diagnostic results or findings  should be appraised by the 
investigator to determine their clinical significance.   Isolated abnormal laboratory results, vital 
sign findings, or othe r diagnostic findings (ie, not part of a reported diagnosis) should be reported 
as AEs if they are symptomatic, lead to study drug discontinuation,  dose reduction,  require 
corrective treatment, or constitute an AE in the investigator ’s clinical judgment . 
For events that are serious due to hospitalization, the reason for hospitalization must be reported 
as the serious adverse event (diagnosis or symptom requiring hospitalization).  A procedure is not 
an AE or SAE, but the reason for the procedure may be an A E or SAE.  Pre -planned (prior to 
signing the Informed Consent Form) procedure s, treatment s requiring hospitalization for pre -
existing conditions that do not worsen in severity, and admission for palliative or social care should 
not be reported as SAEs (see  Section 10.2 for Definitions).  
For deaths, the underlying or immediate cause of death should always be reported as an SAE.  
Any SAE that may occur subsequent to the reporting period (end of the study) that the investigator 
assesses as related to study drug should also be reported.  
All AEs, SAEs, AESIs, and pregnancy reports are to be reported according to the procedures in 
Section 10.1.3 . 
                                        VV-RIM-00138022-1.0 Approved - 13 Jan 2021 GMT-5:00
Clinical Study Protocol  R668-AD-1924 Amendment 2  
Regeneron Pharmaceuticals, Inc.  Page 80 of 108 
CONFIDENTIAL  10.1.2.  Reporting Procedure  
All events (serious and non -serious) must be reported with investigator’s assessment of the event’s 
seriousness, sever ity, and causality to the blinded study  drug.  For SAEs and AESIs, a detailed 
narrative summarizing the course of the event, including its evaluation, treatment, and outcome 
should be provided on the AE CRF.  Specific or estimated dates of event onset, tre atment, and 
resolution should be included, when available.  Medical history, concomitant medications, and 
laboratory data that are relevant to the event should also be summarized in the narrative.  For fatal 
events, the narrative should state whether an au topsy was or will be performed and include the 
results, if available.  Information not available at the time of the initial report must be documented 
in a follow -up report.  Source documents (including hospital or medical records, diagnostic reports, 
etc.) will be summarized in the narrative on the AE CRF and retained at the study center and 
available upon request.  
Urgent safety queries must be followed up and addressed promptly.  Follow -up information and 
response to non -urgent safety queries should be com bined for reporting to provide the most 
complete data possible within each follow -up. 
10.1.3.  Events that Require Expedited Reporting to Sponsor  
The following events also require reporting to the sponsor (or designee) within 24 hours of 
learning of the event:  
• SAEs 
• Adverse Events of Special Interest (serious and nonserious) :  Adverse events of 
special interest for this study include the following:   
• Anaphylactic reaction  
• Systemic hypersensitivity reactions  
• Helminthic infections  
• Any severe type of conjunctivitis or b lepharitis  
• Keratitis 
• Clinically symptomatic eosinophilia (or eosinophilia associated with clinical 
symptoms)  
• Pregnancy:  Although pregnancy is not considered an AE, it is the responsibility 
of the investigator to report to the sponsor (or designee), withi n 24 hours of 
identification, any pregnancy occurring in a female  during the study or within 12 weeks 
of the last dose of study drug.  Any complication of pregnancy affecting a female study 
patient and/or fetus and/or newborn that meets the SAE criteria m ust be reported as an 
SAE.  Outcome for all pregnancies should be reported to the sponsor.  
Refer to the study reference manual for the procedures to be followed.  
                                        VV-RIM-00138022-1.0 Approved - 13 Jan 2021 GMT-5:00
Clinical Study Protocol  R668-AD-1924 Amendment 2  
Regeneron Pharmaceuticals, Inc.  Page 81 of 108 
CONFIDENTIAL  10.2. Definitions  
10.2.1.  Adverse Event  
An AE is any untoward medical occurrence in a patient administered a  study drug which may or 
may not have a causal relationship with the study drug.  Therefore, an AE is any unfavorable and 
unintended sign (including abnormal laboratory finding), symptom, or disease which is temporally 
associated with the use of a study dr ug, whether or not considered related to the study drug (ICH 
E2A Guideline.  Clinical Safety Data Management: Definitions and Standards for Expedited 
Reporting, Oct 1994 ). 
10.2.2.  Serious Adverse Event  
An SAE is any untoward medical occurrence that at any dose:  
• Results in death – includes all deaths, even those that appear to be completely unrelated 
to study drug (eg, a car accident in which a patient is a passenger).  
• Is life-threatening  – in the view of the investigator, the patient is at immediate risk of 
death at the time of the event.  This does not include an AE that had it occurred in a 
more severe form, might have caused death.  
• Requires in -patient hospitalization  or prolongation of existing hospitalization .  In-
patient h ospitalization is defined as a hospital admission (any duration) or an 
emergency room visit for longer than 24 hours.  Prolongation of existing hospitalization 
is defined as a hospital stay that is longer than was originally anticipated for the event, 
or is prolonged due to the development of a new AE as determined by the investigator 
or treating physician.  
• Results in persistent or significant disability/incapacity  (substantial disruption of 
one’s ability to conduct normal life functions).   
• Is a congenital  anomaly/birth defect  
• Is an important medical event - Important medical events may not be immediately 
life-threatening or result in death or hospitalization, but may jeopardize the patient or 
may require intervention to prevent one of the other serious out comes listed above (eg, 
intensive treatment in an emergency room or at home for allergic bronchospasm; blood 
dyscrasias or convulsions that do not result in hospitalization; or development of drug 
dependency or drug abuse).  
Criteria for reporting SAEs must  be followed for these events.  
10.2.3.  Adverse Events of Special Interest  
An AESI (serious or non -serious) is one of scientific and medical interest specific to the sponsor’s 
product or program, for which ongoing monitoring and rapid communication by the investig ator 
to the sponsor can be appropriate.  Such an event might warrant further investigation in order to 
characterize and understand it.   
                                        VV-RIM-00138022-1.0 Approved - 13 Jan 2021 GMT-5:00
Clinical Study Protocol  R668-AD-1924 Amendment 2  
Regeneron Pharmaceuticals, Inc.  Page 82 of 108 
CONFIDENTIAL  10.2.4.  Severity 
The severity of AEs will be graded according to the following scale:  
Mild:  Does not interfere in a significan t manner with the patient normal functioning level.  It may 
be an annoyance.  Prescription drugs are not ordinarily needed for relief of symptoms but may be 
given because of personality of the patient.  
Moderate:   Produces some impairment of functioning but  is not hazardous to health.  It is 
uncomfortable or an embarrassment.  Treatment for symptom may be needed.  
Severe:  Produces significant impairment of functioning or incapacitation and is a definite hazard 
to the subject’s health.  Treatment for symptom may be given and/or patient hospitalized.  
If a laboratory value is considered an AE, its severity should be based on the degree of 
physiological impairment the value indicates.  
Injection Site Reactions  
The severity of injection site reactions will be grade d according to the following scale (semi -colon 
indicates “or” within description of grade:  
Mild:  Pain that does not interfere with activity; mild discomfort to touch; <5 cm of erythema or 
induration that does not interfere with activity  
Moderate :  Pain th at requires repeated use of non -narcotic pain reliever >24 hours or interferes 
with activity; discomfort with movement; 5.1 cm to 10 cm erythema or induration or induration 
that interferes with activity  
Severe:  Pain that requires any use of narcotic pain reliever or that prevents daily activity; 
significant discomfort at rest; >10 cm erythema or induration; prevents daily activity; requires ER 
visit or hospitalization; necrosis or exfoliative dermatitis  
10.2.5.  Causality  
The investigator must provide causality ass essment as whether or not there is a reasonable 
possibility that the drug caused the adverse event, based on evidence or facts, his/her clinical 
judgment, and the following definitions.  The causality assessment must be made based on the 
available information and can be updated as new information becomes available.  
The following factors should be considered when assessing causality:  
• Temporal relationship: time to onset vs. time drug was administered  
• Nature of the reac tions: immediate vs. long term  
• Clinical and pathological features of the events  
• Existing information about the drug & same class of drugs  
• Concomitant medications  
• Underlying and concurrent illnesses  
• Response to dechallenge (drug discontinuation) or dose  reduction  
                                        VV-RIM-00138022-1.0 Approved - 13 Jan 2021 GMT-5:00
Clinical Study Protocol  R668-AD-1924 Amendment 2  
Regeneron Pharmaceuticals, Inc.  Page 83 of 108 
CONFIDENTIAL  • Response to rechallenge (re -introduction of the drug) or dose increase, when 
applicable  
• Patient’s medical and social history  
Causality to the study drug (including study drug administration):  
• Related: 
− The AE follows a reasonable temporal sequence from study drug administration 
and cannot be reasonably explained by the nature of the reaction, patient’s clinical 
(eg, disease under study, concurrent diseases, concomitant medications), or other 
external factors.  
or 
− The AE follows a reasonable temporal sequence from study drug administration 
and is a known reaction to the drug under study or its class of drugs or is 
predicted by known pharmacology.  
• Not Related:  
− The AE does not follow a reasonable sequence from study drug administration or 
can be reasonably explained by the nature of the reaction, patient’s clinical state 
(eg, disease under study, concurrent diseases, and concomitant medications) or 
other external factors.  
Causality to the study conduct (protocol specified procedure):  
• Related: 
− The AE follows a reasonable temporal sequence from a protocol specified 
procedure and cannot be reasonably explained by the nature of the reaction, 
patient’s clinical (eg, disease under study, concurrent diseases, concomitant 
medications), or other external f actors. 
• Not Related:  
− The AE does not follow a reasonable sequence from a protocol specified 
procedure or can be reasonably explained by the nature of the reaction, patient’s 
clinical state (eg, disease under study, concurrent diseases, and concomitant 
medications) or other external factors.  
10.3. Safety Monitoring  
The investigator will monitor the safety of study patient at his/her site(s) as per the requirements 
of this protocol and consistent with current Good Clinical Practice (GCP).  Any questions or 
concerns should be discussed with the sponsor in a timely fashion.  The sponsor will monitor the 
safety data from across all study sites.  The Medical/Study Director will have primary 
responsibility for the emerging safety profile of the compound, but will be supp orted by other 
departments (eg, Pharmacovigilance; Risk Management; Biostatistics and Data Management).  
Safety monitoring will be performed on an ongoing basis and on a periodic cumulative aggregate 
basis. 
                                        VV-RIM-00138022-1.0 Approved - 13 Jan 2021 GMT-5:00
Clinical Study Protocol  R668-AD-1924 Amendment 2  
Regeneron Pharmaceuticals, Inc.  Page 84 of 108 
CONFIDENTIAL  10.4. Notifying Health Authorities, Institutional Revie w Board /Ethics 
Committee, and Investigators  
During the study, the sponsor and/or the CRO will inform health authorities, IECs/IRBs, and the 
participating investigators of any SUSARs (Suspected Unexpected Serious Adverse Reactions) 
occurring in other study  centers or other studies of the active study drug (dupilumab), as 
appropriate per local reporting requirements.  In addition, the sponsor and/or CRO will comply 
with any additional local safety reporting requirements.  All notifications to investigators w ill 
contain only blinded information.   
Upon receipt of the sponsor’s notification of a SUSAR that occurred with the study drug, the 
investigator will inform the Institutional Review Board (IRB)/Ethics Committee (EC) unless 
delegated to the sponsor.  
Event expectedness for study drug (dupilumab) is assessed against the Reference Safety 
Information section of the Investigator’s Brochure that is effective for expedited safety reporting.  
At the completion of the study, the sponsor will report all safety observat ions made during the 
conduct of the trial in the Clinical Study Report to health authorities and IECs/IRB as appropriate.  
11. STATISTICAL PLAN  
This section provides the basis for the SAP for the study.  The SAP will be revised prior to the end 
of the study to accommodate amendments to the clinical study protocol and to make changes to 
adapt to unexpected issues in study execution and data that may affect the planned analyses.  The 
final SAP will be issued before the first database lock.  
Endpoints are listed in Section 4 Analysis variables are listed in Section  5. Handling of missing 
data due to the COVID -19 pandemic and any additional analyses required to investigate the impact 
of COVID -19 to understand estimated treatment effect and safety will be d etailed in the SAP.  
11.1. Statistical Hypothesis  
For comparison of dupilumab treatment to placebo, the following hypothesis of the primary 
endpoint will be tested:  
• Null hypothesis: the success rate (where success is proportion of patients achieving an 
IGA score of 0 or 1 on hand and foot at week 16) is equal between dupilumab and 
placebo  
• Alternative hypothesis: the success rate differs at week 16 between dupilumab and 
placebo. 
                                        VV-RIM-00138022-1.0 Approved - 13 Jan 2021 GMT-5:00
Clinical Study Protocol  R668-AD-1924 Amendment 2  
Regeneron Pharmaceuticals, Inc.  Page 85 of 108 
CONFIDENTIAL  11.2. Justification of Sample Size  
The planned sample size is approximately 130 patients (65 patients in each treatment arm).  This 
sample size will yield >85% power to detect a treatment difference of 24% in the proportion of 
patients achieving IGA hand and foot (0, 1) at week 16 between p lacebo (10%) and dupilumab 
(34%) at a 2 -sided significant level of 5% using Chi -square test and assuming a dropout rate of 
10%. The assumed treatment difference of 24% is based on the effect of 26% observed in 
dupilumab phase 3 monotherapy studies in adult  patients with AD and adjusted to account for the 
potential inclusion of some patients with ACD who would be missed with certain patch testing (ie, 
TRUE test) at screening.  
It is reasonable to assume that the effect size of dupilumab on AD of hands and fe et would be 
similar to that seen in global AD lesions  in previously conducted phase 3 trials as the underlying 
pathophysiology is same.  Moreover, a recent observational study to compare effect of dupilumab 
on hand lesions vs. lesions on other parts of the  body found a high degree of concordance in terms 
of onset of effect and overall effect at week 16  (Oosterhaven, 2018 ). 
11.3. Analysis Sets  
11.3.1.  Efficacy Analysis Sets  
The full analysis set (FAS) includes all randomized patients.  E fficacy analyses will be based on 
the treatment allocated at randomization (as randomized).  
The per protocol set (PPS) includes all patients in the FAS except for those who are excluded 
because of specified important protocol deviations.  A preliminary li st of such important protocol 
deviations is provided below and the final list will be specified in the SAP prior to database lock.   
• Entered study even though entry criteria not satisfied  
• Received an excluded concomitant treatment  
• Received wrong treatment or incorrect dose  
• Other treatment compliance  
All efficacy variables will be evaluated on the FAS; the primary endpoint will also be evaluated 
on the PPS.  Analysis on the FAS will be considered to be primary.  
11.3.2.  Safety Analysis Set  
The safety analysis set (SAF) includes all randomized patients who received any study drug; it is 
based on the treatment received (as treated).  Treatment compliance/administration and all clinical 
safety variables will be analyzed using the SAF.  
11.3.3.  Pharmacokinetic Analysis Set  
The PK analysis population includes all patients who received any study drug and who had at least 
1 non-missing result following the first dose of study drug.  
                                        VV-RIM-00138022-1.0 Approved - 13 Jan 2021 GMT-5:00
Clinical Study Protocol  R668-AD-1924 Amendment 2  
Regeneron Pharmaceuticals, Inc.  Page 86 of 108 
CONFIDENTIAL  11.3.4.  Immunogenicity Analysis Sets  
The ADA analysis set includes all patients who received any study drug a nd had at least 1 non -
missing ADA result following the first study dose.  
The NAb analysis set includes all patients who received any study drug and who are negative in 
the ADA assay or with at least 1 non -missing result in the NAb assay (patients who are ADA 
negative are set to negative in the NAb analysis set).  
11.4. Statistical Methods  
For continuous variables, descriptive statistics will include the following information: the number 
of patients reflected in the calculation (n), mean, standard deviation, Q1, m edian, Q3, minimum, 
and maximum.  
For categorical or ordinal data, frequencies and percentages will be displayed for each category.  
11.4.1.  Patient Disposition  
The following will be provided:  
• The total number of screened patients  
• The total number of randomized pat ients:  received a randomization number  
• The total number of patients who discontinued the study, and the reasons for 
discontinuation  
• The total number of patients who discontinued from study treatment, and the reasons 
for discontinuation  
• A listing of patients treated but not randomized, patients randomized but not treated, 
and patients randomized but not treated as randomized  
• A listing of patients prematurely discontinued from treatment, along with reasons for 
discontinuation  
11.4.2.  Demography and Baseline Ch aracteristics  
Demographic and baseline characteristics will be summarized descriptively by treatment group, 
and by all patients combined.   
11.4.3.  Efficacy Analyses  
For all efficacy variables, the analysis will be comparisons of the dupilumab treatment group with  
the placebo group.  
11.4.3.1.  Primary Efficacy Analysis  
The primary endpoint of proportion of patients achieving an IGA score of 0 or 1 on hand and foot 
at week 16 will be analyzed using the Cochran -Mantel-Haenszel (CMH) test to assess the 
difference in the proporti on of responders in the FAS adjusting for the randomization stratification 
factors (age [adults vs. adolescents], disease severity of IGA hand and foot [3 vs. 4], and 
geographic region [United States v ersus Japan versus other countries]).  
                                        VV-RIM-00138022-1.0 Approved - 13 Jan 2021 GMT-5:00
Clinical Study Protocol  R668-AD-1924 Amendment 2  
Regeneron Pharmaceuticals, Inc.  Page 87 of 108 
CONFIDENTIAL  The primary esti mand of interest, the intercurrent event(s) strategy, and missing data handling 
methods for the primary endpoint (binary response) are described in  Table 2.  
Table 2: Summary of Primary Estimand for Primary Endpoint  
Endpoint  Intercurrent Event(s) Strategy Missing Data 
Handling Method  
Primary efficacy 
endpoint (proportion of 
patients achieving an 
IGA score of 0 or 1 on 
hand and foot at 
week 16) Rescue treatment  Composite strategy: 
Patients will be 
considered as 
non-responders after 
such events.  Patient will be 
considered as 
non-responder if 
patient’s IGA on hand 
and foot is missing at 
week 16 due to patient 
discontinuation from 
study or other reasons.  Treatment 
discontinuation  Treatment policy 
strategy: Data collected 
after the patient 
discontinued treatment 
will be included in the 
analysis. 
To account for use of rescue treatment, patients will be considered as non -responders for all time 
points subsequent to the use of rescue treatment in the primary analysis.   If a patient has missing 
value with any reason for IGA on hand and foot assessment at week 16, the patient will be 
classified as a non -responder at week 16.  
Sensitivity analysis using the last observation carried forward (LOCF) approach or the worst 
observation carried forward (WOCF) approach to determine patient’s status at week 16 will be 
conducted to assess the robustness of the primary e fficacy analysis with regards to handling of 
missing data.  The efficacy data will be set to missing after rescue treatment is used, then the LOCF 
or WOCF method will be used to determine patients’ status at week 16.  
In addition, the CMH method adjusted b y randomization strata will also be performed on all 
observed data regardless if rescue treatment is used.  A patient with missing data will be counted 
as a non-responder.  Other sensitivity analyses may be conducted.  
Subgroup analysis (eg, by age group , by anatomical area of involvement [hand involvement only 
vs. involvement of hand and foot or foot involvement only]) will  also be performed.  
11.4.3.2.  Secondary Efficacy Analysis  
The primary estimand of interest, the intercurrent event(s) strategy, and missing data h andling 
methods for the key secondary endpoint (binary response) are described in  Table 3. 
                                        VV-RIM-00138022-1.0 Approved - 13 Jan 2021 GMT-5:00
Clinical Study Protocol  R668-AD-1924 Amendment 2  
Regeneron Pharmaceuticals, Inc.  Page 88 of 108 
CONFIDENTIAL  Table 3: Summary of Primary Estimand for Key Secondary Endpoint  
Endpoint  Intercurrent Event(s) Strategy Missing Data 
Handling Method  
Key secondary efficacy 
endpoint (proportion of 
patients with 
improvement 
(reduction) of weekly 
average of daily hand 
and foot peak 
Pruritus NRS ≥4 from 
baseline to week 16)  Rescue treatment  Composite strategy: 
Patients will be 
considered as 
non-responders after 
such events.  Patient will be 
considered as 
non-responder if 
patient’s weekly 
average of daily hand 
and foot peak 
Pruritus NRS is missi ng 
at week 16 due to 
patient discontinuation 
from study or other 
reasons. Treatment 
discontinuation  Treatment policy 
strategy: Data collected 
after the patient 
discontinued treatment 
will be included in the 
analysis. 
Secondary efficacy endpoints that measure binary responses (eg, improvement of weekly average 
of daily peak Pruritus NRS ≥4 from baseline to week 16) will be analyzed in the same fashion as 
the primary analysis.  
Continuous secondary efficacy endpoints (eg, percent change mTLSS for hand/foo t lesions from 
baseline to week 16) will be analyzed using an analysis of covariance (ANCOVA) model for the 
FAS with treatment group, randomization stratification factors (age [adults vs. adolescents], 
disease severity of IGA hand and foot [3 vs. 4], and g eographic region [United States v ersus Japan 
versus other countries]), and relevant baseline measurement included in the model.  To account  
for the impact of rescue treatment on the efficacy effect, patients' efficacy data through week 16 
after the rescue treatment use will be set to missing.  The missing data for continuous endpoints 
will be imputed by the pattern -mixture approach where the WOCF approach will be used for the 
missing due to rescue treatment, AE, and lack of efficacy and the multiple imputat ion (MI) 
approach will be used for the missing due to other reasons.  The MI Statistical Analysis Software 
(SAS) procedure with Markov Monte Carlo algorithm will be applied for multiple times.  The 
complete datasets created based on the pattern -mixture app roach will be analyzed using the 
ANCOVA model defined previously, and the SAS MIANALYZE procedure will be used to 
generate valid statistical inferences by combining results from these multiple analyses using 
Rubin’s formula.  
For the endpoint of percent cha nge in mTLSS for hand/foot lesions from baseline to week 16, the 
empirical cumulative distribution function (CDF) curves showing response in dupilumab and 
placebo groups for different responder thresholds will be provided.  
All efficacy data will be used fo r analysis regardless of whether the patient is on study treatment 
or discontinues the study treatment but remains in the study.  In addition, the MI with the 
ANCOVA model and the ANCOVA model based on LOCF or WOCF imputation method will be 
performed as th e sensitivity analyses.  Other sensitivity analysis such as the MI approach with 
ANCOVA model on all observed data regardless of rescue use will be conducted.  Additional 
details on sensitivity analyses will be provided in the SAP.  
                                        VV-RIM-00138022-1.0 Approved - 13 Jan 2021 GMT-5:00
Clinical Study Protocol  R668-AD-1924 Amendment 2  
Regeneron Pharmaceuticals, Inc.  Page 89 of 108 
CONFIDENTIAL  11.4.4.  Control of Multiplicity  
Type I error rate will be controlled using a hierarchical testing procedure for the primary and 
secondary efficacy endpoints at the 2 -sided 0.05 level.  The hierarchy order will be specified in 
the SAP prior to database lock.  
11.4.5.  Safety Analysis  
Safety analysi s will be based on the SAF.  This includes reported TEAEs, AESIs, and other safety 
information (eg, clinical laboratory evaluations, vital signs).  A summary of safety results for each 
treatment group will be presented.  
11.4.5.1.  Adverse Events  
Definitions  
For safety variables, 2 observation periods are defined:  
• The pretreatment period is defined as the time from signing the ICF to before the first 
dose of study drug.  
• The treatment -emergent period is defined as the day from first dose of study drug to 
end of study.  The treatment -emergent period includes the 16 -week treatment period 
and 12-week follow -up period.  
− Treatment period: date of the first dose of study drug to week 16 visit date (study 
day 113 starting from the first dose of study drug if week 16 visit date is 
unavailable) or early termination date, whichever comes first.  
− Follow-up period: date after week 16 visit date (study day 113 starting from first 
dose of study drug if week 16 visit date is unavailable) to end of study.  
Treatment -emergent adverse event s are defined as those that are not present at baseline or represent 
the exacerbation of a pre -existing condition during the treatment -emergent period.  
Analysis 
All AEs reported in this study will be coded using the currently available version of the Medic al 
Dictionary for Regulatory Activities (MedDRA®).  Coding will be to lowest level terms.  The 
preferred term (PT), and the primary system organ class (SOC) will be listed.  
Summaries of all TEAEs by treatment group for overall during the treatment -emergent period, 
during the 16 -week treatment period, and during the follow -up period will include:  
• The number (n) and percentage (%) of patients with at least 1 TEAE by SOC and PT  
• TEAEs by severity (according to the grading scale outlined in Section  10.2.4 ), 
presented by SOC and PT  
• TEAEs by relationship to treatment (related, not related), presented by SOC and PT  
• Treatment -emergent AESIs (defined with a PT or a prespecified grouping)  
Deaths and other SAEs will be listed and summarized by treatment group.  
                                        VV-RIM-00138022-1.0 Approved - 13 Jan 2021 GMT-5:00
Clinical Study Protocol  R668-AD-1924 Amendment 2  
Regeneron Pharmaceuticals, Inc.  Page 90 of 108 
CONFIDENTIAL  Treatment -emergent adverse events leading to permanent treatment discontinuation will be listed 
and summarized by treatment group.  
11.4.5.2.  Other Safety  
Vital Signs  
Vital signs (temperature, pulse, blood pressure, and respiration rate) will be summarized by 
baseline and change from baseline to each scheduled assessment time with descriptive statistics.  
The number and percentage of patients with a treatment -emergent po tentially clinically significant 
value (PCSV) will be summarized for each vital sign variable.  The criteria for treatment -emergent 
PCSV will be defined in the SAP.  
Laboratory Tests  
Laboratory test results will be summarized by baseline and change from bas eline to each scheduled 
assessment time with descriptive statistics.  
Number and percentage of patients with a treatment -emergent PCSV will be summarized for each 
clinical laboratory test.  The criteria for treatment -emergent PCSV will be defined in the SAP .  
Shift tables based on baseline normal/abnormal and other tabular and graphical methods may be 
used to present the results for laboratory tests of interest.  
Listings will be provided with flags indicating the out of laboratory range values.  
11.4.5.3.  Treatment Exp osure 
The duration of exposure during the study will be presented by treatment group and calculated as:  
(Date of last study drug injection – date of first study drug injection) + 14 days  
The number (%) of patients randomized and exposed to double -blind study drug will be presented 
by specific time periods for each treatment group.  The time periods of interest will be specified 
in the SAP.  In addition, duration of exposure during the study will be summarized for each 
treatment group using number of patien ts, means, standard deviation, minimums, Q1, medians, 
Q3, and maximums.  A summary of the number of doses by treatment group will be provided as 
well. 
11.4.5.4.  Treatment Compliance  
The compliance with study treatment will be calculated as follows:  
Treatment Complia nce = (Number of study drug injections during exposure 
period)/(Number of planned study drug injections during exposure period) × 100%  
The treatment compliance will be presented by specific ranges for each treatment group.  The 
ranges of interest will be s pecified in the SAP.  
                                        VV-RIM-00138022-1.0 Approved - 13 Jan 2021 GMT-5:00
Clinical Study Protocol  R668-AD-1924 Amendment 2  
Regeneron Pharmaceuticals, Inc.  Page 91 of 108 
CONFIDENTIAL  11.4.6.  Pharmacokinetics  
11.4.6.1.  Analysis of Drug Concentration Data  
The concentrations of functional dupilumab over time will be summarized by descriptive statistics.  
No formal statistical hypothesis testing will be performed.  
11.4.7.  Analysis of Immunogeni city Data  
Immunogenicity will be characterized by the ADA and NAb response observed:  
• Pre-existing immunoreactivity, defined as a positive ADA assay response at baseline, 
with all post -dose ADA results negative, or a positive assay response at baseline, w ith 
all post-dose ADA assay responses less than 4 -fold over baseline titer levels  
• Treatment -emergent ADA response, defined as any post -dose positive ADA assay 
response when the baseline results are negative or missing  
• Treatment boosted ADA response, define d as any post -dose positive ADA assay 
response that is 4 -fold over baseline titer levels when baseline is positive in the ADA 
assay  
• Maximum ADA titer values  
− Low (titer <1,000)  
− Moderate (1,000≤ titer ≤10,000)  
− High (titer >10,000)  
• NAb status for samples that are positive in the ADA assay  
Listings of pre -existing, treatment -boosted, and treatment -emergent ADA responses, ADA titers 
and NAb positivity presented by patient, time point, and dose group will be provided.  Incidence 
of treatment-emergent ADA and NAb will be assessed as absolute occurrence (N) and percent of 
patients (%), grouped by dose group and ADA titer level.  
Plots of drug concentrations will be examined and the influence of ADAs and NAbs on individual 
PK profiles evalu ated.  Assessment of impact of ADA and NAbs on safety and efficacy may be 
provided.  
11.5. Timing and Operational Considerations of Statistical Analyses  
No interim analysis is planned for this study.  The unblinded primary analysis may be performed 
once all patients in the study have completed the 16 -week treatment period.  This primary analysis 
will be considered the final analysis for the primary and sec ondary efficacy endpoints.  Hence 
there will be no need for alpha adjustment due to the primary analysis.  
If a decision is made to perform the primary analysis, in order to maintain study integrity with 
respect to the post -treatment follow -up visits, safe ty visits and analyses, a dissemination plan will 
be written.  This plan will clearly identify the team (including the statistician) that will perform 
the primary analysis and all related activities, restrict other clinical team members and other 
Sponsor p ersonnel from access to individual patient treatment allocation and site level analysis 
results, and ensure that the dedicated team will not participate in the data review or data decisions 
                                        VV-RIM-00138022-1.0 Approved - 13 Jan 2021 GMT-5:00
Clinical Study Protocol  R668-AD-1924 Amendment 2  
Regeneron Pharmaceuticals, Inc.  Page 92 of 108 
CONFIDENTIAL  for the following post treatment analyses.  However, the dedicated  team can participate in the 
analysis following the final database lock.  
11.6. Statistical Considerations Surrounding the Premature Termination 
of a Study  
If the study is terminated prematurely, only those parameters required for the development 
program and/or r eporting to regulatory authorities will be summarized.  Investigator and sponsor 
responsibilities surrounding the premature termination of a study are presented in Section  15.1. 
12. QUALITY CONTROL AND QUALITY ASSURANCE  
In accordance with ICH E6, the sponsor is responsible for quality assurance to ensure that the 
study is conducted, and the data generated, recorded, and reported in compliance with the pro tocol, 
GCP, and any applicable regulatory requirement(s).  The planned quality assurance and quality 
control procedures for the study are described in this section.  
12.1. Data Management and Electronic Systems  
12.1.1.  Data Management  
A data management plan specifying al l relevant aspects of data processing for the study (including 
data validation [quality -checking], cleaning, correcting, releasing) will be maintained and stored 
at Regeneron (Sponsor).  
A medical coding plan will specify the processes and the dictionary us ed for coding.  All data 
coding (eg, AEs, baseline findings, medication, medical history/surgical) will be done using 
internationally recognized and accepted dictionaries.  
The CRF data for this study will be collected with an electronic data capture (EDC).  
12.1.2.  Electronic Systems  
Electronic systems that may be used to process and/or collect data in this study will include the 
following:  
• IVRS/IWRS system – randomization, study drug supply  
• EDC system – data capture  – Medidata Rave  
• Statistical Analysis System (SAS)  – statistical review and analysis  
• Pharmacovigilance safety database  
• Digital archive system for photographs  
• eCOA instruments/eDiaries/tablet devices for some of the efficacy assessment data  
                                        VV-RIM-00138022-1.0 Approved - 13 Jan 2021 GMT-5:00
Clinical Study Protocol  R668-AD-1924 Amendment 2  
Regeneron Pharmaceuticals, Inc.  Page 93 of 108 
CONFIDENTIAL  12.2. Study Monitoring  
12.2.1.  Monitoring of Study Sites  
The study monitor and/or designee (eg, contract research organization [CRO] monitor) will visit 
each site prior to enrollment of the first patient, and periodically during the study.  This study will 
use the principles of risk -based monitoring (ICH).  This  means that the number of visits for any 
given site may vary based on site risk indicators.  The investigator must allow study -related 
monitoring.  
The study monitors will perform ongoing source data review to verify that data recorded in the 
CRF by authori zed site personnel are accurate, complete, and verifiable from source documents, 
that the safety and rights of patients are being protected, and that the study is being conducted in 
accordance with the current approved protocol version and any other study agreements, ICH GCP, 
and all applicable regulatory requirements.  
12.2.2.  Source Document Requirements  
Investigators are required to prepare and maintain adequate and accurate patient records (source 
documents).  The site is responsible to ensure quality within the ir records and systems and are 
accountable for ensuring that all source data and CRF data are timely, accurate and complete.  
The investigator must keep all source documents on file with the CRF (throughout this protocol, 
CRF refers to either a paper CRF or  an electronic CRF).  Case report forms and source documents 
must be available at all times for inspection by authorized representatives of the sponsor and 
regulatory authorities.  
12.2.3.  Case Report Form Requirements  
Study data obtained in the course of the clini cal study will be recorded on electronic Case Report 
Forms (CRFs) within the EDC system by trained site personnel.  All required CRFs must be 
completed for each and every patient enrolled in the study.  The investigator must ensure the 
accuracy, completene ss, and timeliness of the data reported to the sponsor in the CRFs.  After 
review of the clinical data for each patient, the investigator must provide an electronic signature.  
A copy of each patient CRF casebook is to be retained by the investigator as pa rt of the study 
record and must be available at all times for inspection by authorized representatives of the sponsor 
and regulatory authorities.  
Corrections to the CRF will be entered in the CRF by the investigator or an authorized designee.  
All changes,  including date and person performing corrections, will be available via the audit trail, 
which is part of the EDC system.  For corrections made via data queries, a reason for any alteration 
must be provided.  
12.3. Audits and Inspections  
This study may be subjec t to a quality assurance audit or inspection by the sponsor or regulatory 
authorities.  Should this occur, the investigator is responsible for:  
• Informing the sponsor of a planned inspection by the authorities as soon as 
notification is received, and author izing the sponsor’s participation in the inspection  
                                        VV-RIM-00138022-1.0 Approved - 13 Jan 2021 GMT-5:00
Clinical Study Protocol  R668-AD-1924 Amendment 2  
Regeneron Pharmaceuticals, Inc.  Page 94 of 108 
CONFIDENTIAL  • Providing access to all necessary facilities, study data, and documents for the 
inspection or audit  
• Communicating any information arising from inspection by the regulatory authorities 
to the sponsor immed iately 
• Taking all appropriate measures requested by the sponsor to resolve the problems 
found during the audit or inspection  
Documents subject to audit or inspection include but are not limited to all source documents, CRFs, 
medical records, correspondence , ICFs, IRB/EC files, documentation of certification and quality 
control of supporting laboratories, and records relevant to the study maintained in any supporting 
pharmacy facilities.  Conditions of study material storage are also subject to inspection.  In 
addition, representatives of the sponsor may observe the conduct of any aspect of the clinical study 
or its supporting activities both within and outside of the investigator's institution.  
In all instances, the confidentiality of the data must be respec ted. 
12.4. Study Documentation  
12.4.1.  Certification of Accuracy of Data  
A declaration assuring the accuracy and content of the data recorded on the eCRF must be signed 
electronically by the investigator.  This signed declaration accompanies each set of patient final 
eCRF that will be provided to the sponsor.  
12.4.2.  Retention of Records  
The investigator must retain all essential study documents, including ICFs, source documents, 
investigator copies of CRFs, and drug accountability records for at least 15  years following the 
completion or discontinuation of the study, or longer, if a longer period is required by relevant 
regulatory authorities.  The investigator must obtain written approval from the sponsor before 
discarding or destroying any essential study documents during the retention period following study 
completion or discontinuation.  Records must be destroyed in a manner that ensures 
confidentiality.  
If the investigator's personal situation is such that archiving can no longer be ensured, the 
investigator must inform the sponsor (written notification) and the relevant records will be 
transferred to a mutually agreed -upon destination.  
                                        VV-RIM-00138022-1.0 Approved - 13 Jan 2021 GMT-5:00
Clinical Study Protocol  R668-AD-1924 Amendment 2  
Regeneron Pharmaceuticals, Inc.  Page 95 of 108 
CONFIDENTIAL  13. ETHICAL AND REGULATO RY CONSIDERATIONS   
13.1. Good Clinical Practice Statement  
It is the responsibility of both the sponsor and the investigator(s) to ensure that this clinical study 
will be conducted in accordance with the ethical principles that have their origin in the Declaration 
of Helsinki, and that are consistent with the ICH guidelines for GCP and applicable regulatory 
requirements.  
13.2. Informed C onsent 
Adult Patients  
The principles of informed consent are described in ICH guidelines for GCP.  
The ICF used by the investigator must be reviewed and approved by the sponsor prior to 
submission to the appropriate IRB/EC.  A copy of the IRB/EC  -approved ICF and documentation 
of approval must be provided to the sponsor before study drug will be shipped to the study site.  
It is the responsibility of the investigator or designee (if acceptable by local regulations) to obtain 
written informed conse nt from each patient prior to his/her participation in the study and after the 
aims, methods, objectives, and potential hazards of the study have been explained to the patient in 
language that he/she can understand.  The ICF should be signed and dated by t he patient and by 
the investigator or authorized designee who reviewed the ICF with the patient.   
• Patients who can write but cannot read will have the ICF read to them before signing 
and dating the ICF.  
• Patients who can understand but who can neither writ e nor read will have the ICF 
read to them in presence of an impartial witness, who will sign and date the ICF to 
confirm that informed consent was given.  
The original ICF must be retained by the investigator as part of the patient’s study record, and a 
copy of the signed ICF must be given to the patient.  
If new safety information results in significant changes in the risk/benefit assessment, or if there 
are significant changes to the study procedures, the ICF must be reviewed and updated 
appropriately.  All  study patients must be informed of the new information and provide their 
written consent if they wish to continue in the study.  The original signed revised ICF must be 
maintained in the patient’s study record and a copy must be given to the patient.  
Pediatric Patients  
The principles of informed consent are described in ICH guidelines for Good Clinical Practice.  
The ICF used by the investigator must be reviewed and approved by the sponsor prior to 
submission to the appropriate IRB/EC.  A copy of the IRB/EC  -approved ICF and documentation 
of approval must be provided to the sponsor before study drug will be shipped to the study site.  
It is the responsibility of the investigator or designee (if acceptable by local regulations) to obtain 
written informed conse nt from each patient and his/her parent(s) or legal guardian(s) prior to the 
patient’s participation in the study and after the aims, methods, objectives, and potential hazards 
of the study have been explained to the fullest possible extent in language tha t the patient and the 
                                        VV-RIM-00138022-1.0 Approved - 13 Jan 2021 GMT-5:00
Clinical Study Protocol  R668-AD-1924 Amendment 2  
Regeneron Pharmaceuticals, Inc.  Page 96 of 108 
CONFIDENTIAL  parent(s) or legal guardian(s) can understand.  The ICF should be signed and dated by the patient’s 
parent(s) or legal guardian(s) and the same investigator or designee who explained the ICF.  
Local law must be observed in deciding whe ther 1 or both parents/guardians consent is required.  
If only 1 parent or guardian signs the consent form, the investigator must document the reason the 
other parent or guardian did not sign.  The patient may also be required to sign and date the ICF, 
as determined by the IRB/EC and in accordance with the local regulations and requirements.  
• Patients who can write but cannot read will have the assent form read to them before 
writing their name on the form.  
• Patients who can understand but who can neither wri te nor read will have the ICF 
read to them in presence of an impartial witness, who will sign and date the ICF to 
confirm that informed consent was given.  
The original ICF must be retained by the investigator as part of the patient’s study record, and a 
copy of the signed ICF must be given to the patient’s parent(s) or legal guardian(s).  
If new safety information results in significant changes in the risk/benefit assessment, or if there 
are significant changes to the study procedures, the ICF must be review ed and updated 
appropriately.  All study patients and their parent(s) or legal guardian(s) must be informed of the 
new information and provide their written consent if they wish the patient to continue in the study.  
The original signed revised ICF must be  maintained in the patient’s study record and a copy must 
be given to the patient’s parent(s) or legal guardian(s).  
13.3. Patients Confidentiality and Data Protection  
The investigator must take all appropriate measures to ensure that the anonymity of each study 
patient will be maintained.  Patients should be identified by a patient identification number only, 
on CRFs or other documents submitted to the sponsor.  Documents that will not be submitted to 
the sponsor (eg, signed ICF) must be kept in strict confidence . 
The patient’s and investigator's personal data, which may be included in the sponsor database, will 
be treated in compliance with all applicable laws and regulations.  The sponsor shall take all 
appropriate measures to safeguard and prevent access to thi s data by any unauthorized third party.  
13.4. Institutional Review Board/Ethics Committee  
An appropriately constituted IRB/EC, as described in ICH guidelines for GCP, must review and 
approve: 
• The protocol, ICF, and any other materials to be provided to the patie nts 
(eg, advertising) before any patient may be enrolled in the study  
• Any amendment or modification to the study protocol or ICF before implementation, 
unless the change is necessary to eliminate an immediate hazard to the patient, in 
which case the IRB/EC  should be informed as soon as possible  
• Ongoing studies on an annual basis or at intervals appropriate to the degree of risk  
In addition, the IRB/EC should be informed of any event likely to affect the safety of patients or 
the continued conduct of the c linical study.  
                                        VV-RIM-00138022-1.0 Approved - 13 Jan 2021 GMT-5:00
Clinical Study Protocol  R668-AD-1924 Amendment 2  
Regeneron Pharmaceuticals, Inc.  Page 97 of 108 
CONFIDENTIAL  A copy of the IRB/EC approval letter with a current list of the IRB/EC members and their functions 
must be received by the sponsor prior to shipment of drug supplies to the investigator.  The 
approval letter should include the study number a nd title, the documents reviewed, and the date of 
the review.  
Records of the IRB/EC review and approval of all study documents (including approval of ongoing 
studies) must be kept on file by the investigator.  
13.5. Clinical Study Data Transparency  
Final study re sults will be published on a public clinical trial website according to applicable local 
guidelines and regulations.  Treatment codes will be disseminated to each investigation site 
thereafter.  
14. PROTOCOL AMENDMENTS  
The sponsor may not implement a change in the design of the protocol or ICF without an IRB/EC -
approved amendment.  Where required per local legislation, regulatory authority approval will also 
be sought.  
15. PREMATURE TERMINATIO N OF THE STUDY OR CL OSE-
OUT OF A  SITE 
15.1. Premature Termination of the Study  
The sponsor has the right to terminate the study prematurely.  Reasons may include efficacy, 
safety, or futility, among others.  Should the sponsor decide to terminate the study, the 
investigator(s) will be notified  in writing.  
15.2. Close-out of a Site  
The sponsor and the investigator have the right to close -out a site prematurely.  
Investigator’s Decision  
The investigator must notify the sponsor of a desire to close -out a site in writing, providing at least 
30 days’ notic e.  The final decision should be made through mutual agreement with the sponsor.  
Both parties will arrange the close -out procedures after review and consultation.  
Sponsor’s Decision  
The sponsor will notify the investigator(s) of a decision to close -out a study site in writing.  
Reasons may include the following, among others:  
• The investigator has received all items and information necessary to perform the 
study, but has not enrolled any patient within a reasonable period of time  
• The investigator has viola ted any fundamental obligation in the study agreement, 
including but not limited to, breach of this protocol (and any applicable amendments), 
                                        VV-RIM-00138022-1.0 Approved - 13 Jan 2021 GMT-5:00
Clinical Study Protocol  R668-AD-1924 Amendment 2  
Regeneron Pharmaceuticals, Inc.  Page 98 of 108 
CONFIDENTIAL  breach of the applicable laws and regulations, or breach of any applicable ICH 
guidelines  
• The total number of pat ients required for the study are enrolled earlier than expected  
In all cases, the appropriate IRB/EC and Health Authorities must be informed according to 
applicable regulatory requirements, and adequate consideration must be given to the protection of 
the patients’ interests.  
16. CONFIDENTIALITY  
Confidentiality of information is provided as a separate agreement.  
17. FINANCING AND INSURA NCE 
Financing and insurance information is provided as a separate agreement.  
18. PUBLICATION POLICY  
Publication rights and procedures w ill be outlined in a separate clinical study agreement.  
                                        VV-RIM-00138022-1.0 Approved - 13 Jan 2021 GMT-5:00
Clinical Study Protocol  R668-AD-1924 Amendment 2  
Regeneron Pharmaceuticals, Inc.  Page 99 of 108 
CONFIDENTIAL  19. REFERENCES  
Agner T, Aalto -Korte K, Andersen KE, Foti C, Gimenez -Arnau A, Goncalo M, et al. 
Classification of hand eczema. J Eur Acad Dermatol Venereol 2015; 29(12):2417 -22. 
Agner T, Andersen KE, Brand ao FM, Bruynzeel DP, Bruze M, Frosch P, et al. Hand eczema 
severity and quality of life: a cross -sectional, multicentre study of hand eczema patients. Contact 
Dermatitis 2008; 59(1):43 -7. 
Bagel J, Duffin KC, Moore A, Ferris LK, Siu K, Steadman J, et al. Th e effect of secukinumab on 
moderate-to-severe scalp psoriasis: Results of a 24 -week, randomized, double -blind, placebo -
controlled phase 3b study. J Am Acad Dermatol 2017; 77(4):667 -74. 
Behroozy A, Keegel TG. Wet -work Exposure: A Main Risk Factor for Occupa tional Hand 
Dermatitis. Saf Health Work 2014; 5(4):175 -80. 
Blauvelt A, de Bruin -Weller M, Gooderham M, Cather JC, Weisman J, Pariser D, et al. Long -
term management of moderate -to-severe atopic dermatitis with dupilumab and concomitant 
topical corticosteroi ds (LIBERTY AD CHRONOS): a 1 -year, randomised, double -blinded, 
placebo-controlled, phase 3 trial. Lancet 2017; 389(10086):2287 -303. 
Brans R, Hubner A, Gediga G, John SM. Prevalence of foot eczema and associated occupational 
and non-occupational factors in patients with hand eczema. Contact Dermatitis 2015; 
73(2):100  - 7. 
Charman CR, Venn AJ, Williams HC.  The patient -oriented eczema measure: development and 
initial validation of a new tool for measuring atopic eczema severity from the patients' 
perspective.  Archives of Dermatology. 2004; 140(12):1513 -9. 
Coenraads PJ. Hand eczema. N Engl J Med 2012; 367(19):1829 -37. 
Diepgen TL, Agner T, Aberer W, Berth -Jones J, Cambazard F, Elsner P, et al. Management of 
chronic hand eczema. Contact Dermatitis 2007; 57(4):203 -10. 
Elewski BE, Okun MM, Papp K, Baker CS, Crowley JJ, Guillet G, et al. Adalimumab for nail 
psoriasis: Efficacy and safety from the first 26 weeks of a phase 3, randomized, placebo -
controlled trial. J Am Acad Dermatol 2018; 78(1):90 -9.e1. 
FDA. 2009  Guidance for Industry Drug -Induced Liver Injury: Premarketing Clinical Evaluation, 
Final. 
https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/
UCM174090.pdf Accessed 10 Sept 2018.  
Fowler JF, Ghosh A, Sung J, Emani S, C hang J, Den E, et al. Impact of chronic hand dermatitis 
on quality of life, work productivity, activity impairment, and medical costs. J Am Acad 
Dermatol 2006; 54(3):448 -57. 
Gittler JK, Krueger JG, Guttman -Yassky E. Atopic dermatitis results in intrinsic b arrier and 
immune abnormalities: implications for contact dermatitis. J Allergy Clin Immunol 2013; 
131(2):300 -13. 
Granlund H, Erkko P, Eriksson E, Reitamo S. Comparison of cyclosporine and topical 
betamethasone -17,21-dipropionate in the treatment of severe  chronic hand eczema. Acta Derm 
Venereol 1996; 76(5):371 -6. 
                                        VV-RIM-00138022-1.0 Approved - 13 Jan 2021 GMT-5:00
Clinical Study Protocol  R668-AD-1924 Amendment 2  
Regeneron Pharmaceuticals, Inc.  Page 100 of 108 
CONFIDENTIAL  Hanifin J, Rajka G. Diagnostic features of atopic dermatitis. Acta Derm Venereol Suppl (Stockh) 
1980; 92 (44 –7. 
Hanifin JM, Thurston M, Omoto M, Cherill R, Tofte SJ, Graeber M. The eczema area and  
severity index (EASI): assessment of reliability in atopic dermatitis. EASI Evaluator Group. Exp 
Dermatol 2001; 10(1):11 -8. 
Held E, Skoet R, Johansen JD, Agner T. The hand eczema severity index (HECSI): a scoring 
system for clinical assessment of hand ecz ema. A study of inter - and intraobserver reliability. Br 
J Dermatol 2005; 152(2):302 -7. 
Holm JG, Agner T, Clausen ML, Thomsen SF. Quality of life and disease severity in patients 
with atopic dermatitis. J Eur Acad Dermatol Venereol 2016; 30(10):1760 -7. 
ICH E2A Guideline.  Clinical Safety Data Management: Definitions and Standards for Expedited 
Reporting.  Oct 1994.   International Conference on Harmonization of Technical Requirements 
for Registration of Pharmaceuticals for Human Use.     
Johansen JD, Hald M , Andersen BL, Laurberg G, Danielsen A, Avnstorp C, et al. Classification 
of hand eczema: clinical and aetiological types. Based on the guideline of the Danish Contact 
Dermatitis Group. Contact Dermatitis 2011; 65(1):13 -21. 
Lee HJ, Ha SJ, Ahn WK, Kim D, Pa rk YM, Byun DG, et al. Clinical evaluation of atopic hand -
foot dermatitis. Pediatr Dermatol 2001; 18(2):102 -6. 
Leung DY. Pathogenesis of atopic dermatitis. J Allergy Clin Immunol 1999; 104(3 Pt 2):S99 -
108. 
Meding B, Lantto R, Lindahl G, Wrangsjo K, Bengtss on B. Occupational skin disease in 
Sweden--a 12-year follow -up. Contact Dermatitis 2005; 53(6):308 -13. 
Menne T, Johansen JD, Sommerlund M, Veien NK. Hand eczema guidelines based on the 
Danish guidelines for the diagnosis and treatment of hand eczema. Conta ct Dermatitis 2011; 
65(1):3-12. 
Nanda S, Nagrani N, MacQuhae F, Nichols A. A Case of Complete Resolution of Severe Plantar 
Dyshidrotic Eczema With Dupilumab. J Drugs Dermatol 2019; 18(2):211 -2. 
Oosterhaven JAF, Romeijn GLE, Schuttelaar MLA. Dupilumab Treat ment of Very Severe 
Refractory Atopic Hand Eczema. JAMA Dermatol 2018; 154(8):969 -70. 
Petersen AH, Johansen JD, Hald M. Hand eczema -prognosis and consequences: a 7 -year follow -
up study. Br J Dermatol 2014; 171(6):1428 -33. 
Politiek K, Oosterhaven JA, Vermeu len KM, Schuttelaar ML. Systematic review of cost -of-
illness studies in hand eczema. Contact Dermatitis 2016; 75(2):67 -76. 
Ruff SMD, Engebretsen KA, Zachariae C, Johansen JD, Silverberg JI, Egeberg A, et al. The 
association between atopic dermatitis and ha nd eczema: a systematic review and meta -analysis. 
Br J Dermatol 2018; 178(4):879 -88. 
Ruzicka T, Lynde CW, Jemec GB, Diepgen T, Berth -Jones J, Coenraads PJ, et al. Efficacy and 
safety of oral alitretinoin (9 -cis retinoic acid) in patients with severe chroni c hand eczema 
                                        VV-RIM-00138022-1.0 Approved - 13 Jan 2021 GMT-5:00
Clinical Study Protocol  R668-AD-1924 Amendment 2  
Regeneron Pharmaceuticals, Inc.  Page 101 of 108 
CONFIDENTIAL  refractory to topical corticosteroids: results of a randomized, double -blind, placebo -controlled, 
multicentre trial. Br J Dermatol 2008; 158(4):808 -17. 
Scalone L, Cortesi PA, Mantovani LG, Belisari A, Ayala F, Fortina AB, et al. Clinical 
epidemiology of hand eczema in patients accessing dermatological reference centres: results 
from Italy. Br J Dermatol 2015; 172(1):187 -95. 
Simpson EL, Bieber T, Guttman -Yassky E, Beck LA, Blauvelt A, Cork MJ, et al. Two Phase 3 
Trials of Dupilumab versus Place bo in Atopic Dermatitis. N Engl J Med 2016; 375(24):2335 -48. 
Simpson EL, Thompson MM, Hanifin JM. Prevalence and morphology of hand eczema in 
patients with atopic dermatitis. Dermatitis 2006; 17(3):123 -7. 
Stout M, Silverberg JI. Variable impact of dupiluma b on patch testing results and allergic contact 
dermatitis in adults with atopic dermatitis. J Am Acad Dermatol 2019; 81(1):157 -62. 
Suresh R, Murase JE. The role of expanded series patch testing in identifying causality of 
residual facial dermatitis follow ing initiation of dupilumab therapy. JAAD Case Rep 2018; 
4(9):899-904. 
Thaci D, Simpson EL, Beck LA, Bieber T, Blauvelt A, Papp K, et al. Efficacy and safety of 
dupilumab in adults with moderate -to-severe atopic dermatitis inadequately controlled by topical 
treatments: a randomised, placebo -controlled, dose -ranging phase 2b trial. Lancet 2016; 
387(10013):40 -52. 
Zirwas MJ. Dupilumab for hand eczema. J Am Acad Dermatol 2018; 79(1):167 -9. 
                                        VV-RIM-00138022-1.0 Approved - 13 Jan 2021 GMT-5:00
Clinical Study Protocol  R668-AD-1924 Amendment 2  
Regeneron Pharmaceuticals, Inc.  Page 102 of 108 
CONFIDENTIAL  20. INVESTIGATOR’S AGREE MENT 
I have read the attached protocol: A MULT ICENTER, RANDOMIZED, DOUBLE -BLIND, 
PLACEBO -CONTROLLED, PARALLEL -GROUP STUDY TO EVALUATE THE EFFICACY 
AND SAFETY OF DUPILUMAB IN ADULT AND ADOLESCENT PATIENTS WITH 
MODERATE -TO-SEVERE ATOPIC HAND AND FOOT DERMATITIS and agree to abide by 
all provisions set f orth therein.  
I agree to comply with the current International Council for Harmonisation Guideline for Good 
Clinical Practice and the laws, rules, regulations, and guidelines of the community, country, state, 
or locality relating to the conduct of the clin ical study.  
I also agree that persons debarred from conducting or working on clinical studies by any court or 
regulatory agency will not be allowed to conduct or work on studies for the sponsor or a partnership 
in which the sponsor is involved.  I will imm ediately disclose it in writing to the sponsor if any 
person who is involved in the study is debarred, or if any proceeding for debarment is pending, or, 
to the best of my knowledge, threatened.  
This document contains confidential information of the sponso r, which must not be disclosed to 
anyone other than the recipient study staff and members of the IRB/EC.  I agree to ensure that this 
information will not be used for any purpose other than the evaluation or conduct of the clinical 
investigation without th e prior written consent of the sponsor.  
 
 
 
   
(Signature of Investigator)   (Date) 
   
(Printed Name)    
 
 
                                        VV-RIM-00138022-1.0 Approved - 13 Jan 2021 GMT-5:00
Clinical Study Protocol  R668-AD-1924 Amendment 2  
Regeneron Pharmaceuticals, Inc.  Page 103 of 108 
CONFIDENTIAL  APPENDIX  1. HANIFIN AND RAJKA DI AGNOSTIC CRITERIA FO R 
ATOPIC DERMATITIS – MAJOR AND MINOR 
CRITERIA  
Hanifin and Rajka criteria (Hanifin, 1980)  
 
Major criteria:  
• pruritus 
• dermatitis affecting flexural surfaces in adults and the face and extensors in infants  
• chronic or relapsing dermatitis  
• personal or family history of cutaneous or respiratory atopy.  
 
Minor criteria:  
• features of the so -called “atopic facies”: facial  pallor or erythema, hypopigmented patches, 
infraorbital darkening, infraorbital folds or wrinkles, cheilitis, recurrent conjunctivitis, and 
anterior neck folds  
• triggers of atopic dermatitis: foods, emotional factors, environmental factors, and skin irrita nts 
such as wool, solvents, and sweat  
• complications of atopic dermatitis: susceptibility to cutaneous viral and bacterial infections, 
impaired cell -mediated immunity, immediate skin -test reactivity, raised serum IgE, 
keratoconus, anterior subcapsular catar acts 
• others: early age of onset, dry skin, ichthyosis, hyperlinear palms, keratosis pilaris (plugged 
hair follicles of proximal extremities), hand and foot dermatitis, nipple eczema, white 
dermatographism, and perifollicular accentuation  
 
                                        VV-RIM-00138022-1.0 Approved - 13 Jan 2021 GMT-5:00
Clinical Study Protocol  R668-AD-1924 Amendment 2  
Regeneron Pharmaceuticals, Inc.  Page 104 of 108 
CONFIDENTIAL  APPENDIX  2. INVESTIGATOR GLOB AL ASSESSMENT FOR HA ND 
AND FOOT ATOPIC DERM ATITIS 
The assessment of the IGA should be based on overall impression of disease severity in hands and 
feet as per clinical judgment of investigator at time of assessment.  
It is not necessary that all signs be pr esent for a patient to be assigned to an IGA category.  
Score  Category  IGA Morphological Descriptors  
0 Clear Absence of inflammatory signs of hand and foot atopic dermatitis 
(erythema, scaling, lichenification, vesicles, fissures, edema).  
1 Almost 
clear Barely perceptible erythema, barely perceptible scaling, barely 
perceptible lichenification and/or barely perceptible edema. No 
vesicles/erosions or fissures.  
2 Mild  Slight but definite erythema (pink), slight but definite scaling (fine 
scales), slight but definite lichenification (slight thickening of the skin 
with skin markings minimally exaggerated), slight but definite edema 
(elevation of skin surface discernible only by palpation), slight but 
definite vesicles/erosions (scattered, small vesicles or erosions) and/or 
slight but definite fissures (only superficial fissures are present).  
3 Moderate  Clearly perceptible erythema (dull red), clearly perceptible scaling 
(moderately coarse scales), clearly perceptible lichenification (definite 
thickening of the skin with skin markings clearly exaggerated), clearly 
perceptible edema (visible elevation of skin surface), clearly perceptible 
vesicles/erosions ( larger vesicles or erosions) and/or clearly perceptible 
fissures (predominantly superficial fissures but  deep fissures may be 
present)  
4 Severe Prominent erythema (deep dark red), prominent scaling (thick, large 
scales), prominent lichenification (thickened indurated skin with skin 
markings visibly portraying an exaggerated criss -cross pattern or with 
deep furrows), prominent edema (skin surface g rossly swollen/elevated), 
prominent vesicles/erosions (bullae, or densely, clustered vesicles or 
erosions, often with oozing and crusting) and/or prominent fissures 
(predominantly deep fissures are present)  
Notes: 
1. In case of indeterminate cases :  
a. Use extent to guide rating of IGA severity for , example, a patient with prominent 
erythema and clearly perceptible scaling, with limited extent of disease which would 
be classified as moderate IGA.  
b. Use severity rating for vesicles and fissures (signs with g reater impact on 
patient’s QoL) to step up rating of IGA severity. For example, a patient with clearly 
perceptible vesicles and slight but definite erythema should be assigned moderate 
IGA score. 
2. Non-inflammatory signs of atopic dermatitis such as post -inflammatory hyper - or 
hypo-pigmentation, skin dryness etc . should not be used in assessment of IGA.  
                                        VV-RIM-00138022-1.0 Approved - 13 Jan 2021 GMT-5:00
Clinical Study Protocol  R668-AD-1924 Amendment 2  
Regeneron Pharmaceuticals, Inc.  Page 105 of 108 
CONFIDENTIAL  APPENDIX  3. mTLSS: MODIFIED TOTAL  LESION SIGN SCORE F OR 
HAND AND FOOT ATOPIC  DERMATITIS  
Instructions:  
Assign a score to each of the 6 features (erythema, scaling/flaking, lichenification, 
vesiculation/erosion, edema, fissures) on a scale of 0 to 3 (0=absent, 1=mild, 2=moderate, 
3=severe) based on the morphological descriptions of severity provided in the t ables below.  
A separate score should be assigned for hands and feet.  
mTLSS Table for Hand:  
Feature Description of Severity  
Erythema  0 = Absent 
1 = Barely perceptible (pink) redness (mild)  
2 = Clearly perceptible (dull red) OR prominent (deep/dark red) 
redness in limited areas (moderate)  
3 = Prominent (deep/dark red) redness over widespread areas 
(severe) 
Scaling/Flakinga 
a Hyperkeratosis is not 
explicitly included as a 
separate sign, but 
hyperkeratosis as seen in 
hyperkeratotic eczema 
should be captured by 
scaling, fissures, and skin 
thickening 0 = Absent 
1 = Barely perceptible (fine) scales/flakes (mild)  
2 = Clearly perceptible (medium sized scales/flakes that are 
identifiable as individual scales/flakes on close inspection) 
scales/flakes OR  prominent (thick, large scales/flakes that are easily 
identifiable as individual scales/flakes) scales/flakes over a limited 
area (moderate)  
3 = Prominent (thick, large scales/flakes that are easily identifiable 
as individual scales/flakes) scales/flak es over widespread areas  
(severe) 
Lichenificationb 
b Palmar hyperlinearity as 
seen in ichthyosis vulgaris 
is not to be taken into 
account while assessing 
exaggerated skin markings  0 = Absent 
1 = Barely perceptible ( slight thickening of the skin with skin 
markings minimally exaggerated) thickening/exaggerated skin 
markings 
2 = Clearly perceptible ( definite thickening of the skin with skin 
markings clearly exaggerated) thickening/exaggerated skin markings 
OR prominent ( thickened indurated skin with sk in markings visibly 
portraying an exaggerated criss -cross pattern) 
thickening/exaggerated skin markings over a limited area (moderate)  
3 = Prominent (thickened indurated skin with skin markings visibly 
portraying an exaggerated criss -cross pattern) 
thickening/exaggerated skin markings over widespread areas 
(severe) 
Vesiculation/Erosion  0 = Absent 
                                        VV-RIM-00138022-1.0 Approved - 13 Jan 2021 GMT-5:00
Clinical Study Protocol  R668-AD-1924 Amendment 2  
Regeneron Pharmaceuticals, Inc.  Page 106 of 108 
CONFIDENTIAL  1 = Vesicles or erosions affecting up to 10% of the hands (mild)  
2 = Vesicles or erosions affecting between 10 %-30% of the hands 
(moderate)  
3 = Vesicles or erosions affecting more than 30% of the hands 
(severe) 
Edema 0 = Absent 
1 = Barely perceptible ( slight elevation of skin surface discernible 
only by palpation) dermal swelling (mild)  
2 = Clearly perceptible ( visible elevation of skin surface) derma l 
swelling OR prominent ( skin surface grossly swollen/elevated) 
dermal swelling over a limited area (moderate)  
3 = Prominent ( skin surface grossly swollen/elevated) dermal 
swelling over widespread areas (severe)  
Fissures 0 = Absent 
1 = Barely perceptible (superficial) fissuring (mild)  
2 = Clearly perceptible (a single deep) fissuring OR prominent 
(multiple deep) fissuring over limited areas (moderate)  
3 = Prominent (multiple deep) fissuring over widespread areas 
(severe) 
 
Total hand mTLSS (0-18) _______  
 
mTLSS Table for Foot:  
Feature Description of Severity  
Erythema  0 = Absent 
1 = Barely perceptible (pink) redness (mild)  
2 = Clearly perceptible (dull red) OR prominent (deep/dark red) 
redness in limited areas (moderate)  
3 = Prominent (deep/dark red) redness over widespread areas 
(severe) 
Scaling/Flakinga 
a Hyperkeratosis is not 
explicitly included as a 
separate sign, but 
hyperkeratosis as seen in 
hyperkeratotic eczema 
should be captured by 0 = Absent 
1 = Barely perceptible (fine) scales/flakes (mild)  
2 = Clearly perceptible (medium -sized scales/flakes that are 
identifiable as individual scales/flakes on close inspection) 
scales/flakes OR prominent (thick, large scales/flakes that are easily 
identifiable as individual scales/flakes) scales/flakes over a limited 
area (moderate)  
                                        VV-RIM-00138022-1.0 Approved - 13 Jan 2021 GMT-5:00
Clinical Study Protocol  R668-AD-1924 Amendment 2  
Regeneron Pharmaceuticals, Inc.  Page 107 of 108 
CONFIDENTIAL  scaling, fissures, and skin 
thickening 3 = Prominent (thick, large scales/flakes that are easily identifiable 
as individual scales/flakes) scales/flakes over widespread areas  
(severe) 
Lichenificationb 
b Plantar hyperlinearity as 
seen in ichthyosis vulgaris 
is not to be taken into 
account while ass essing 
exaggerated skin markings  0 = Absent 
1 = Barely perceptible ( slight thickening of the skin with skin 
markings minimally exaggerated) thickening/exaggerated skin 
markings 
2 = Clearly perceptible ( definite thickening of the skin with skin 
markings clearly exaggerated) thickening/exaggerated skin markings 
OR prominent ( thickened indurated skin with skin markings visibly 
portraying an exaggerated criss -cross pattern) 
thickening/exaggerated skin markings over a limited area (moderate)  
3 = Prominent (thickened indurated skin with skin markings visibly 
portraying an exaggerated criss -cross pattern) 
thickening/exaggerated skin markings over widespread areas 
(severe) 
Vesiculation/ Erosion  0 = Absent 
1 = Vesicles or erosions affecting up to 10% of the feet (mild)  
2 = Vesicles or erosions affecting between 10 %-30% of the feet 
(moderate)  
3 = Vesicles or erosions affecting more than 30% of the feet (severe)  
Edema 0 = Absent 
1 = Barely perceptible ( slight elevation of skin surface discernible 
only by palpation) dermal swelling (mild)  
2 = Clearly perceptible ( visible elevation of skin surface) dermal 
swelling OR prominent ( skin surface grossly swollen/elevated) 
dermal swelling over a limited area (moderate)  
3 = Prominent ( skin surface grossly swoll en/elevated) dermal 
swelling over widespread areas (severe)  
Fissures 0 = Absent 
1 = Barely perceptible (superficial) fissuring (mild)  
2 = Clearly perceptible (a single deep) fissuring OR prominent 
(multiple deep) fissuring over limited areas (moderate)  
3 = Prominent (multiple deep) fissuring over widespread areas 
(severe) 
 
Total foot mTLSS (0 -18) _______  
A total mTLSS score will be calculated as the sum of hand score and foot score:  
Total hand and foot mTLSS (0 -36) _______  
                                        VV-RIM-00138022-1.0 Approved - 13 Jan 2021 GMT-5:00
Clinical Study Protocol  R668-AD-1924 Amendment 2  
Regeneron Pharmaceuticals, Inc.  Page 108 of 108 
CONFIDENTIAL  SIGNATURE OF SPONSOR’S RESPONSIBL E OFFICERS  
(Medical/Study Director, Regulatory Representative, Clinical Study Lead, and 
Biostatistician)  
To the best of my knowledge, this report accurately describes the planned conduct of the study.  
Study Title:   A MULTICENTER, RANDOMIZED, DOUBLE -BLIND, PLACEBO -
CONTROLLED, PARALLEL -GROUP STUDY TO EVALUATE THE EFFICACY AND 
SAFETY OF DUPILUMAB IN ADULT AND ADOLESCENT PATIENTS WITH 
MODERATE -TO-SEVERE ATOPIC HAND AND FOOT DERMATITIS  
 
Protocol Number:  R668-AD-1924 
Protocol Version:  R668-AD-1924 Amendment 2 
 
See appended electronic signature page  
Sponsor’s Responsible Medical/Study Director  
 
 
See appended electronic signature page  
Sponsor’s Responsible Regulatory Liaison  
 
 
See appended electronic signature page  
Sponsor’s Responsible Cli nical Study Lead  
 
 
See appended electronic signature page  
Sponsor’s Responsible Biostatistician  
 
                                        VV-RIM-00138022-1.0 Approved - 13 Jan 2021 GMT-5:00
Signature Page for VV-RIM-00138022 v1.0
Signature Page for VV-RIM-00138022 v1.0 ApprovedESig Approval
13-Jan-2021 14:38:51 GMT+0000
ESig Approval
13-Jan-2021 14:50:10 GMT+0000
ESig Approval
13-Jan-2021 19:55:20 GMT+0000
ESig Approval
14-Jan-2021 00:14:26 GMT+0000                                        VV-RIM-00138022-1.0 Approved - 13 Jan 2021 GMT-5:00
